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Staphylococcus aureus is a versatile pathogen that can survive in diverse host 
environments. This versatility depends on its ability to sense nutrients and respond by 
modulating gene expression, including the synthesis of virulence determinants. In addition to its 
ability to synthesize virulence factors, the capacity of S. aureus to form biofilms is an important 
mediator of virulence in certain infections. Biofilms are a complex aggregation of bacteria 
commonly encapsulated by an adhesive exopolysaccharide matrix (polysaccharide intercellular 
adhesin; PIA). To study S. aureus biofilm formation, we assessed the metabolic requirements of 
S. aureus growing in a biofilm and found the bacteria extracted glucose and accumulated lactate, 
acetate, formate, and acetoin. Additionally, S. aureus selectively extracted six amino acids from 
the culture medium (serine, proline, arginine, glutamine, glycine, and threonine). The major 
staphylococcal exopolysaccharide, PIA, is synthesized when the tricarboxylic acid (TCA) cycle 
is repressed. To better understand TCA cycle-dependent regulation of PIA and virulence factor 
synthesis in S. aureus, we artificially induced the TCA cycle by limiting its ability to 
exogenously acquire a TCA cycle-derived amino acid (i.e., glutamine) by inactivating the 
glutamine permease gene (glnP) and assessed the effects on biofilm formation and virulence 
factor synthesis. We found that inactivation of this major glutamine transporter increased TCA 
cycle activity, transiently decreased PIA synthesis, and significantly reduced in vivo virulence in 
a rabbit endocarditis model, establishing a causal relationship between TCA cycle activity and 
virulence factor synthesis. This causal relationship between the TCA cycle and virulence factor 
synthesis suggests there are regulatory proteins connecting metabolism and the regulation of 
virulence factor synthesis. This regulation is likely to occur when a metabolite-responsive 
regulator responds to changes in TCA cycle associated biosynthetic intermediates, the redox 
status, and/or ATP. In related work, NMR metabolomic analysis of S. epidermidis indicated that 
TCA cycle stress altered the intracellular concentration of ribose. Using this information, three 
putative ribose-responsive RpiR-family regulators (orfs SAV0317, SAV0193 and SAV2315) 
were identified in S. aureus strain UAMS-1. The proteins encoded by sav0317 and sav0193 
regulate hexose monophosphate shunt transcription and alter virulence factor synthesis by 
increasing the transcription or stability of RNAIII. These data confirm a close linkage of central 
metabolism and virulence factor synthesis in S. aureus and establish that this metabolic linkage 
can be manipulated to alter infectious outcomes. 
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I. Introduction 
Staphylococcus aureus is a Gram-positive bacterium and an important human and 
animal pathogen. Humans and animals are the natural reservoir of S. aureus. In fact, 
approximately 20% of the population carry S. aureus chronically and 60% intermittently 
on the skin and mucosa, usually in the anterior nares (Sivaraman, Venkataraman et al. 
2009). S. aureus causes a wide variety of infections ranging from mild skin infections, to 
life-threatening diseases such as necrotizing pneumonia and bacteremia. S. aureus is the 
most common cause of bloodstream, skin and soft tissue, and lower respiratory tract 
infections in the United States and Canada (Diekema, Pfaller et al. 2001). It is also the 
leading cause of hospital-associated infections in the United States (Styers, Sheehan et al. 
2006). The economic impact on the U.S. healthcare system from S. aureus infections is 
$14.5 billion annually (Noskin, Rubin et al. 2007). With the increasing incidence of both 
community and hospital acquired staphylococcal infections and the prevalence of multi-
drug resistance strains, S. aureus infections remain a huge challenge to scientists and 
physicians (Bamberger and Boyd 2005; Grundmann, Aires-de-Sousa et al. 2006). 
S. aureus is a versatile bacterial pathogen that can survive in diverse host 
environments. This versatility depends on its ability to acquire and utilize nutrients from 
different sources; hence, S. aureus use nutrient availability as an indicator of their 
environment. Bacteria can sense nutrients and respond by modulating gene expression 
including the synthesis of virulence factors. Therefore, the metabolic signals encountered 
by bacteria not only help them survive in temporary adverse conditions, but also play a 
crucial role in pathogenesis. The evolutionary advantage of this linkage allows the 
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bacteria to adapt to ever-changing microenvironments during the establishment and 
progression of infections by regulating its virulence pattern. Recent advances have 
provided further support for the close linkage between metabolism and virulence 
synthesis, as evidenced by the fact that some metabolic regulatory protein, such as CcpA 
and MgrA, are regulators of virulence (Ingavale, van Wamel et al. 2005; Luong, Dunman 
et al. 2006; Seidl, Stucki et al. 2006; Seidl, Goerke et al. 2008; Seidl, Muller et al. 2009; 
Majerczyk, Dunman et al. 2010).  
This review will first give an overview of staphylococcal central metabolism, 
virulence factors and their regulation. Subsequently, we will focus on how the metabolic 
regulators affect virulence in S. aureus. 
 
II. Overview of Central Metabolism in S. aureus 
Staphylococci metabolize glucose through the Embden-Meyerhof-Parnas 
(glycolytic), pentose phosphate, and tricarboxylic acid (TCA) cycle pathways. Glucose 
enters the glycolytic pathway in the form of glucose-6-phosphate that can be generated 
during the PTS-mediated transport or undergo direct phosphorylation by glucose kinase. 
The processing of glucose-6-phosphate by the glycolytic pathway produces 2 molecules 
of pyruvate. During anaerobic growth, pyruvate is primarily reduced to lactic acid with 
the concomitant oxidation of reducing equivalents. Under aerobic conditions, the end 
product of the glycolytic pathway, pyruvate, is decarboxylated to acetyl-coenzyme A. 
Acetyl-coenzyme A is converted into acetylphosphate that is used to produce ATP and 
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acetate by substrate level phosphorylation. Acetate accumulates in the culture medium 
during the exponential phase of growth. When the growth becomes nutrient-limited, 
bacteria exit the exponential growth phase and utilize the accumulated acetate as a carbon 
source; this process requires a fully functional TCA cycle (Somerville, Chaussee et al. 
2002). The glycolytic pathway and TCA cycle produce ATP, as well as large quantities of 
reducing equivalents in the form of NADH and FADH2. To maintain redox balance, these 
reducing equivalents must be oxidized. Under aerobic conditions, staphylococci use the 
electron transport chain to fulfill this purpose. Electrons flow from NADH and FADH2 to 
menaquinone, then transfer to cytochrome c, finally to oxygen to produce water and 
proton gradient. The proton gradient drives the transmembrane F0F1ATPase to produce 
ATP.  
Bacteria need to shift their metabolic pattern to grow most efficiently under 
different carbon sources and growth phases. For example, when glucose is abundantly 
available during the exponential phase, the TCA cycle is repressed. In contrast, during the 
post-exponential phase of growth, S. aureus begin to reintroduce the products of carbon 
overflow, such as acetate, into central metabolism through activation of the TCA cycle. In 
this process, bacteria drive not only gluconeogenesis but the synthesis of biosynthetic 
precursors of amino acids and nucleic acids, and the generation of reducing potential. 
Biosynthetic reactions often require oxidized dinucleotides as cofactors; hence, TCA 
cycle generated reducing potential must be oxidized. In staphylococci, oxidation of 
reduced dinucleotides is achieved through the electron transfer chain and oxidative 
phosphorylation. In other words, the growth phase change leads to dramatic changes in 
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the metabolic status of the bacterium. At the same time, virulence factor synthesis 
parallels the events of the metabolic changes during the phase change, namely, the 
bacterial transition from cell wall-associated to secreted virulence factor synthesis 
(Novick and Geisinger 2008). In the next chapter I will discuss those changes in detail. 
 
III. Overview of Virulence Factors and Their Regulation in S. aureus 
 Bacteria cause disease by two major mechanisms: (1) Invasion and inflammation. 
This includes mechanisms for colonization, synthesis of extracellular molecules that 
facilitate adherence and the ability to evade host defenses. (2) Toxin production. 
Exotoxins produced by S. aureus are responsible for damaging host tissue and promoting 
dissemination. A third virulence mechanism that is important in certain infections is the 
ability to form biofilms. Biofilms are a complex aggregation of bacteria encapsulated by 
an extracellular polymeric matrix and are usually attached to a surface (Costerton, 
Stewart et al. 1999; Götz 2002; Otto 2008). Biofilms are of great clinical significance 
because bacteria in a biofilm have increased resistance to environmental stress, 
antimicrobial agents and host immunological defenses (Otto 2008). In the first section, I 
will give a brief introduction to cell wall-associated virulence factors that are involved in 
invasion and inflammation, and, in the latter sections, toxins and biofilms will be 
discussed.  
 
Overview of virulence factors  
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Cell wall-associated virulence factors include adhesins, exopolysaccharides, and 
cell wall components such as peptidoglycan and teichoic acid. S. aureus synthesizes two 
broad categories of adhesins, microbial surface components recognizing adhesive matrix 
molecules (MSCRAMMs) and secreted expanded-repertoire adhesive molecules 
(SERAMs) (Clarke and Foster 2006). MSCRAMMs are covalently bound to the 
peptidoglycan and function in helping bacteria adhere to different host extracellular 
matrices such as collagen, fibrinogen and fibronectin. This group of adhesins include 
protein A (Spa), collagen adhesin (Cna), clumping factor (ClfA and ClfB), and 
fibronectin-binding proteins (FnBPs). In addition to adhesion functions, they also 
participate in other aspects of pathogenesis such as evasion of the host immune response. 
As an example, protein A interferes with the host immune response by sensitizing B cells 
or depleting innate-like B cells (Goodyear and Silverman 2004; Bekeredjian-Ding, 
Inamura et al. 2007). Protein A can enhance platelet aggregation and undermine 
phagocytosis by binding to antibodies including IgG, IgA and IgE (O'Brien, Kerrigan et 
al. 2002). Protein A also contributes to the adherence to damaged endothelial surfaces by 
binding to von-Willebrand factor (Hartleib, Kohler et al. 2000), and induces local 
inflammation by binding to tumor-necrosis factor receptor-1 (TNFR-1) (Gomez, Lee et 
al. 2004). 
The second group of adhesins, SERAMs, is secreted but partially bound to the 
cell wall. SERAMs include the extracellular adhesive protein (Eap), extracellular 
fibrinogen-binding protein (Efb), and extracellular matrix protein (Emp), and their main 
function is to modulate the host immune system. For instance, Eap inhibits leukocyte 
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migration by interacting with inter-cellular adhesion molecule-1 (ICAM-1) on the 
endothelial cell surface and altering T cell function (Chavakis, Wiechmann et al. 2005). 
Efb can prevent complement activation by changing the conformation of component 3 
(C3) (Hammel, Nemecek et al. 2007). 
 Exopolysaccharides are important virulence factors in S. aureus. There are two 
types of exopolysaccharides: capsule polysaccharides and polysaccharide intercellular 
adhesin (PIA). There are a total of 11 capsule serotypes identified in S. aureus, with 
serotype 5 and 8 being the most common (O'Riordan and Lee 2004). Capsular 
polysaccharides are involved in the protection of bacteria from the host immune response 
by interfering with phagocytosis (Peterson, Wilkinson et al. 1978; Guidry, Oliver et al. 
1991). Capsule also contributes to the survival of bacteria in neutrophils (Kampen, 
Tollersrud et al. 2005). PIA, a biofilm exopolysaccharide, is chemically composed of 
poly-N-acetyl-glucosamine (Götz 2002) and it is important for bacterial aggregation of 
staphylococci during biofilm formation.  
The staphylococcal secreted toxins include cytotoxins, superantigens, proteases, 
lipase and coagulase. Cytotoxins are a group of toxins that can lyse host cells and include 
α-toxin (Hla), β-toxin (Hlb), γ-toxin (Hld), and leukocidins (LukF-PV). These toxins not 
only lyse host cells, but also alter the host immune response such as inducing caspase-
dependent and caspase-independent apoptosis (Haslinger, Strangfeld et al. 2003). 
Superantigens are a class of protein toxins that can cause nonspecific T-cell activation 
and massive cytokines release (Fraser and Proft 2008). S. aureus superantigens include 
several enterotoxins (SEs), toxic shock toxin-1 (TSST-1), and exfoliative toxins (ETs). 
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Enterotoxins cause food poisoning, whereas toxic shock toxin is responsible for toxic 
shock syndrome (Fraser and Proft 2008). Exfoliative toxin can change the conformation 
of desmoglein-1, a cell-cell adhesin in the epidermis, eventually causing degradation and 
exfoliation (Nishifuji, Sugai et al. 2008). Proteases (SspA, SspB) are involved in tissue 
invasion and immunomodulation (Rudack, Sachse et al. 2009). For example, proteases 
can degrade or activate extracellular proteins such as host immunoglobulin, antimicrobial 
peptides, and host tissues (Bergmann and Hammerschmidt 2007).  
Recently biofilm formation by S. aureus has been recognized as an important 
mechanism for causing disease (Stewart and Costerton 2001; Otto 2008). Biofilm 
formation is a well regulated multi-step process in which bacteria undergo a dramatic 
lifestyle switch from a planktonic unicellular state to an adherent multicellular state. 
Biofilms can form by attaching to a biotic or an abiotic surface where they will grow and 
secrete several small molecules (adhesin) that bind the bacterial cells together. In an S. 
aureus biofilm, the predominant adhesin that facilitates binding bacteria together is the 
exopolysaccharide PIA (Götz 2002). In some cases, cell wall-related proteins may 
function as alternative aggregating substances, such as accumulation-associated protein 
(Aap) (Hennig, Nyunt Wai et al. 2007), fibronectin binding protein (FnBP) and biofilm-
associated protein (Bap) (O'Neill, Humphreys et al. 2009). Additionally, extracellular 
genomic DNA (eDNA) and teichoic acids from lysed cells may also facilitate aggregation 
presumably due to their polyanionic nature (Gross, Cramton et al. 2001; Rice, Mann et al. 
2007). Upon maturation, portions of biofilms detach from the surface and disseminate. 
Two mechanisms of biofilm detachment have been proposed in S. aureus: enzymatic 
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degradation of proteinaceous aggregation factor and disruption of non-covalent forces by 
surfactant-like small molecules (Kong, Vuong et al. 2006; Boles and Horswill 2008). 
During infection, attachment is a crucial part of the colonization on host tissues or on 
indwelling medical devices, whereas detachment is a prerequisite for the dissemination of 
an infection. 
 
Regulatory mechanisms of virulence factors 
Expression of virulence factors is controlled by bacterial cell density and many 
environmental factors such as pH, oxygen and carbon dioxide. These factors function 
through different regulatory systems which can be divided into two broad categories: 
two-component signal transduction systems and global transcriptional regulators (Cheung 
and Zhang 2002; Cheung, Bayer et al. 2004). The best studied two-component regulatory 
system is the accessory gene regulator (agr) quorum sensing system. Bacteria 
communicate their presence by releasing and sensing signaling molecules, a phenomenon 
called quorum sensing. Many bacterial behaviors including growth, virulence, and 
antibiotic resistance are regulated by quorum sensing (Keller and Surette 2006). Quorum 
sensing is also involved in biofilm formation and dispersal (Boles and Horswill 2008).  
The agr locus regulates more than 70 genes including 23 virulence genes 
(Ziebandt, Becher et al. 2004). It contains two divergent promoters, P2 and P3. The P2 
promoter drives transcription of an auto-inducing signal transduction module which is 
composed of four genes, agrBDCA. agrD encodes the auto-inducing peptide precursor 
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which is processed by the trans-membrane endopeptidase AgrB. The mature AIP is a 
short peptide of 7-9 amino acids with a pentopeptide thiolactone ring. AgrC and AgrA 
comprise a two-component histidine kinase system, where AgrC is histidine kinase, and 
AgrA is the response regulator. AgrC has an N-terminal transmembrane sensor domain, 
and a C-terminal histidine protein kinase domain (Novick and Geisinger 2008). When the 
level of AIP reaches a threshold concentration, AgrC will be auto-phosphorylated leading 
to the phosphorylation of AgrA. Phosphorylated AgrA activates transcription from the P2 
and P3 promoters. Activation of the P2 promoter completes the auto-inducing circuit. P3 
promoter activation produces a regulatory RNA called RNAIII that is the effector 
molecule of the system. RNAIII is a large regulatory RNA with fourteen hairpin stem 
loops (Benito, Kolb et al. 2000) and it also encodes for δ-toxin (hld) (Janzon and 
Arvidson 1990). RNAIII activates the expression of exoprotein genes such as hla (α-
toxin) (Morfeldt, Taylor et al. 1995) and sspA (serine proteinase) (Oscarsson, Tegmark-
Wisell et al. 2006), and represses several cell wall-associated protein genes, such as fnbA, 
fnbB (fibronectin binding protein A, B) and spa (protein A) (Novick, Ross et al. 1993). 
RNAIII acts at both the transcriptional and post-transcriptional levels. For example, the 
interaction of RNAIII and spa mRNA involves base-pairing of these two RNAs, which 
prevents hair-pin formation in the ribosome-binding region of the spa mRNA (Novick, 
Ross et al. 1993; Gao and Stewart 2004). RNAIII also can function as an antisense RNA 
at the post-transcriptional level, which leads to a rapid degradation of target mRNA 
(Huntzinger, Boisset et al. 2005; Chevalier, Boisset et al. 2010). 
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The staphylococcal accessory element (sae) locus codes for another “two-
component” system that is comprised of SaePQRS (Giraudo, Calzolari et al. 1999). SaeR 
and SaeS display strong homology to a response regulator (RR) and histidine kinase 
(HK) of typical bacterial two-component systems. The function of SaeP and SaeQ in 
regulation is unknown (Steinhuber, Goerke et al. 2003). The sae system regulates the 
expression of many virulence factors involved in bacterial adhesion, toxicity and immune 
evasion (Rogasch, Ruhmling et al. 2006). For example, , , and -hemolysins are 
positively regulated by SaeR (Goerke, Fluckiger et al. 2005; Liang, Yu et al. 2006), and 
protein A is negatively regulated by SaeR (Giraudo, Cheung et al. 1997). Additionally, 
the sae locus is important for in vivo virulence in S. aureus animal infection models, and 
inactivation of sae locus decreases the virulence (Novick and Jiang 2003; Goerke, 
Fluckiger et al. 2005; Liang, Yu et al. 2006).  
In addition to two-component systems, several global transcriptional regulators 
function in the regulation of virulence in S. aureus (Cheung, Nishina et al. 2008). 
Staphylococcal accessory regulator A (SarA) is a well-studied example of a global 
transcriptional regulator. SarA was originally thought to antagonize the effect of agr, but 
later was found to have an additive effect (Cheung, Koomey et al. 1992; Gillaspy, Lee et 
al. 1998; Bronner, Monteil et al. 2004). Mutations in either agr or sarA attenuate 
virulence, however, agr-sarA double mutant leads to the loss of virulence (Cheung, 
Nishina et al. 2008). SarA regulates the expression of a numerous virulence factors 
including increasing the expression of FnBPs, α-toxin and decreasing the expression of 
protein A and proteases. SarA acts by either directly binding to the promoter region, 
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stabilizing mRNA, or indirectly through other regulators such as the agr system 
(Bronner, Monteil et al. 2004). In addition, SarA is a positive regulator of ica operon 
transcription, and enhances biofilm formation (Tsang, Cassat et al. 2008). Mutation of 
sarA leads to decreased biofilm formation and increased antimicrobial susceptibility in S. 
aureus (Weiss, Spencer et al. 2009). Staphylococci have several sar homologues which 
fall into two categories: small proteins and large proteins. Both categories are members of 
the MarR winged-helix family of transcriptional regulators (Bronner, Monteil et al. 
2004). The small proteins are 13-16kDa in size and include SarA, SarR, SarT and SarX. 
The large proteins are 29-30kDa in size and include Rot, SarS, SarT, SarU, SarV, MgrA 
and TcaR. 
 In bacteria, the RNA polymerase holoenzyme is composed of core enzyme and σ 
factor. The core enzyme contains four subunits α2, β and β'. The holoenzyme can 
recognize specific promoter regions and initiate transcription. The alternative sigma 
factor σB  was first identified as a master regulator of non-growing Bacillus subtilis 
(Haldenwang and Losick 1979). σB regulates more than 150 genes involved in the general 
stress response during stress and energy depletion conditions (Hecker, Pane-Farre et al. 
2007). Similarly, σB in S. aureus participates in the general stress response; however, it 
also has a significant function during an infection (Wu, de Lencastre et al. 1996; Kullik, 
Giachino et al. 1998). σB affects at least 30 virulence genes including sarA transcription, 
by binding to the P3 promoter region of sarA (Bischoff, Entenza et al. 2001). It is a 
positive regulator of capsule, fibronectin A, coagulase and a negative regulator of 
hemolysins and serine protease A (Bischoff, Dunman et al. 2004; Ziebandt, Becher et al. 
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2004; Entenza, Moreillon et al. 2005). In S. epidermidis, σB promotes biofilm formation 
by repressing icaR transcription (Knobloch, Jager et al. 2004); however, it has only a 
minor function in S. aureus biofilm formation (Valle, Toledo-Arana et al. 2003). The 
regulatory activity of σB is modulated by rsb genes (regulator of sigma B) that are located 
within the four-gene sigB operon (Kullik and Giachino 1997). In S. aureus there are three 
Rsb proteins: RsbU, RsbV and RsbW (Gertz, Engelmann et al. 2000). RsbU is a strong 
activator of σB, functioning as a putative sensor that can respond to micro-environmental 
changes by autophosphorylation (Jonsson, Arvidson et al. 2004; Palma, Bayer et al. 
2006). Mutation of RsbU leads to defects in biofilm formation in S. epidermidis 
(Knobloch, Jager et al. 2004). RsbW and RsbV act as an anti-σB and an anti-anti-σB. The 
anti-σB RsbW can bind to the σB protein, which prevents interaction of σB with RNA 
polymerase. Phosphorylated RsbU dephosphorylates RsbV, which then binds to the anti- 
σB RsbW. This binding disassociates RsbW from σB (Miyazaki, Chen et al. 1999); 
consequently, σB is free to associate with RNA polymerase core enzyme to activate the 
target genes (Bischoff, Dunman et al. 2004).  
 
IV. Metabolic regulation of virulence 
Catabolite-responsive regulators 
Bacteria have evolved intricate mechanisms to use preferred carbohydrates that 
allow fastest growth (Görke and Stulke 2008). These mechanisms include induction of 
specific carbohydrate transport and utilization systems in the presence of the 
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corresponding carbon source and their repression when a more efficiently utilizable 
carbohydrate is present. This phenomenon is called carbon catabolite repression and it is 
a common mechanism by which both Gram-positive and Gram-negative bacteria regulate 
gene expression in response to carbon availability. In many low-GC Gram-positive 
bacteria such as B. subtilis (Sonenshein 2007; Fujita 2009), Lactococcus lactis (Zomer, 
Buist et al. 2007), and Streptococcus pneumonia (Iyer, Baliga et al. 2005) carbon 
catabolite regulation is mediated by the Catabolite control protein A (CcpA). CcpA is a 
member of the LacI/GalR family of transcription regulators that binds to catabolite 
responsive elements sites (cre-sites), a cis-acting sequence usually in the operator 
sequence.    
The activity of CcpA depends on binding the co-repressor HPr (histidine-
containing protein) or Crh (catabolite repression Hpr) in B. subtilis (Jankovic and 
Bruckner 2002; Jankovic and Bruckner 2007). However, in S. aureus only Hpr 
homologues has been identified (Deutscher, Francke et al. 2006). HPr is a dual function 
protein that functions as a component of the sugar phosphotransferase system (PTS 
system) and as a co-repressor of CcpA. Hpr has two phosphorylation sites, one is Ser46, 
and the other one is His15. When His15 is phosphorylated, HPr functions as a component 
of the PTS system. In the presence of a PTS sugar such as glucose, Ser46 is 
phosphorylated and HPr functions as a corepressor. The phosphorylation of Ser46 is 
catalyzed by Hpr kinase/phosphatase. A high concentration of ATP or fructose-1, 6-
bisphosphate (FBP) enhances the kinase function of Hpr kinase/phosphatase, whereas a 
high concentration of inorganic phosphate favors its phosphatase activity. The complex of 
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CcpA and phosphorylated Hpr (CcpA-Hpr-Ser46-P) has an increased affinity to cre-sites, 
and enhances or represses gene expression (Seidel, Diel et al. 2005; Singh, Schmalisch et 
al. 2008).  
CcpA regulates more than 100 genes in S. aureus (Seidl, Muller et al. 2009). 
Considering the importance of carbon metabolism in bacteria for energy and 
biosynthesis, it is reasonable to expect that virulence factor synthesis also responds to the 
availability of carbon sources; this is in fact the case. In addition to genes involving 
carbon acquisition and metabolism, several genes associated with virulence and antibiotic 
resistance are also regulated by CcpA (Iyer, Baliga et al. 2005; Seidl, Stucki et al. 2006; 
Abranches, Nascimento et al. 2008). The effect of CcpA on virulence regulation is 
complex, involving both direct and indirect effects. An example of direct regulation is tst 
gene encoding toxic shock toxin-1 (TSST-1) in S. aureus (Seidl, Bischoff et al. 2008). 
There are cre-sites present in all known tst genes. CcpA binding represses tst 
transcription and deletion of ccpA derepress the expression of TSST-1 (Seidl, Bischoff et 
al. 2008). Since a majority of CcpA regulated genes lack apparent cre-sites, CcpA may 
perform regulation without binding to cre-sites (Seidl, Muller et al. 2009). Staphylococci 
possess many metabolite responsive regulators, so the regulation may be mediated by 
those regulators that can sense the dramatic metabolic changes created by CcpA 
regulation. Some global regulators affected by CcpA, such as RNAIII may be involved in 
this indirect regulation, as inactivation of ccpA decreases RNAIII transcripts (Seidl, 
Stucki et al. 2006). Considering RNAIII is the negative regulator of spa (protein A) and a 
positive regulator of hla (α-toxin), CcpA may be the true regulator of spa and hla. 
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Support for this conjecture was observed when it was shown that a ccpA mutant has an 
increased protein A expression (Huntzinger, Boisset et al. 2005). Despite the CcpA-
dependent regulation of spa, mutation of ccpA does not affect hla transcription (Seidl, 
Goerke et al. 2008), even with a putative cre-site present in the hla promoter region. 
Taken together, the mechanism of CcpA-dependent regulation remains to be clarified. 
In addition to affecting virulence factor synthesis, CcpA positively affects biofilm 
formation. Deletion of ccpA in S. aureus strain SA113 significantly decreased biofilm 
formation under both stationary and flow-cell conditions (Seidl, Goerke et al. 2008). The 
decreased biofilm formation is likely due to its inability to synthesize PIA and release 
eDNA, which are two key components of the extracellular matrix of a staphylococcal 
biofilm (Mann, Rice et al. 2009). The enzymes necessary for PIA biosynthesis are 
encoded within the ica operon. The holin-like protein CidA enhances cell lysis and the 
release of eDNA (Rice, Mann et al. 2007). Transcription of both of ica and cidA are up-
regulated by CcpA.  
In addition to CcpA, CodY is another catabolite-responsive regulator involving 
virulence regulation in staphylococci. CodY was first identified in the non-pathogenic 
bacterium B. subtilis as a nutrient and stress condition responder (Sonenshein 2005; 
Sonenshein 2007). In B. subtilis, CodY represses the transcription of more than 100 genes 
during the exponential phase and derepresses them as nutrients become limited, making 
this a key regulator for entering the stationary phase and during sporulation (Slack, Serror 
et al. 1995; Sonenshein 2007). CodY regulated genes are primarily involved in carbon 
and nitrogen metabolism such as proteases, peptide transport, and amino acid synthesis. 
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CodY binds as a dimer to a conserved A/T rich region of DNA (AATTTTCWGAAATT) 
(Belitsky and Sonenshein 2008) in response to changes in the concentration of GTP, 
which is an indicator of the energy status of the cell (Sonenshein 2007). The intracellular 
concentration of GTP varies dramatically between rapidly growing bacteria (2mM) and 
stationary phase bacteria (300μM). When the concentration of GTP is high, the 
probability that it will bind CodY is increased and late gene expression is repressed. 
During the post-exponential phase, the lower GTP level results in a decreased affinity of 
CodY for its operator site, de-repressing transcription of the CodY regulon (Inaoka, 
Takahashi et al. 2003). In addition to GTP, branched-chain amino acids (BCAAs) also 
enhance CodY repressor activity by increasing its affinity for target DNA. Hence, the 
biosynthesis of BCAAs such as isoleucine, leucine, and valine are under CodY control 
(Shivers and Sonenshein 2004). In total, CodY activity is controlled by GTP and BCAAs, 
particularly isoleucine or valine. Decreased concentrations of any of these molecules will 
derepress CodY regulated genes.  
 Homologues of CodY have been identified in most low G+C Gram-positive 
bacteria including Listeria monocytogenes (Bennett, Pearce et al. 2007), Streptococcus 
pneumoniae (Hendriksen, Bootsma et al. 2008), Clostridium difficile (Dineen, 
Villapakkam et al. 2007) and S. aureus (Majerczyk, Sadykov et al. 2008; Pohl, Francois 
et al. 2009). In S. aureus more than 200 genes are direct targets of CodY (Majerczyk, 
Dunman et al. 2010). In addition to its role in amino acid metabolism and transport, 
CodY regulates synthesis of many virulence factors. Some of them are regulated directly 
by CodY, whereas others are regulated indirectly through the agr system. Several 
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virulence genes including the gene for α-toxin (hla) and the genes coding for capsule 
synthesis are regulated by CodY. The effect of CodY on -toxin appears to be mediated 
by RNAIII as CodY inactivation leads to increased RNAIII transcription and a 
corresponding increase in hla transcription (Majerczyk, Sadykov et al. 2008). Similarly, 
CodY affects biofilm formation, as inactivation of CodY leads to increased ica 
transcription, and biofilm formation in S. aureus (Majerczyk, Sadykov et al. 2008). Since 
increased expression of hemolysins and proteases can provide amino acids and peptides 
to the bacteria, the regulatory linkage between CodY and virulence genes may provide 
evolutionary advantages especially during infections. 
Nitrogen-responsive regulators 
Nitrogen metabolism is critical for bacterial survival and is therefore tightly 
regulated. Glutamine and glutamate are the primary nitrogen donors in the bacteria; 
glutamine is also important for maintaining the osmotic balance (Anderson and Witter 
1982). In B. subtilis, there are two repressors involved in glutamine metabolism, GlnR 
and TnrA (Schreier, Brown et al. 1989; Wray, Ferson et al. 1996). Both of regulators 
belong to the MerR transcriptional regulator family (Brown, Stoyanov et al. 2003). The 
glnRA operon is composed of two genes glnA which encodes glutamine synthetase and 
glnR (Schreier, Caruso et al. 2000). Together GlnR and TnrA regulate gene expression in 
response to the availability of nitrogen (Sonenshein 2007). GlnR only represses genes 
with excess nitrogen, whereas TnrA can repress or activate the target genes when 
nitrogen is limited. Both GlnR and TnrA functions require the transcription of glnA, 
which is repressed when nitrogen is excessive (Hendriksen, Kloosterman et al. 2008). 
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Despite its importance in regulating nitrogen metabolism in B. subtilis, a TnrA 
homologue has not been identified in staphylococci. Importantly, inactivation of glnR 
increased methicillin sensitivity by altering peptidoglycan synthesis and structure in 
methicillin resistance S. aureus (MRSA) (Gustafson, Strassle et al. 1994). 
S. aureus is a facultative anaerobic bacterium and it can grow in a low-oxygen 
environment by fermentation or nitrate respiration (Burke and Lascelles 1975). So 
adaptation to different levels of oxygen, nitrogen, or other electron acceptor is very 
important. The two-component Staphylococcal respiratory response AB (SrrAB) system 
is the major regulatory system responsible for anaerobic gene regulation (Pragman, 
Yarwood et al. 2004). The SrrAB system will be discussed in the oxygen response 
regulator portion. The NreBC system is another two-component system that regulates 
nitrogen metabolism and it was first identified in S. carnosus (Schlag, Fuchs et al. 2008). 
NreB is a sensor kinase and NreC is a response regulator. Under low-oxygen conditions, 
the histidine kinase activity of NreB is increased, which activates the response regulator 
NreC. This system activates genes involving nitrogen metabolism including narT (nitrite 
and nitrate transport), narGHJI (respiratory nitrate reductase), and nasDE (nitrite 
reductase). The narGHJI operon encodes the membrane-bound respiratory nitrate 
reductase that reduces nitrate to nitrite, and nitrite can be further reduced to ammonia by 
nitrite reductase (nasDE). The first reductase is coupled with a proton pump, while the 
latter reaction does not produce proton force. Both narGHJI and nasDE operons are 
found in S. aureus genome. In the absence of oxygen and nitrate, NreC activates 
transcription of fermentative metabolism including the lactate dehydrogenase (lctE) and 
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the 2,3-butanediol pathway (alsS) (Schlag, Fuchs et al. 2008). It has been shown that 
nitrite affects biofilm formation. Nitrite decreases PIA biosynthesis and inhibits biofilm 
formation in S. aureus strain SA113 and S. epidermidis strain RP62A (Schlag, Nerz et al. 
2007). 
Metal-dependent regulator 
 Metal ions, especially iron, magnesium, and manganese are important enzymatic 
cofactors for bacteria, and they have multiple roles in bacterial metabolism. These metals 
can be used in many biochemical reactions as cofactors as well as in maintaining a redox 
potential. In addition to being necessary for enzymatic function, transition metals produce 
harmful reactive oxygen species (ROS) by Fenton chemistry; therefore, staphylococci 
have evolved mechanisms to maintain metal ion homeostasis. Regulation of metal ion 
homeostasis is achieved by regulators belonging to two protein families, the ferric uptake 
regulator (Fur) family, and diphtheria toxin regulator (DtxR) family. There are three Fur 
family members in S. aureus including the ferric uptake regulator (Fur), iron storage and 
antioxidant protein regulator (PerR), and zinc homeostasis regulator (Zur). Only one 
DtxR family member has been identified named MntR, which is a manganese dependent 
regulator.  
Free iron is present in a eukaryotic host at a concentration of 10
-18
 M, a 
concentration well below what is required to support bacterial growth. Considering the 
great difficulty for bacteria to obtain iron from the host, S. aureus has evolved multiple 
means to acquire iron. One of the primary mechanisms is siderophore-based iron 
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acquisition, which plays an essential role in getting the iron from transferrin (Park, Sun et 
al. 2005). Consistent with idea, defects in siderophore biosynthesis significantly decrease 
the virulence of bacteria in a kidney abscess model (Dale, Sebulsky et al. 2004). In many 
bacteria, regulation of siderophore biosynthesis and iron transport is mediated by Fur. Fur 
acts by binding to an inverted repeat motif called the Fur box located in the promoter 
region. The S. aureus strain N315 genome contains 11 confirmed Fur boxes and 11 
putative Fur boxes (Horsburgh, Ingham et al. 2001). When iron is abundant in a 
bacterium, Fur binds to DNA and represses transcription of target genes. On the other 
hand, when iron is limiting supply, the dissociation of Fur derepresses the target genes. 
Fur mutants demonstrate a significant defect of growth, which is caused by unregulated 
iron transport, which dramatically increases the intracellular iron concentration 
(Horsburgh, Ingham et al. 2001). At the same time the iron concentration is increasing, 
transcription of catalase decreases because Fur is a positive regulator of katA (encodes 
catalase). In addition to regulation iron homeostasis, inactivation fur in S. aureus 
decreased in vivo virulence by altering expression of virulence factors in a murine 
pneumonia model (Torres, Attia et al. 2010). Taken together, these observations indicate 
that Fur has an important function in the overall fitness of staphylococci.   
PerR, the second Fur homologue in S. aureus, is a transcriptional repressor of 
peroxide resistance operons (Horsburgh, Clements et al. 2001). PerR is a redox sensor 
that can sense hydrogen peroxide by metal-catalyzed histidine oxidation, using Mn (II) as 
a co-repressor (Lee and Helmann 2006; Traore, El Ghazouani et al. 2009). Based on the 
level of Mn (II) and iron, PerR has different functions. The PerR regulon is repressed in 
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the presence of Mn (II), whereas the regulon is derepressed in the presence of iron. 
Generally the concentration of iron has a dominant role (Horsburgh, Clements et al. 
2001). PerR regulated genes include katA, trxB (thioredoxin reductase), two putative iron 
storage genes ftn (ferritin), and mrgA (ferritin-like DNA-binding proteins from starved 
cells homologue). Consistent with its proposed regulatory function, an S. aureus perR 
mutant has an increased resistance to hydrogen peroxide due to the over expression of 
catalase. In contrast, perR mutants of S. aureus strain 8325-4 have reduced virulence 
relative to the wild-type strain (Horsburgh, Ingham et al. 2001). However, the mechanism 
of decreased virulence is still unknown.   
Manganese is an important metal ion that is used as a cofactor in many enzymatic 
reactions, signal transduction, and to protect the cell from oxidative stress. S. aureus has 
two manganese transporters, an ABC type transporter encoded by mntABC operon that is 
proposed to play a major role in manganese transport, and a proton-coupled metal ion 
transporter encoded by mntH (Horsburgh, Wharton et al. 2002). Both of them are 
regulated by MntR, a DtxR like protein (Que and Helmann 2000). Transcription of the 
mntABC operon is repressed by Mn, which is MntR dependent. By contrast, the 
transcription of mntH is not repressed by high Mn concentration (Que and Helmann 
2000). Although single mutants of mntA and mntH genes do not decrease virulence, the 
double mntAH mutant has decreased survival in a host, which indicates manganese 
transport is important during an infection (Horsburgh, Wharton et al. 2002).   
The Zinc uptake regulator (Zur) is a third Fur-like protein (Lee and Helmann 
2007). Zur is the third gene following two putative zinc transporters. Zur binds as a dimer 
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to a conserved DNA region called Zur box (Gaballa, Wang et al. 2002) and represses 
transcription. Zur is the regulator of Zn uptake system and ribosomal protein paralogs 
(Panina, Mironov et al. 2003). Zur also involved in the regulation of some potential 
virulence factors such as metalloprotease in Streptococcus suis (Feng, Li et al. 2008) and 
zur mutant has attenuated virulence in a murine intraperitoneal infection model of 
Salmonella enterica (Campoy, Jara et al. 2002). However, zur inactivation seems no 
attenuation in virulence in a S. aureus mouse skin infection model (Lindsay and Foster 
2001). 
Oxygen-responsive regulator 
S. aureus is a facultative anaerobe, meaning that it is able to grow under both 
aerobic and anaerobic conditions; thus, oxygen sensing and regulation of genes necessary 
for survival in an oxygen containing environment is critical. There is a dramatic 
metabolic change during the switch from aerobic to anaerobic growth. In S. aureus this 
change is mediated by the staphylococcal respiratory response regulator SrrAB 
(staphylococcal respiratory response) (Throup, Zappacosta et al. 2001). SrrAB is a 
homologue of the ResDE two-component regulatory system in B. subtilis, which is 
regulated by oxygen. Mutation of srrAB leads to slower growth during anaerobiosis, a 
diminished ability to ferment carbohydrates, and decreased transcription of lactate 
dehydrogenase and alcohol dehydrogenase (Yarwood, McCormick et al. 2001). SrrB is a 
membrane-associated histidine kinase that is capable of autophosphorylation (Pragman, 
Yarwood et al. 2004). SrrA is a cytoplasmic DNA binding protein. Once phosphorylated 
by SrrB, SrrA activates or represses target genes including downregulating toxic shock 
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syndrome toxin (TSST-1) and protein A expression. SrrA also affects RNAIII expression 
and strongly downregulates RsbW (Pragman, Yarwood et al. 2004). In anaerobic 
conditions, phosphorylated SrrA directly binds to the ica operon promoter region in S. 
aureus and up-regulates its transcription (Ulrich, Bastian et al. 2007).  
 MgrA is a transcriptional regulator belonging to the MarR protein family that has 
a dimerization domain and a conserved helix-turn-helix domain (Chen, Bae et al. 2006). 
MgrA was first identified as a negative regulator of bacterial autolysis (Ingavale, Van 
Wamel et al. 2003); however, it was later found to be a positive regulator of RNAIII 
(Ingavale, van Wamel et al. 2005). The MgrA regulation pathway is involved in thiol-
based oxidation. The only cysteine residue Cys 12 in the MgrA sequence is located in the 
dimerization region (Chen, Bae et al. 2006). Oxidation of this Cys residue leads to the 
dissociation of MgrA from the DNA, derepressing transcription of antibiotic resistance 
genes such as norA, norB, and tet38 and more than 300 other genes including cap, spa, 
coa, hla, and global regulatory genes such as agr, sarS, sarZ, and sarV (Ingavale, van 
Wamel et al. 2005; Luong, Dunman et al. 2006; Ballal, Ray et al. 2009; Chen, Nishida et 
al. 2009; Trotonda, Xiong et al. 2009). Despite the derepression of antibiotic resistance 
genes, mutation of MgrA decreases resistance to cell wall active antibiotics (Trotonda, 
Xiong et al. 2009). MgrA also represses S. aureus biofilm formation by negative 
regulation of CidA and LrgA expression, which are involved in eDNA release (Luong, 
Dunman et al. 2006). 
 SarZ is another Cys-based oxidation sensor protein that is similar to MgrA and 
was first identified as a regulator of hemolysin expression (Kaito, Morishita et al. 2006). 
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Recent studies have demonstrated that SarZ indirectly regulates virulence factors by 
synthesis by repressing sarA transcription and activating the agr system (Tamber and 
Cheung 2009). SarZ can also directly regulate transcription by binding to the promoter 
region of a target gene, such as hla. The overall effect of SarZ is decreased expression of 
surface proteins and increased synthesis of secreted virulence factors; therefore, it was 
proposed that SarZ is important in facilitating the dissemination of S. aureus infections 
(Tamber and Cheung 2009). The sarZ locus also represses biofilm formation, possibly by 
repressing surface adhesins and enhancing protease expression (Tamber and Cheung 
2009). 
Redox-responsive regulator 
In addition to SrrAB, a redox-dependent transcription repressor (Rex) was found 
to play a key role in the regulation of anaerobic metabolism in S. aureus (Hecker, Reder 
et al. 2009; Pagels, Fuchs et al. 2010). In comparison to the regulators directly sensing 
and responding to oxygen changes, Rex employed a unique mechanism by sensing redox 
status through responding to NADH/NAD
+
 ratio (Brekasis and Paget 2003). Rex was 
originally identified in Thermus aquaticus (Du and Pene 1999). Later Rex homologues 
have been found in other bacteria such as Streptomyces coelicolor (Brekasis and Paget 
2003), B. subtilis (Gyan, Shiohira et al. 2006) and L. monocytogenes (Brekasis and Paget 
2003). Rex contains two conserved domains: N-terminal winged-helix DNA binding 
domain and C-terminal NADH/NAD
+
 binding domain (Wang, Bauer et al. 2008). Rex 
can bind a highly conserved sequence (TTGTGAAW4TTCACAA) in S. aureus (Pagels, 
Fuchs et al. 2010) and represses downstream genes. The binding activity of Rex is 
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regulated by NADH/NAD
+
 ratio. NAD
+
 enhances the DNA binding ability of Rex, 
whereas NADH inhibits this ability (Sickmier, Brekasis et al. 2005). That is to say, an 
increase in NADH/NAD ratio causes dissociation of Rex-DNA binding and consequently 
to derepress downstream genes. 
A recent study demonstrated that at least 19 genes are direct targets of Rex 
including lactate fermentation gene such as ldh1 (lactate dehydrogenase) and 25 genes 
are indirect target (Pagels, Fuchs et al. 2010). It is no surprise that Rex is the major 
regulator of lactate dehydrogenase as this is the one-step pathway leading to rapid NAD 
regeneration to achieve redox rebalance. Rex also regulates the genes related to anaerobic 
metabolism and genes aiming to decrease the intracellular NADH concentration, which 
include a series of mixed acids fermentation, nitrite/nitrate respiration and electron 
transport chain genes. Rex also regulates some virulence genes. Rex represses α-toxins 
expression and regulates lukM encoding leukocidin by suppressing the SrrAB two-
component system et al. (Pragman, Herron-Olson et al. 2007; Ulrich, Bastian et al. 2007; 
Somerville and Proctor 2009). 
TCA cycle-responsive regulator 
 The TCA cycle has three major functions in metabolism, first it provides 
intermediates for macromolecular biosynthesis; second it provides reducing potential in 
the form of NADH and FADH2; and third it provides energy in the form of ATP. The TCA 
cycle participates in the regulation of staphylococcal virulence factor synthesis directly 
and indirectly (Somerville, Chaussee et al. 2002; Somerville, Cockayne et al. 2003; 
Vuong, Kidder et al. 2005; Sadykov, Olson et al. 2008; Sadykov, Mattes et al. 2010). 
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Since one of the TCA cycle functions is providing intermediates, TCA cycle-dependent 
virulence regulation may be carried out by the supply of metabolites (Somerville, 
Cockayne et al. 2003). For instance, the expression of delta toxin is inhibited by 
glutamate auxotrophy that is caused by TCA cycle inactivation (Somerville, Cockayne et 
al. 2003). Lacking glutamate limits delta toxin synthesis even though its template RNA is 
abundantly present. This repression can be reversed by adding glutamate to the culture 
media. Another example of metabolic regulation is that TCA cycle mutants fail to 
synthesize capsule due to decreased carbon flow into gluconeogenesis, which provides 
the biosynthetic precursors of capsule (Sadykov, Mattes et al. 2010).  
Genetic regulation may also be used in TCA cycle-dependent regulation of 
virulence factors. A good example is its effect on the icaADBC operon which is 
responsible for PIA biosynthesis (Vuong, Kidder et al. 2005; Sadykov, Olson et al. 2008). 
There is no evidence that an enzyme of the TCA cycle directly regulates the ica operon; 
therefore, this regulation is likely mediated by a response regulator that can respond to 
metabolic changes caused by fluctuation in TCA cycle activity. As mentioned above, 
three major functions of TCA cycle is to provide the intermediates for biosynthesis, to 
generate reducing potential, and also to provide energy. So an indirect regulation is likely 
to occur when a metabolite-responsive regulator (e.g., CcpA) responds to changes in TCA 
cycle associated biosynthetic intermediates, the redox status, and/or ATP. 
GlnR, a regulator for nitrogen metabolism, is a good candidate of metabolite-
responsive regulator. It can sense the concentration of glutamate, glutamine and 
ammonium level. Glutamate and glutamine are closely associated with the TCA cycle 
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because the TCA cycle provides the carbon skeleton α-ketoglutarate for those 
metabolites. GlnR affects many virulence factors expression and methicillin resistance. 
CodY and CcpA also can respond the TCA cycle induced metabolic change. As stated 
earlier, the affinity of CodY to DNA is increased while binding to BCAA and GTP. The 
concentration of BCAA such as valine, leucine, and isoleucine is associated with TCA 
cycle activity. It was reported that the TCA cycle mutant has a higher concentration of 
BCAA compared with wild type (Sadykov, Olson et al. 2008). The regulation of CcpA is 
modulated by the level of fructose-1,6-bisphosphate or glucose-6-phosphate which is 
increased by the inactivation of the TCA cycle. So it is reasonable to hypothesize that 
CcpA may respond to the TCA cycle-induced changes. In addition to the biosynthetic 
intermediate-responsive regulators, Cys-based oxidation sensor like MgrA and SarZ may 
also respond to the changes induced by TCA cycle. When the TCA cycle is more active, 
more oxidative stress is present inside the cells, and the DNA binding ability of MgrA 
and SarZ decreases. In this way, the downstream gene expression is affected. As we 
stated earlier, MgrA and SarZ are involved in autolysis of the cell. The TCA cycle mutant 
cannot perform cell autolysis (Somerville, Chaussee et al. 2002). 
 
V. Conclusions  
S. aureus elaborates many virulence factors that allow the organism to establish 
and spread infections under various conditions. The regulation of these virulence factors 
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is intimately linked with metabolism by the metabolic regulators. Understanding the 
linkage may help find a new and effective target of antimicrobial therapy. 
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ABSTRACT 
 
Staphylococcus aureus and S. epidermidis are the leading causes of nosocomial 
infections in the USA and often associated with biofilms attached to indwelling medical 
devices. Despite the importance of biofilms, there is very little consensus about the 
metabolic requirements of S. aureus during biofilm growth. To assess the metabolic 
requirements of S. aureus growing in a biofilm, we grew USA200 and USA300 clonal 
types in biofilm flow cells, and measured the extraction and accumulation of metabolites. 
In spite of the genetic differences, both clonal types extracted glucose and accumulated 
lactate, acetate, formate, and acetoin, suggesting glucose was catabolized to pyruvate that 
was then catabolized via the lactate dehydrogenase, pyruvate formate-lyase, and 
butanediol pathways. Additionally, both clonal types selectively extracted the same six 
amino acids from the culture medium (serine, proline, arginine, glutamine, glycine, and 
threonine). These data and recent speculation about the importance of arginine in biofilm 
growth and the function of arginine deiminase in USA300 clones, led us to genetically 
inactivate the sole copy of the arginine deiminase operon by deleting the 
arginine/ornithine antiporter (arcD) in the USA200 clonal type and assess the effect on 
biofilm development and pathogenesis. Although inactivation of arcD did completely 
inhibit arginine transport and did reduce polysaccharide intercellular adhesin 
accumulation, arcD mutants formed biofilms and achieved cell densities in catheter 
infection studies equivalent to isogenic wild-type strains.  
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INTRODUCTION 
 
Staphylococcus aureus is a leading cause of nosocomial and community-acquired 
infections. Although the types and severity of diseases produced by this opportunistic 
pathogen vary, it is a frequent cause of infections associated with indwelling medical 
devices (e.g., catheters and artificial heart valves). Indwelling device-associated 
infections commonly involve the formation of a bacterial biofilm on an uncoated plastic 
surface, or a plastic surface coated with host proteins (Vuong and Otto 2002). Due to the 
importance of S. aureus biofilms in medical device-associated infections, a considerable 
amount of research has been directed at understanding the mechanisms of biofilm 
formation. Much of this research has focused on the bacterial mediators of biofilm 
formation [e.g., (Rachid, Ohlsen et al. 2000; Vuong, Saenz et al. 2000; Trotonda, Manna 
et al. 2005; Pamp, Frees et al. 2006)], the environmental effectors of biofilm formation 
[e.g., (Karaolis, Rashid et al. 2005; Jones, Muller et al. 2006; Shanks, Sargent et al. 
2006)], and more recently the global changes that occur during biofilm development 
(Beenken, Dunman et al. 2004; Resch, Rosenstein et al. 2005; Yao, Sturdevant et al. 2005; 
Resch, Leicht et al. 2006). The consensus from transcriptional profiling studies of S. 
aureus biofilms is that bacteria are growing microaerobically or anaerobically relative to 
planktonic cultures (Beenken, Dunman et al. 2004; Resch, Rosenstein et al. 2005). This is 
exemplified by increased expression of genes of the arginine deiminase and mixed acid 
fermentation pathways and pyruvate formate lyase. Support for the idea that 
staphylococci growing in a biofilm are growing microaerobically can be found in the 
observations that anaerobiosis increases biofilm formation and polysaccharide 
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intercellular adhesin (PIA) synthesis (Cramton, Ulrich et al. 2001; Stepanovic, Djukic et 
al. 2003).  
Although the number of known requirements for S. aureus biofilm formation is 
low, a considerable amount of research has provided important information regarding 
potential mediators of biofilm formation. As examples, S. aureus regulates the formation 
of biofilms in response to nutrient availability, oxygen tension, and a variety of stresses 
(Rachid, Ohlsen et al. 2000; Cramton, Ulrich et al. 2001; Götz 2002; Lim, Jana et al. 
2004; Johnson, Cockayne et al. 2005). Importantly, these observations highlight a 
recurrent regulatory theme in pathogenesis; environmental factors alter the metabolic 
status of the bacteria, resulting in an alteration of virulence (Mekalanos 1992) or, in this 
incidence, biofilm-forming capacity (Bowden and Li 1997). Despite this being a common 
regulatory theme, the relationship between environmental factors and pathogenesis is 
poorly defined. Addressing this relationship is particularly important in the era of 
“omics”, when genomics, proteomics, and high throughput mutagenesis screens 
consistently identify the genes of bacterial physiology and metabolism as being important, 
or essential, for pathogenesis (Dunman, Murphy et al. 2001; Kohler, von Eiff et al. 2003; 
Kuroda, Kuroda et al. 2003; Mongodin, Finan et al. 2003; Beenken, Dunman et al. 2004; 
Bischoff, Dunman et al. 2004). 
To enhance our understanding of the metabolic requirements of S. aureus biofilm 
development, two S. aureus strains (UAMS-1 and UAMS-1182) were grown in flow cells 
and the culture medium effluent was collected and analyzed for nutrient extraction, 
secondary metabolite accumulation, and oxygen concentration. These two strains were 
chosen because they represent both methicillin susceptible and methicillin resistant S. 
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aureus (MSSA and MRSA) phenotypes and are from distinct genetic backgrounds 
(USA200 and USA300 clonal types).   
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MATERIALS AND METHODS 
 
Bacterial strains and growth conditions. By pulsed-field gel electrophoresis (PFGE), 
strain UAMS-1 is an MSSA strain of the USA200 clonal group, while UAMS-1182 is an 
MRSA strain indistinguishable from the USA300 clonal group (data not shown) 
(McDougal, Steward et al. 2003). PFGE control strains (i.e., known USA clonal groups) 
were provided by NARSA (Network on Antimicrobial Resistance in Staphylococcus 
aureus; www.narsa.net). In addition, UAMS-1182 was identified as belonging to the 
USA300 clonal group based on the presence of the arginine catabolic mobile element 
(Goering, McDougal et al. 2007) as determined by PCR (data not shown). Strains and 
plasmids used in this study are listed in Table 1. Escherichia coli strains were grown in 
2xYT broth (Sambrook and Russell 2001) or on
 
2xYT agar and S. aureus strains were 
grown in tryptic soy
 
broth containing 0.25% glucose (TSB) (BD Biosciences) or on TSB 
containing 1.5% agar. Unless otherwise stated, all bacterial cultures were inoculated 
1:200 from an overnight culture (normalized for growth) into TSB, incubated at 37ºC, 
and aerated at 225 rpm with a flask-to-medium ratio of 10:1. Antibiotics were purchased
 
from Fisher Scientific or Sigma Chemical and, when used, were used at the
 
following 
concentrations: ampicillin, 100 µg/ml (E. coli);
 
erythromycin, 8 µg/ml and 
chloramphenicol, 8 µg/ml
 
(S. aureus). 
 
Construction of S. aureus arc mutants. A 1.8-kb internal fragment of arcD gene was 
amplified by PCR and cloned into the
 
SmaI site of pBluescript II K/S (+) (Stratagene) to 
construct the plasmid pYF-1. The ermB cassette of pEC4 (Bruckner 1997) was inserted
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into the NdeI site within the arcD fragment of pYF-1 to generate the plasmid pYF-2. 
Next, the arcD::ermB fragment was cloned into the KpnI and EcoRI site of the 
temperature-sensitive shuttle plasmid pTS1 (Greene, McDevitt et al. 1995) to generate 
the plasmid pYF-3. The temperature-sensitive
 
plasmid pYF-3 was electroporated into S. 
aureus strain RN4220 (Schenk and Laddaga 1992)
 
and was then introduced into strain 
UAMS-1 by Φ85 phage transduction (Novick 1991). Strain UAMS-1 containing pYF-3 
was used to construct an arcD
 
mutant by the method described by Foster (Foster 1998). 
Putative mutants
 
were confirmed by PCR, Southern blotting (Southern 1975), and 
enzymatic assays. 
 
To facilitate monitoring the course of the catheter-associated infections, we 
generated an arcD mutation in S. aureus strain Xen40 (Caliper Life Sciences, Hopkinton, 
MA). Xen40 is strain UAMS-1 with a chromosomal insertion of the luxABCDE operon 
modified for expression in gram-positive bacteria (Kadurugamuwa, Sin et al. 2004). The 
mutant was made using the pKOR1 mutagenesis vector as previously described (Bae and 
Schneewind 2006) using upstream primers ArcD1-attB2F and ArcD1-SacIIR and 
downstream primers ArcD2-SacIIF and ArcD2-attB1R (Table 2). The PCR products were 
digested with SacII, ligated together, amplified using the two outside primers (ArcD1-
attB2F and ArcD2-attB1R), and ligated into pKOR1. The recombinant pKOR1 arcD 
construct was transformed into strain Xen40 and the arcD
 
mutant was constructed as 
previously described (Bae and Schneewind 2006). Inactivation of arcD was verified by 
PCR using the ArcD1-attB2F and ArcD2-attB1R primers, by confirming bioluminescence 
using the IVIS-200 imaging system (Caliper Life Sciences), and enzymatic assays. A 
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Xen40 arcD mutant strain (UAMS-1272) with growth characteristics indistinguishable 
from UAMS-1-arcD::ermB was chosen for the animal experiments.  
 
PIA Immunoblot assay. PIA accumulation was determined essentially as described 
(Vuong, Kidder et al. 2005). Briefly, bacterial cultures were grown for 16 h at 37° C with 
a flask-to-medium ratio of 5:1 and aerated at 160 rpm. Equivalent cell densities of S. 
aureus were harvested by centrifugation and PIA was extracted with 0.5 M EDTA (pH 
8.0) by boiling for 5 min. After boiling, the samples were centrifuged and the 
supernatants were harvested and incubated with
 
Proteinase K (20 mg/ml;
 
Sigma-Aldrich) 
for 30 min.
 
100 µl aliquots of PIA samples were applied
 
to Nytran nylon membranes 
(Waterman Inc.) in triplicate, air-dried,  and blocked overnight with
 
5% skim milk.
 
Membranes were incubated for 2h with anti-PIA antiserum and for 2 h with an anti-rabbit 
immunoglobulin G (IgG) alkaline phosphatase conjugate. The presence of PIA was 
detected by the addition of Sigma Fast BCIP/NBT substrate (Sigma-Aldrich). The 
integrated density values of spots on autoradiographs were determined with the TotalLab 
software (Nonlinear Dynamics Ltd.). 
 
Flow cell biofilm formation. S. aureus strains were grown in flow-cell apparatuses 
(Stovall Life Sciences, Greensboro, NC) coated with 20% human serum.  To initiate the 
biofilm, 500 µl of dilute overnight cultures (O.D.600 = 0.15) were injected into each 
chamber and the flow-cell was incubated upside down at 37º C for 1 hour.  Following 
the incubation period, a continuous flow of TSB containing 0.5% glucose and 3% NaCl 
was delivered at a flow rate of 0.5 ml per minute per chamber. 12 hours post-inoculation, 
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effluent samples were collected at 4 h intervals and analyzed for pH and dissolved 
oxygen concentration or stored at -20º C until required. 
 
Measurement of dissolved oxygen. The dissolved oxygen (DO) concentration was 
monitored using an Accumet AR60 meter equipped with YSI 5905 oxygen sensor (Fisher 
Scientific).  
 
Measurement of glucose, lactate, acetate, formate, ammonia and acetoin 
concentrations. Glucose, lactate, acetate, formate and ammonia concentrations were 
determined with kits purchased from R-Biopharm, Inc. and used according to the 
manufacturer’s directions. 
Acetoin concentrations were determined essentially as described (Grundy, Waters 
et al. 1993). Briefly, 1 ml of effluent was mixed sequentially with 0.2 ml 0.5% creatine, 
0.2 ml 5% α-naphthol, and 0.2 ml 40% potassium hydroxide. The mixture was vortexed 
for 30 seconds and incubated at room temperature for 1h. The absorbance at 540 nm was 
measured and the unknown acetoin concentrations were determined with a standard curve 
generated using known acetoin concentrations. 
 
Enzymatic activity assays. Bacteria were grown without agitation overnight in TSB 
supplemented with 20 mM arginine. Cell-free lysates of S. aureus were prepared as 
follows: Aliquots (3 ml) were harvested by centrifugation, washed with cold 0.01 M 
potassium phosphate buffer (pH 7.0), and suspended in 3.0 ml of lysis buffer containing 
0.1 M potassium phosphate buffer and 25 μg/ml lysostaphin (AMBI). The samples were 
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incubated at 37º C for 15 min and passed through a French press (2 x at 15,000 psi). The 
lysate was centrifuged for 5 min at 20,800 x g at 4º C. Arginine deiminase activity assays 
were performed essentially as described (34). In brief, cell-free lysates (100 μl) were 
added to Eppendorf tubes containing pre-warmed (37° C) reaction buffer (400 μl) [5.8 
mM L-arginine and 131 mM potassium phosphate (pH 5.8)] and incubated at 37° C for 
15 min. After 15 min, the reaction was stopped by the addition of 50 μl of ice-cold 70% 
perchloric acid and the samples were clarified by centrifugation. The supernatant (400 μl) 
was analyzed for citrulline production as described by Sugawara (Sugawara, Yoshizawa 
et al. 1998). One unit of ADI activity was defined as the amount of enzyme that catalyzed 
the formation of 1 μmol of citrulline per min. Protein concentrations were determined by 
the Lowry method (Lowry, Rosebrough et al. 1951). 
 
Assay of amino acids.  The concentrations of free amino acids in TSB were determined 
with a Beckman Model 6300 amino acid analyzer (Scientific Research Consortium, Inc., 
St. Paul, MN).  
 
In vivo biofilm formation. A catheter-based murine model was used to assess biofilm 
formation in vivo (Christensen, Simpson et al. 1983; Rupp, Ulphani et al. 1999). Briefly, 
anesthesia was induced by intraperitoneal injection of 0.75 mg of a 2,2,2 tribromoethanol 
in tert-amyl alcohol (Sigma-Aldrich) per gram of body weight. Sterile 1 cm Teflon 
intravenous catheter segments (B. Braun, Bethlehem, PA) were then implanted 
subcutaneously in each flank of 6-8 week old NIH-Swiss mice (Harlan Industries, Inc., 
Indianapolis, IN). After wound closure with Vetbond  surgical adhesive (3M, St. Paul, 
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MN), each catheter lumen was inoculated with 100 μl of phosphate-buffered saline (PBS) 
containing 5x10
5
  colony forming units (cfu). Groups of 10 mice (20 catheters total) 
were infected with each strain. Mice were imaged immediately after inoculation for 5 min 
using the IVIS-200 imaging system. All mice from each group were humanely sacrificed 
2 days post-infection and imaged a second time immediately following sacrifice. To 
quantify bioluminescence, a defined region of interest corresponding to the size of the 
implanted catheter was created and used to measure total flux (photons/sec) from each 
catheter. This was done both immediately after inoculation and at the time of sacrifice. 
Statistical significance was assessed using the One Way Analysis of Variance with All 
Pairwise Multiple Comparison Procedure (Tukey Test) as formatted in SigmaStat 
software (SPSS Inc., Chicago, IL). To quantify biofilm formation by each strain, infected 
catheters were removed immediately after sacrifice, gently washed three times in sterile 
PBS to remove non-adherent bacteria, and subsequently placed in 5 ml of sterile PBS. 
Adherent bacteria were removed from the catheters by sonication. The number of 
recovered bacteria was then quantified by serial dilution and plate counting on the 
appropriate selective media. Statistical significance of quantitative plate counts was 
assessed using the Mann Whitney Rank Sum test as formatted in SigmaStat software. All 
mouse infection experiments were reviewed and approved by the University of Arkansas 
for Medical Sciences Animal Care and Use Committee, and comply with Animal Welfare 
Legislation and NIH guidelines and policies. 
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RESULTS 
 
Staphylococcus aureus carbohydrate metabolism during biofilm growth. 
Transcriptional profiling experiments suggest that S. aureus growing in a biofilm are 
growing microaerobically or anaerobically (Beenken, Dunman et al. 2004; Resch, 
Rosenstein et al. 2005). To biochemically test this possibility, we grew strains UAMS-1 
and UAMS-1182 in a flow cell apparatus with a continuous flow of TSB culture medium 
and analyzed the effluent for the extraction of glucose and accumulation of common 
fermentation products (Fig. 1 and 2). Consistent with the transcriptional profiling data, S. 
aureus growing in a biofilm extracted glucose from the culture medium and accumulated 
the fermentation products lactic acid, acetic acid, and formic acid (Fig. 2). The 
accumulation of organic acids in the culture medium occurred coincident with a 
decreased pH and induction of the butanediol pathway, as suggested by the accumulation 
of acetoin (Fig. 2). Bacteria induce the butanediol pathway in response to a decrease in 
the environmental pH (Booth and Kroll 1983) and as a means to prevent a redox 
imbalance by oxidizing NADH to NAD
+
. The accumulation of organic acids and alcohols 
in the culture medium effluent is strongly indicative of oxygen-limited growth. To 
determine if the biofilm was oxygen-limited, we measured the oxygen concentration of 
the culture medium effluent for strains UAMS-1 and UAMS-1182 (Fig. 3). As expected, 
as the biofilm matured, it depleted oxygen from the culture medium (Fig. 3). Taken 
together, these data suggest that reduced oxygen tension induced a fermentative 
metabolism resulting in increased pH stress.  
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S. aureus growing in a biofilm selectively extract amino acids. Bacteria regulate the 
selective transport of amino acids into the cytosol; that is to say, they take what they need 
when they need it (Dunman, Murphy et al. 2001; Somerville, Chaussee et al. 2002; 
Beenken, Dunman et al. 2004; Horsburgh, Wiltshire et al. 2004; Schwan, Wetzel et al. 
2004). This is an advantageous adaptation allowing bacteria to acquire necessary amino 
acids from their environment and redirect energy from amino acid biosynthesis into 
growth. It has been postulated that amino acid catabolism is important for staphylococcal 
biofilm formation and pH homeostasis (Beenken, Dunman et al. 2004; Resch, Rosenstein 
et al. 2005; Resch, Leicht et al. 2006). To determine which amino acids S. aureus 
extracted from the culture medium during biofilm growth, we measured the free amino 
acid concentrations of culture medium effluent and expressed this as function of the free 
amino acid concentration in sterile culture medium (Fig. 2E and 2F). Although the extent 
to which amino acids were extracted varied, strains UAMS-1 and UAMS-1182 
immediately began selectively extracting the free amino acids glutamine, serine, proline, 
glycine, threonine, and arginine, while other amino acids remained in the medium (e.g., 
valine, tryptophan). The extraction of these six amino acids differs somewhat from that 
seen in planktonic growth, where during exponential growth serine, glycine, glutamine, 
glutamate, alanine, and threonine are selectively extracted from  the culture medium and 
proline and arginine are not extracted until carbon becomes limiting [(Somerville, 
Chaussee et al. 2002) and Somerville unpublished data]. The selective extraction of 
amino acids from the culture medium during biofilm growth, suggested the amino acids 
were being used for carbon and/or energy production, and not just protein synthesis. 
Amino acid catabolism usually involves the release of ammonia through a deamination 
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step; thus, it is possible to determine the fate of amino acids by measuring the 
concentration of ammonia in the culture medium effluent (Fig 2B). Concomitant with the 
extraction of amino acids from the culture medium was the accumulation of ammonia in 
the effluent, indicating amino acid catabolism. These data led us to speculate that 
interfering with amino acid transport and/or catabolism might limit biofilm formation, 
PIA synthesis, or virulence. To test these possibilities, we chose to genetically inactivated 
the arcD gene (arcD encodes the arginine/ornithine antiporter) of strain UAMS-1 and 
assessed its ability to synthesize PIA and form a biofilm. The choice to inactivate the 
arginine transporter, as opposed to a transporter of one of the other selectively extracted 
amino acids, was based on previous transcriptional profiling data (Beenken, Dunman et al. 
2004; Resch, Rosenstein et al. 2005; Yao, Sturdevant et al. 2005), proteomic data (Resch, 
Leicht et al. 2006), and speculation about the potential importance of the arginine 
deiminase pathway in staphylococcal pathogenesis (Diep, Gill et al. 2006). 
 
Growth of UAMS-1 arcD mutant strain. In S. aureus, the genes coding for the 
anaerobic catabolism of arginine are contained within the arginine deiminase (arc) operon. 
The arc operon is comprised of arginine deiminase (arcA), ornithine transcarbamylase 
(arcB), the arginine/ornithine antiporter (arcD), and carbamate kinase (arcC). The 
arginine/ornithine antiporter is a cationic exchange system that catalyzes a one-to-one 
stoichiometric exchange of arginine and ornithine (Crow and Thomas 1982; Driessen, 
Poolman et al. 1987; Poolman, Driessen et al. 1987); hence, as the bacteria extract 
arginine from the culture medium, ornithine accumulates in the medium. As expected, 
inactivation of the arcD gene prevented the extraction of arginine from the culture 
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medium and the accumulation of ornithine in the medium during biofilm growth (Fig. 
4A). Inactivation of arcD also reduced the accumulation of ammonia in the culture 
medium (after 48 h growth, the concentration of ammonia in the culture medium effluent 
was 3.31 mM in UAMS-1 and 1.38 mM in UAMS-1-arcD::ermB.) Additionally, under 
microaerobic growth conditions (5:1 flask-to-medium ratio and 100 rpm aeration), the 
arcD mutant strain (UAMS-1-arcD::ermB) accumulated a significantly lower 
concentration of ammonia in the culture medium relative to the isogenic wild-type strain 
(Fig. 4D), suggesting that arginine catabolism was inhibited. Taken together, these data 
confirm the correct gene was inactivated and that it was the sole arginine transporter.  
 
Arginine transport and/or catabolism enhance the accumulation of PIA. Two 
different S. aureus clonal types selectively extracted six amino acids, including arginine, 
from the culture medium during growth in a biofilm (Fig. 2E and 2F). These data and the 
fact that arcD inactivation does not cause a growth defect during planktonic growth (Fig. 
4B) suggest that arginine may be important for one or more aspects of biofilm maturation. 
To test this possibility, we assessed the ability of UAMS-1 and UAMS-1-arcD::ermB 
strains to grow in biofilm flow-cells. The gross morphology of biofilms formed by strain 
UAMS-1-arcD::ermB and strains UAMS-1 and UAMS-1182 was very similar (Fig. 1), 
demonstrating that bacterial attachment and biofilm maturation can occur independent of 
arginine transport or catabolism. To determine if arcD inactivation affected PIA 
accumulation, we determined the amount of cell-associated PIA during the exponential 
and stationary phases of planktonic growth. Interestingly, the accumulation of PIA was 
lower in strain UAMS-1-arcD::ermB relative to the isogenic strain UAMS-1 (46-51% 
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reduction, P = 0.0015), suggesting the biofilm formed by the arcD mutant strain (Fig. 1) 
might be PIA-limited.  
 
The affect of arginine transport on catheter-associated infections. To facilitate 
monitoring the course of the catheter-associated infections, we deleted the arcD gene 
from a strain of UAMS-1 carrying the luxABCDE operon (strain Xen40) and measured in 
vivo bioluminescence. Consistent with strain UAMS-1-arcD::ermB, the Xen40 arcD 
deletion mutant (strain UAMS-1272) had reduced PIA accumulation (46-51% reduction, 
P = 0.0015) and formed a biofilm in a flow cell equivalent to the isogenic wild-type 
strain (data not shown). Additionally, genetic inactivation of arcD in both UAMS-1 and 
Xen40 inhibited arginine deiminase activity (data not shown). The in vivo growth of the 
arc operon mutant and the wild-type strains was statistically equivalent using the Mann 
Whitney rank sum test (p = 0.218). Similarly, bioluminescence on day 2 was equivalent 
between the wild-type and arcD mutant strains (data not shown). Taken together, these 
demonstrate that in vitro and in vivo biofilms can mature in the absence of the arginine 
deiminase/arc operon.  
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DISCUSSION 
 
Indwelling medical device-associated infections caused by bacterial biofilms are a 
significant source of morbidity in the United States, with two of the more common 
causative agents of these infections being S. aureus and S. epidermidis (Trampuz and 
Widmer 2006). In spite of the prevalence of biofilm-associated staphylococcal infections, 
there is little consensus about the requirements necessary to form a biofilm. To address 
the metabolic aspects of this deficiency, we grew two genetically distinct S. aureus strains 
in biofilm flow cells, measured the extraction and accumulation of metabolites, and 
assessed the importance of one metabolite, arginine, on biofilm development and 
pathogenesis.  
Consistent with previous observations (Beenken, Dunman et al. 2004; Resch, 
Rosenstein et al. 2005), our data demonstrate that S. aureus growing in a biofilm are 
growing microaerobically (Fig. 2 and 3). We found that mature biofilms maintain a 
dynamic metabolic flux of carbon and amino acid uptake and excretion (Fig. 2), a 
situation similar to that proposed for static S. aureus biofilms (Resch, Rosenstein et al. 
2005). This dynamic metabolic flux contrasts with that observed in S. epidermidis 
biofilms where it was determined that growth in a biofilm leads to “low metabolic” 
activity (Yao, Sturdevant et al. 2005). Specifically, our data strongly suggest that S. 
aureus catabolize glucose to pyruvate by glycolysis and then catabolize pyruvate via 
lactate dehydrogenase (EC 1.1.1.27) and pyruvate formate-lyase (EC 2.3.1.54) (Fig. 2C 
and D). Glycolysis generates two molecules of pyruvate for every molecule of glucose 
consumed; however, in the process it reduces two molecules of NAD
+
 to NADH. 
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Reduction of NAD
+
 to NADH, without an equivalent means to oxidize NADH, can 
create a redox imbalance and inhibit growth. Under microaerobic or anaerobic growth 
conditions, the majority of pyruvate is reduced to lactic acid (Kendall, Friedmann et al. 
1930; Krebs 1937), concomitant with a 1:1 stoichiometric oxidation of NADH back to 
NAD
+
. To compensate for the diversion of pyruvate into pyruvate formate-lyase, S. 
aureus also shunt pyruvate into the butanediol pathway via acetolactate synthase (EC 
2.2.1.6) (Fig. 2C and D). Shunting pyruvate into the butanediol pathway will facilitate 
oxidation of NADH and decrease the accumulation of organic acids. These data and 
deductions suggest that a tenuous redox balance exists during biofilm growth, a 
potentially exploitable weakness for therapeutic intervention. This suggestion is 
supported by the observation that inactivation of the butanediol pathway at acetolactate 
decarboxylase (EC 4.1.1.5) inhibits biofilm formation (Cassat, Dunman et al. 2006). In 
addition, this suggestion is a reasonable explanation for the absence of dramatic effects 
on in vivo or in vitro biofilm formation in arginine transport and/or catabolism deficient 
strains; specifically, the arginine deiminase pathway is not involved in the reduction or 
oxidation of NAD
+
 or NADH. 
In a complex medium containing glucose, S. aureus will preferentially catabolize 
glucose for carbon and energy through the glycolytic and pentose phosphate pathways 
(Kendall, Friedmann et al. 1930; Goldschmidt and Powelson 1953; Collins and Lascelles 
1962; Mah, Fung et al. 1967; Cohen 1972). Despite a preference for glucose and a high 
concentration of glucose in the medium (>15 mM; Fig. 2A), S. aureus strains growing in 
a biofilm selectively extract and catabolize six amino acids, including arginine, from the 
culture medium (Fig. 2 and 4). These data lend credence to the speculation that arginine 
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metabolism may be important for staphylococcal survival and/or pathogenesis (Beenken, 
Dunman et al. 2004; Resch, Rosenstein et al. 2005; Diep, Gill et al. 2006; Resch, Leicht 
et al. 2006).  This speculation generated two very reasonable hypotheses regarding the 
role of arginine catabolism in staphylococcal host-pathogen interactions: First, the 
deamination of arginine by the arginine deiminase pathway results in the extracellular 
accumulation of ammonia, facilitating bacterial pH homeostasis (Beenken, Dunman et al. 
2004; Resch, Rosenstein et al. 2005; Resch, Leicht et al. 2006). Second, the 
staphylococcal arginine deiminase may function in a capacity similar to that in 
Streptococcus pyogenes (Diep, Gill et al. 2006); specifically, arginine deiminase may aid 
in evasion of the host immune response by inhibiting peripheral blood mononuclear cell 
proliferation (Degnan, Palmer et al. 1998; Degnan, Fontaine et al. 2000). Hence, one 
function of arginine may be to induce transcription of the arginine deiminase (arc) operon. 
To test the first hypothesis, we genetically inactivated the arcD gene, eliminating arginine 
transport (Fig. 4A), and assessed the affect on ammonia accumulation and the 
extracellular pH (Fig. 4). Inactivation of arcD completely inhibited the transport of 
arginine, the accumulation of ornithine (Fig. 4A), and significantly decreased the 
accumulation of ammonia; however, the pH of the biofilm effluent was unchanged (Fig. 
4B). Therefore, in contrast to previous speculation (Beenken, Dunman et al. 2004; Resch, 
Rosenstein et al. 2005; Diep, Gill et al. 2006; Resch, Leicht et al. 2006), our results 
demonstrate that the ammonia generated by the arginine deiminase pathway is 
insufficient to offset the pH decrease due to the accumulation of organic acids (Fig. 4B 
and C). To test the second hypothesis, we assessed the affect arcD inactivation in a mouse 
indwelling device infection model. Mutants lacking arcD have dramatically reduced 
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arginine deiminase activity (data not shown), yet they achieved in vivo cell densities 
equivalent to the isogenic wild-type strain, suggesting that arginine deiminase is not 
required for biofilm formation and survival in vivo at least as defined by this model. It is 
possible that arginine deiminase is important in certain types of infections, such as when 
preferred nutrients are limiting or during a more active and prolonged immune response; 
however, additional work will be needed to address these possibilities.   
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Table 1. Strains and plasmids used in this study. 
Plasmid or 
strain Relevant genotype and/or characteristic(s) Source or Reference 
 
pBluescript II 
KS(+) 
E. coli phagemid cloning vector Stratagene 
pTS1 
S. aureus - E. coli temperature-sensitive 
shuttle vector 
(Greene, McDevitt et 
al. 1995) 
pEC4 
pBluescript II KS(+) with ermB inserted into 
ClaI site 
(Bruckner 1997) 
pYF-1 
pBluescript II KS(+) containing an internal 
fragment of the arcD gene of UAMS-1 
inserted into SmaI site 
This study 
pYF-2 
pYF-1 containing the ermB cassette of pEC4 
inserted into the NdeI site of the arcD 
fragment 
This study 
pYF-3 
The arcD::ermB PCR product pYF-2 inserted 
into the KpnI and EcoRI site of pTS1 
This study 
RN4220 Restriction-negative S. aureus (Novick 1991) 
UAMS-1 S. aureus clinical isolate 
Mark Smeltzer strain 
collection 
UAMS-1182 S. aureus clinical isolate 
Mark Smeltzer strain 
collection 
UAMS-1-
arcD::ermB 
UAMS-1 containing an ermB insertion into 
arcD 
This study 
Xen40 Strain UAMS-1 containing luxABCDE Caliper Life Sciences 
UAMS-1272 Xen40 arcD deletion strain  This study 
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Table 2. Primers used in this study. 
Primer Nucleotide sequence (5' - 3') 
arcDf GCGAGTCAATATGGTGGTTCAG 
arcDr ACCCGATAACTGCAAGTACG 
ermBNdeIf CCGATTCATATGGTGATTACGCAGATAAATAAATACG 
ermBNdeIr CCGATTCATATGCAAAAGCGACTCATAGAATTATTTCC 
arcDKpnIf GCGGGTACCGCGAGTCAATATGGTGGTTCAG 
arcDEcoRIr GCGGAATTCACCCGATAACTGCAAGTACG 
arcDVf GAAGGAATAAACTTAACTTACGTTGGA 
arcDVr GCTTCTGTTGTCTGTATCGCATT 
arcAf ACACGGTATAACAATCAATCGG 
arcAr TCACTACAACGCCTGGTC 
arcBf GTAGAGGATACTGCGAAAG 
arcBr TGGAATGCTGGTAAACAA 
arcCf TGCGTCACCACTACCTCA 
arcCr GCTTCGTATGCCTGCTCT 
icaAf CTTGCCTGTTATAACGAAAGTGAAAC 
icaAr GAGTGAAGACACCCGAAATAGTATTG 
ArcD1-attB2F 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTGTTGTGCTTC
AGCTGTTGCTTCTTT 
ArcD1-SacIIR ATATTTCCCGCGGTCAATTAGATTCGCCAAGTATGGCACA 
ArcD2-SacIIF TATAACCCGCGGAT TATATTGAACGCACCGCCACCAAT 
ArcD2-attB1R 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTAACA
GACGATTGGCATCCTACACAAA 
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Fig. 1. Growth of S. aureus strains UAMS-1, UAMS-1182, and UAMS-1-arcD::ermB in 
a 3-chamber flow cell. Bacterial strains were grown at 37° C with a continuous flow (0.5 
ml per minute per chamber) of TSB containing 0.5% glucose and 3% NaCl. The results 
are representative of multiple (>3) independent experiments. In the figure, strain UAMS-
1-arcD::ermB is abbreviated as U1-arcD::ermB.  
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Fig. 2. Metabolite extraction and accumulation by S. aureus strains UAMS-1 and UAMS-
1182 during biofilm growth in flow cells. (A) The decreased pH of the culture medium 
corresponds to decreasing glucose concentrations. (B) Ammonia accumulation in the 
culture medium effluent. (C) Accumulation of organic acids and acetoin in the culture 
medium effluent of strains UAMS-1 and (D) UAMS-1182. (E) Free amino acid 
extraction from the culture medium by strains UAMS-1 and (F) UAMS-1182. The results 
presented are representative of at least two independent experiments. Symbols are 
defined in the figure insets. 
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Fig. 3. Dissolved oxygen concentration in the culture medium effluent of strains UAMS-
1 and UAMS-1182 grown in flow cells. Symbols are defined in the figure insets. The 
results presented are representative of at least three independent experiments.  
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Fig. 4. Growth characteristics of strains UAMS-1 and UAMS-1-arcD::ermB grown under 
biofilm and planktonic conditions. (A) Arginine extraction and ornithine accumulation in 
culture medium of strains UAMS-1 and UAMS-1-arcD::ermB grown in biofilm flow 
cells. (B) pH of the biofilm culture medium effluent from panel A. (C and D) Planktonic 
growth of  strains UAMS-1 and UAMS-1-arcD::ermB under microaerobic conditions 
(5:1 flask-to-medium ratio, TSB, and 100 rpm aeration.) (C) Growth and pH of the 
culture medium of strains UAMS-1 and UAMS-1-arcD::ermB. (D) Ammonia 
accumulation in the culture medium as a function of growth (A600) for the cultures in 
panel C. The results presented are representative of at least two independent experiments. 
 
  
57 
 
CHAPTER III  
 
 
TRICARBOXYLIC ACID CYCLE-DEPENDENT ATTENUATION OF 
STAPHYLOCOCCUS AUREUS IN VIVO VIRULENCE BY SELECTIVE 
INHIBITION OF AMINO ACID TRANSPORT 
 
 
Yefei Zhu
1†
, Yan Q. Xiong
 2,3†
, Marat R. Sadykov
1
, Paul D. Fey
4
, Mei G. Lei
5
, Chia Y. Lee
5
, 
Arnold S. Bayer
2,3
, and Greg A. Somerville
1* 
 
1 
Department of Veterinary and Biomedical Sciences, University of Nebraska, Lincoln, NE, 
2
 Department of Medicine, Division of Infectious Diseases, Los Angeles Biomedical Research 
Institute at Harbor-UCLA Medical Center, Torrance, CA 
3
 Geffen School of Medicine at UCLA, Los Angeles, CA 
4 
Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, 
NE  
5
 Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, 
Little Rock, AR 
 
 
 
This study was published in Infection and Immunity, 2009 
Infect Immun. 2009; 77(10): 4256-64 
58 
 
ABSTRACT 
 
Staphylococci are the leading causes of endovascular infections worldwide. 
Commonly, these infections involve the formation of biofilms on the surface of 
biomaterials. Biofilms are a complex aggregation of bacteria commonly encapsulated by 
an adhesive exopolysaccharide matrix. In staphylococci, this exopolysaccharide matrix is 
comprised of polysaccharide intercellular adhesin (PIA). PIA is synthesized when the 
tricarboxylic acid (TCA) cycle is repressed. The inverse correlation between PIA 
synthesis and TCA cycle activity led us to hypothesize that increasing TCA cycle activity 
would decrease PIA synthesis, biofilm formation, and reduce virulence in a rabbit 
catheter-induced model of biofilm infection. TCA cycle activity can be induced by 
preventing staphylococci from exogenously acquiring a TCA cycle-derived amino acid 
necessary for growth. To determine if TCA cycle induction would decrease PIA synthesis 
in Staphylococcus aureus, the glutamine permease gene (glnP) was inactivated and TCA 
cycle activity, PIA accumulation, biofilm forming ability, and virulence in an 
experimental catheter-induced endovascular biofilm (endocarditis) model were 
determined. Inactivation of this major glutamine transporter increased TCA cycle activity, 
transiently decreased PIA synthesis, and significantly reduced in vivo virulence in the 
endocarditis model in terms of achievable bacterial densities in biofilm-associated cardiac 
vegetations, kidneys and spleen. These data confirm the close linkage of TCA cycle 
activity and virulence factor production and establish that this metabolic linkage can be 
manipulated to alter infectious outcomes. 
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INTRODUCTION 
 
The number of patients in whom indwelling biomaterials are implanted annually 
(e.g. vascular access catheters) is steadily increasing (Eltchaninoff, Zajarias et al. 2008). 
Moreover, the implantation of such biomaterials predisposes an individual to life-long, 
device-related infective endocarditis (IE), an extremely serious complication with a high 
incidence of mortality (Piper, Korfer et al. 2001; El-Ahdab, Benjamin et al. 2005). The 
most common causative agents of IE are low-G+C Gram-positive bacteria, with the 
predominant bacterial etiological agents being Staphylococcus aureus and coagulase-
negative staphylococci (e.g., Staphylococcus epidermidis) (Fowler, Miro et al. 2005). 
These biomaterial-associated infections frequently involve the formation of a bacterial 
biofilm, featuring an aggregation of bacteria usually encapsulated in an 
exopolysaccharide matrix (Donlan 2001). The exopolysaccharide provides structural 
stability to biofilms, enhanced adhesion to surfaces, and protection from host defenses 
and antibiotics (Vuong, Kocianova et al. 2004; Olson, Garvin et al. 2006; Begun, Gaiani 
et al. 2007). In staphylococci, this exopolysaccharide matrix is composed of 
polysaccharide intercellular adhesin (PIA) (Mack, Fischer et al. 1996). 
PIA is an N-acetyl-glucosamine polymer (Mack, Fischer et al. 1996) whose 
biosynthesis requires the enzymes encoded within the intercellular adhesin (ica) operon 
(icaADBC) (Heilmann, Schweitzer et al. 1996). Regulation of the ica operon is complex, 
involving at least two DNA binding proteins (IcaR and SarA) (Conlon, Humphreys et al. 
2002; Beenken, Blevins et al. 2003; Valle, Toledo-Arana et al. 2003; Tormo, Marti et al. 
2005; Handke, Slater et al. 2007), the alternative sigma factor σB, and the tricarboxylic 
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acid (TCA) cycle (Vuong, Kocianova et al. 2004; Majerczyk, Sadykov et al. 2008). IcaR 
is homologous to the TetR family of transcriptional regulatory proteins and is a 
transcriptional repressor of icaADBC (Conlon, Humphreys et al. 2002). SarA is a DNA 
binding protein (Cheung, Koomey et al. 1992) that affects the expression of many genes 
in S. aureus and S. epidermidis (Blevins, Gillaspy et al. 1999). σB affects PIA synthesis 
by controlling the expression of icaR (Knobloch, Jager et al. 2004). Inhibition of TCA 
cycle activity de-represses transcription of the ica operon, linking central metabolism to 
PIA synthesis (Vuong, Kidder et al. 2005; Sadykov, Olson et al. 2008).  
One function of the TCA cycle is to supply intermediates (i.e., oxaloacetate, α-
ketoglutarate, and succinyl-CoA) for biosynthesis. For this reason, transcription of genes 
encoding the first three enzymes of the TCA cycle is regulated by the availability of 
amino acids (Goldschmidt and Powelson 1953; Somerville, Said-Salim et al. 2003). That 
is to say, during exponential growth when amino acids are exogenously available to 
staphylococci, TCA cycle activity is repressed. De-repression of TCA cycle activity 
occurs during the post-exponential growth phase when the availability of exogenous 
amino acids becomes growth limiting. This amino acid-dependent repression of TCA 
cycle activity and the reciprocal relationship between TCA cycle activity and PIA 
biosynthesis led us to hypothesize that hindering exogenous amino acid uptake would 
increase TCA cycle activity resulting in reduced PIA synthesis, limiting biofilm 
formation, and attenuating virulence in an in vivo biofilm model, catheter-induced 
experimental IE. To test this hypothesis, the major glutamine transport gene, glutamine 
permease (glnP), in S. aureus strain UAMS-1 was inactivated and the effects on TCA 
cycle activity, PIA accumulation, the ability to form a biofilm, and the capacity to initiate 
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and propagate IE were determined.  
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MATERIALS AND METHODS 
 
Bacterial strains and growth conditions. Strains and plasmids used in this study are 
listed in Table 1. Escherichia coli strains were grown in 2xYT broth (Sambrook and 
Russell 2001) or on 2xYT agar and S. aureus strains were grown in tryptic soy broth 
(TSB) (BD Biosciences) or on TSB-containing 1.5% agar (TSA). Unless otherwise stated, 
all bacterial cultures were inoculated 1:200 from an overnight culture (normalized for 
growth) into TSB, incubated at 37°C, and aerated at 225 rpm with a flask-to-medium 
ratio of 10:1. Antibiotics were purchased from Fisher Scientific or Sigma Chemical and, 
when used, were used at the following concentration: E. coli: ampicillin (100µg/ml); S. 
aureus: erythromycin (5-8µg/ml), chloramphenicol (8µg/ml), minocycline (2µg/ml), and 
tetracycline (10µg/ml). 
 
Selection of amino acid transporter to inactivate. The amino acid transporter to be 
inactivated was selected based on three inclusion criteria: i) the amino acid must be 
extensively extracted by S. aureus during growth in a biofilm (Zhu, Weiss et al. 2007); ii) 
there must be a complete biosynthetic pathway for the amino acid identified as being 
extracted; and iii) the amino acid must be derived from one or more TCA cycle 
biosynthetic intermediates. These three criteria define an amino acid that is important 
during growth in a biofilm but that can be synthesized from the coordinated action of the 
TCA cycle and an amino acid biosynthetic pathway. Previously we determined that Gln, 
Ser, Pro, Gly, Thr, and Arg were the most extensively extracted amino acids by S. aureus 
strains UAMS-1 and UAMS-1182 during growth in biofilm flow cells (Zhu, Weiss et al. 
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2007). Of these amino acids, Ser and Gly are not synthesized from TCA cycle 
intermediates; therefore, they do not fulfill our inclusion criteria. Although Thr fulfills all 
inclusion criteria, it is transported by a multiple amino acid transporter; hence, 
inactivating this transporter would affect the transport of other amino acids. This left the 
transporters of Gln, Pro, and Arg as possible candidates for genetic inactivation. 
Mutational studies involving the Pro transporter (putP) and the Arg transporter (arcD) 
have been reported (Schwan, Coulter et al. 1998; Bayer, Coulter et al. 1999; Zhu, Weiss 
et al. 2007); hence, inactivating putP or arcD would be unnecessarily duplicative of prior 
research. In addition, the TCA cycle was not significantly induced in an arcD mutant 
strain ((Zhu, Weiss et al. 2007) and data not shown), presumably due to the bacteria’s 
ability to generate arginine from ornithine by acquiring exogenous glutamate. Taken 
together, the Gln permease (glnP) was selected for inactivation and testing of our central 
hypothesis.  
 
Construction of S. aureus glutamine permease mutant. PCR primers (Table 2) were 
designed primarily using the S. aureus COL genome sequence (GenBank # NC_002951). 
A 1.4-kb PCR product encompassing orf1916 (putative glutamine permease, glnP) was 
amplified using primers COL1916-f and COL1916-r and cloned into the SmaI site of 
pBluescript II K/S (+) (Stratagene) to generate plasmid pYF-4. The ermB cassette of 
pEC4 (Bruckner 1997)was amplified using primers ErmBNsiI-f and ErmBBbvI-r and 
ligated into pYF-4 digested with NsiI and BbvCI (this deletes 576 bp of glnP) to generate 
the plasmid pYF-5. The glnP::ermB fragment of pYF-5 was inserted into the SmaI site of 
the temperature-sensitive shuttle vector pTS1 (Foster 1998) to create pYF-6. The 
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temperature-sensitive plasmid pYF-6 was electroporated into S. aureus strain RN4220 
and then introduced into strain UAMS-1 by Φ85 phage transduction. Strain UAMS-1 
containing pYF-6 was used to construct the glnP mutant by the method of Foster (Foster 
1998). To minimize the possibility that any phenotypes were the result of random 
mutations occurring during the temperature shifts, the resulting glnP::ermB mutation was 
backcrossed into wild-type strain UAMS-1 using transducing phage 85. Mutants were 
confirmed by PCR and Southern blotting. 
 
Construction of glnP complementing plasmid. Plasmid pCL15 (Table 1) containing a 
Pspac promoter, was used to construct the glnP complementation plasmid pYM6. A 1.5 kb 
promoterless glnP gene from S. aureus strain UAMS-1 was PCR amplified using the 
primers HindIII-SD-glnP-f and EcoRI-glnP-r and ligated into plasmid pCL15 digested 
with HindIII and EcoRI. The ligation mixture was used to transform S. aureus strain 
RN4220. After isolation of pYM6 from RN4220 it was electroporated into S. aureus 
strain UAMS-1-glnP::ermB. 
 
γ-L-Glutamyl hydrazide (GGH) susceptibility assay. To determine if the glnP gene 
codes for a glutamine transporter, S. aureus strains were grown overnight in a chemically 
defined media lacking glutamate and glutamine (Horsburgh, Ingham et al. 2001) and 
diluted into sterile medium to an OD600 of 0.005 containing different concentrations of 
the glutamine analogue GGH (Sigma Chemical). Cultures were grown at 37°C with 
shaking (225 rpm) for 12 h. Bacterial densities were determined by measuring the optical 
density at 600 nm.  
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Enzymatic activity assays. To confirm activation of the TCA cycle, we performed two 
enzymatic assays querying the oxidative and reductive branches of the TCA cycle. 
Isocitrate dehydrogenase (oxidative branch) enzymatic activity assays were performed as 
described (Somerville, Chaussee et al. 2002). Fumarase (reductive branch) activity was 
measured as described (Hill and Bradshaw 1969). Protein concentrations were 
determined by the modified Lowry assay (Pierce Chemical).  
 
Determination of NAD
+
 and NADH concentrations. TCA cycle activity requires 
oxidized nicotinamide adenine dinucleotide (NAD); therefore, an increase in TCA cycle 
activity can alter the NAD
+
/NADH redox balance. The intracellular concentrations of 
NAD
+
 and NADH were determined using an enzymatic cycling assay kit (Biovision). 
Total NAD
+
 and NADH concentrations were normalized to the bacterial density and were 
performed in quadruplicate for three independent experiments.  
 
PIA Immunoblot assay. PIA accumulation was determined as described (Zhu, Weiss et 
al. 2007). The data are presented as the percentage difference in PIA accumulation 
relative to UAMS-1 at 2 h. 
 
Northern blot analysis. Decreasing TCA cycle activity increases the transcription or 
message stability of the global regulator RNAIII (Somerville, Chaussee et al. 2002; Shaw, 
Golonka et al. 2004) and RNAIII regulates the expression of secreted (e.g., serine 
protease, sspA) and cell-associated (e.g., protein A, spa) virulence determinants. To 
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determine if increasing TCA cycle activity affected RNAIII message levels northern blot 
analysis of transcripts was performed as described (Sambrook and Russell 2001), except 
that total RNA was isolated using the FastRNA Pro Blue kit (Qbiogene) and purified 
using an RNeasy kit (Qiagen). Probes for northern blotting were generated by PCR 
amplification of unique internal regions of RNAIII, spa, cna, and fnbA (Table 2) and 
labeled using the North2South random prime labeling kit (Pierce). Detection was 
performed using the chemiluminescent nucleic acid detection module (Pierce). 
 
Construction of sspA-xylE and icaA-xylE reporter plasmids. To assess the effect of 
TCA cycle mediated RNAIII changes on serine protease transcription, a reporter plasmid 
was constructed. Similarly, to validate changes in PIA biosynthesis an icaA reporter 
plasmid was constructed. To construct the sspA reporter plasmid, an 822-bp region of 
strain UAMS-1 genomic DNA, containing the sspA promoter and the first 189 
nucleotides of sspA, was amplified by PCR using primers sspA(SA)-PstI-f and sspA(SA)-
BamHI-r (Table 2). The PCR product was ligated to the xylE gene of pLL38 (Chen, 
Luong et al. 2007) after digestion of both with PstI and BamHI to generate the reporter 
plasmid pMRS13. The icaA-xylE transcriptional fusion was made by PCR amplification 
of a 394 bp region containing the promoter and the first 216 nucleotides of icaA using 
primers icaA-P1 and icaA-P2 (Table 2). The resulting PCR product was ligated to the 
xylE gene in pLL38 at the PstI-BamHI sites to generate pML3783. Reporter plasmids 
were introduced into strains UAMS-1 and UAMS1-glnP::ermB by phage transduction. 
Catechol 2,3-dioxygenase activity was assayed as described (Chen, Luong et al. 2007). 
Promoter activity was defined as the absorbance at 375 nm for one OD660 unit and 
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expressed relative to the mean activity present in strain UAMS-1 at 2 h post-inoculation. 
 
Western blot analysis. As mentioned, RNAIII regulates protein A expression. To 
determine if TCA cycle mediated changes in RNAIII levels effected protein A 
biosynthesis, protein A was collected as described (Vytvytska, Nagy et al. 2002) and 
western blot analysis was performed as described (Towbin, Staehelin et al. 1979). 
 
Polystyrene primary attachment assay. The primary attachment assay was performed 
as described by Lim et al. (Lim, Jana et al. 2004). Briefly, bacterial cultures (2 h post-
inoculation) were diluted into TSB to yield approximately 300 CFU. Bacteria were 
poured onto polystyrene Petri dishes (Fisher Scientific) and incubated at 37ºC for 30 min. 
Following incubation, the Petri dishes were rinsed three times with sterile phosphate-
buffered saline (pH 7.5) and covered with 15 ml of TSB containing 0.8% agar maintained 
at 48°C. The percentage of bacterial attached to the polystyrene was defined as the 
number of CFU remaining in Petri dishes after washing compared to the number of CFU 
in control plates. The experiment was repeated three times. 
 
Flow cell biofilm formation. S. aureus were grown in flow-cell chambers (Stovall Life 
Sciences) as described (Zhu, Weiss et al. 2007). To assess bacterial growth, 12 h post-
inoculation and every 4 h thereafter, effluent samples were collected and the pH and 
lactic acid accumulation were measured. 
 
Experimental infective endocarditis (IE). A well-characterized rabbit model of IE 
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(Dhawan, Yeaman et al. 1997; Xiong, Bayer et al. 2004) was used to study three infection 
outcomes of S. aureus UAMS-1 parental vs. UAMS-1-glnP::ermB: 1) early bacteremia 
clearance; 2) initial vegetation colonization; and 3) intrinsic virulence in a rabbit model 
of IE.  In brief, female New Zealand white rabbits (Irish Farms Products and Services) 
underwent transcarotid-transaortic valve catheterization (Dhawan, Yeaman et al. 1997; 
Xiong, Kupferwasser et al. 1999; Xiong, Bayer et al. 2004). Subsequent infection 
challenge studies are described below: 
i) Early clearance of bacteremia and initial colonization of vegetations.  Animals 
were challenged by the intravenous (iv) injection of S. aureus strains UAMS-1 parental 
or UAMS-1-glnP::ermB (10
9
 CFU/animal) at 24 hr post-catheterization.  At 1 and 30 
minutes post-challenge, blood samples were obtained for quantitative culture.  Previous 
studies in this model suggest that initial clearance of the bloodstream maximally occurs 
between 30-60 min post-challenge in this model (Dhawan, Yeaman et al. 1997).  In 
addition, to assess vegetation colonization, animals were sacrificed by a rapid iv injection 
of sodium pentobarbital (200 mg/kg; Abbott Laboratories) at 30 minutes post-challenge: 
all vegetations were removed and processed for quantitative culture onto TSA plates and 
incubated at 37
o
C for 24 hr. S. aureus densities were expressed as mean ± SD log10 
colony-forming units per gram of vegetation.  
ii) Intrinsic virulence.  The intrinsic virulence of IE can be measured as a 
composite of: i) induction rates of IE over an inoculum challenge range; and ii) target 
tissue bacterial densities at 48 hr after infection at the ID95 inoculum.  Thus, animals 
were challenged at 10
4
 or 10
5
 CFU iv with strains UAMS-1 or UAMS-1-glnP::ermB at 
24 hr post-catheterization (the inoculum range encompassing the ID95 for most S. aureus 
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strains in this model (Bayer, Coulter et al. 1999)).  At 48 hr after infection, all animals 
were euthanized, their cardiac vegetations, kidneys and spleen removed and 
quantitatively cultured as detailed above.  
All experiments involving animals were reviewed and approved by the LA Biomedical 
Research Institute’s Institutional Animal Care and Use Committee, and comply with 
Animal Welfare Legislation and NIH guidelines and policies. 
 
Statistical analysis. The statistical significance of changes between wild-type and mutant 
strains (e.g., NADH concentrations) was assessed with Student’s t test. P values less than 
0.05 were considered significant. 
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RESULTS 
 
Staphylococcus aureus glnP mutant physiology. The TCA cycle can be induced by 
inhibiting the ability of staphylococci to acquire a TCA cycle-derived amino acid, thus 
forcing the bacteria to synthesize that amino acid for growth. To do this, a 576 bp portion 
of the putative Gln permease (glnP, orf SACOL1916) was deleted in S. aureus strain 
UAMS-1 and replaced with an ermB cassette and TCA cycle activity was assessed. 
Inactivation of glnP did not alter the growth rate, growth yield, or the pH profile of the 
culture medium (Fig. 1A), demonstrating the absence of any growth defects in the glnP 
mutant strain relative to strain UAMS-1. It is possible that phenotypic differences could 
occur in different media and growth conditions. To confirm that orf SACOL1916 encodes 
for the glutamine permease glnP, the susceptibility of strains UAMS-1 and UAMS-1-
glnP::ermB to the toxic glutamine analog γ-L-glutamyl hydrazide was determined (Fig. 
1B). As expected, glnP inactivation significantly (P < 0.01) decreased the susceptibility 
of strain UAMS-1-glnP::ermB to γ-L-glutamyl hydrazide, strongly suggesting that orf 
SACOL1916 encodes a Gln transporter. Complementation of strain UAMS-1-glnP::ermB 
with plasmid pYM6 restores susceptibility to γ-L-glutamyl hydrazide equivalent to 
parental strain UAMS-1 (Fig. 1B). Of note, although the glnP mutant strain is less 
susceptible to γ-L-glutamyl hydrazide than is the parental strain, it does remain 
susceptible at higher concentrations of γ-L-glutamyl hydrazide, suggesting there is lower 
affinity transporter capable of transporting glutamine.  
As stated, the TCA cycle is repressed during growth in nutrient rich conditions. 
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The carbon backbone of glutamate is th α-ketoglutarate; 
therefore, if Gln transport is hindered, then bacteria will increase synthesis of α-
ketoglutarate to offset the decrease in Gln transport. This increase in synthesis of α-
ketoglutarate means that there will be an increase in TCA cycle activity at a time when 
the TCA is normally repressed, which is analogous to the TCA cycle repression in biofilm 
growth under nutrient rich conditions. To assess the effect of glnP inactivation on TCA 
cycle activity under nutrient rich conditions that are most similar to the nutrient rich 
conditions of a biofilm, the exponential to early post-exponential growth phase TCA 
cycle activity was assessed in strains UAMS-1 and UAMS-1-glnP::ermB by measuring 
the activities of one enzyme in the oxidative branch (isocitrate dehydrogenase) and one 
enzyme in the reductive branch (fumarase) and by measuring the intracellular 
concentrations of NADH (Fig. 1C, 1D, and1F). Consistent with the central hypothesis, 
glnP inactivation increased TCA cycle activity relative to the isogenic parental strain 
UAMS-1 (Fig. 1C) under conditions that are similar to the nutrient rich conditions 
encountered in a biofilm flow cell. Complementation of strain UAMS-1-glnP::ermB with 
a plasmid encoded copy of glnP restored TCA cycle activity to levels consistent with the 
wild-type strain UAMS-1 (Fig. 1D). As expected, increased TCA cycle activity was 
accompanied by a transient increase in the intracellular concentration of NADH (Fig. 1F). 
Overall, these data confirm that selective inhibition of amino acid transport increased 
TCA cycle activity and altered the metabolic status of the bacteria and that this altered 
metabolic status was due to glnP inactivation.  
Inactivation of glnP alters the temporal pattern of virulence factor synthesis. Our 
central hypothesis predicts that increased TCA cycle activity will decrease PIA 
72 
 
biosynthesis. To determine if increased TCA cycle activity altered transcription of 
icaADBC and/or synthesis of PIA, the relative amounts of cell-associated PIA produced 
by strains UAMS-1 and UAMS-1-glnP::ermB were determined using a PIA immunoblot 
assay, while icaADBC transcription was assessed using a PicaA-xylE reporter plasmid (Fig. 
2A-C). As hypothesized, increased TCA cycle activity correlated with decreased 
icaADBC transcription (Fig. 2A) and PIA accumulation (Fig. 2B and C); however, these 
results persisted only while the intracellular NADH concentration in strain UAMS-1-
glnP::ermB was greatest (2 h; Fig. 1D). To assess if glnP inactivation would affect 
biofilm formation, the gross morphology of biofilms was assessed by growth of strains 
UAMS-1 and UAMS-1-glnP::ermB in biofilm flow cells under nutrient rich conditions 
(Fig. 3). These nutrient rich conditions are similar to the exponential growth phase of 
planktonic cultures (Fig. 1C and 1D). Inactivation of glnP delayed biofilm maturation; 
however, the morphology of the biofilms formed by the wild-type and glnP mutant 
strains was similar after approximately 40-48 h of growth (Fig. 3).  
TCA cycle activity is linked with the synthesis of virulence factors and virulence 
factor regulators (Recsei, Kreiswirth et al. 1986; Somerville, Chaussee et al. 2002; 
Somerville, Cockayne et al. 2003), including RNAIII, part of the agr quorum sensing 
system (Recsei, Kreiswirth et al. 1986). The transcription and/or stability of RNAIII is 
increased in an S. aureus TCA cycle mutant (Somerville, Chaussee et al. 2002), raising 
the possibility that increased TCA cycle activity (Fig. 1C) could decrease RNAIII 
transcript levels and alter the temporal pattern of virulence factor synthesis. To determine 
if increased TCA cycle activity altered RNAIII levels in strain UAMS-1-glnP::ermB 
relative to the parental strain UAMS-1, northern blot analysis of RNAIII transcript levels 
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was performed (Fig. 4A). As expected, increased TCA cycle activity correlated with 
decreased RNAIII transcript levels relative to the parental strain (Fig. 4A). RNAIII is a 
negative regulator of adhesin biosynthesis (Recsei, Kreiswirth et al. 1986) and a positive 
regulator of secreted virulence determinants (Shaw, Golonka et al. 2004); hence, glnP 
inactivation should increase adhesin synthesis such as protein A (spa), collagen adhesin 
(cna), and fibronectin binding protein A (fnbA) and decrease transcription of secreted 
proteins like serine protease (sspA). Consistent with decreased RNAIII levels, glnP 
inactivation increased the exponential phase synthesis of protein A (Fig. 4B) and 
moderately increased transcription of fnbA and cna (data not shown) and decreased 
transcription of sspA (Fig. 4C). These data are consistent with strain UAMS-1-
glnP::ermB having an increased ability to adhere to surfaces. To determine if glnP 
inactivation enhanced bacterial adherence to polystyrene, a polystyrene primary 
attachment assay was performed with strains UAMS-1 and UAMS-1-glnP::ermB. 
Primary attachment of strains UAMS-1 and UAMS-1-glnP::ermB to polystyrene was 
equivalent (data not shown).  These data demonstrate the altered bacterial metabolic 
status changed the temporal pattern of virulence factor synthesis. 
Experimental infective endocarditis (IE).  i) Clearance of early bacteremia and 
initial colonization of vegetations. No significant differences in the rates of early 
bacteremia clearance were observed in rabbits challenged with the parental strain UAMS-
1 or its glnP mutant at either 1 or 30 minutes post-infection (data not shown).  Similarly, 
no significant differences were observed in the extent of initial colonization of 
vegetations between strains UAMS-1 and UAMS-1-glnP::ermB (5.60 ± 0.4 and 5.99 ± 
0.36 log10CFU/g. veg., respectively).  
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ii) Intrinsic virulence in the IE model.  At the 10
4
 and 10
5
 CFU challenge inocula of S. 
aureus strains UAMS-1 or the isogenic glnP mutant, all catheterized animals developed 
IE. Importantly, animals individually infected with strain UAMS-1 had significantly 
higher bacterial densities in all three target tissues vs. animals infected with strain 
UAMS-1-glnP::ermB (Table 3; P < 0.05).  
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DISCUSSION 
 
Inactivation of glnP in strain UAMS-1 increased TCA cycle activity at a time 
when it is normally repressed (Fig. 1C). Consistent with our central hypothesis, 
inactivation of glnP also correlated with transient decreases in PIA synthesis (Fig. 1C) 
and RNAIII levels (Fig. 4A), delayed maturation of biofilms (Fig. 3), and significantly 
reduced bacterial densities in cardiac vegetations, kidneys and spleen in an endocarditis 
model. Precedence for amino acid permease inactivation attenuating S. aureus virulence 
was shown for the high affinity proline permease (putP) (Bayer, Coulter et al. 1999). 
Inactivation of putP significantly reduced bacterial densities in cardiac vegetations in an 
experimental endocarditis model; however, no data are available regarding the effects on 
virulence factor synthesis. Similar to glnP inactivation, inhibition of arginine transport by 
deletion of the arginine/ornithine antiporter (arcD) decreased PIA accumulation; however, 
deletion of arcD did not affect S. aureus virulence in a catheter-based murine infection 
model (Zhu, Weiss et al. 2007). These data demonstrate that S. aureus amino acid 
transporter inactivation does not produce a uniform effect on virulence and this may be 
due to the differing metabolic changes necessitated by the specific transporter inactivated.  
The TCA cycle supplies biosynthetic intermediates, reducing potential, and a 
small amount of ATP. In nutrient rich growth conditions, the bacterial demand for 
biosynthetic intermediates is supplied exogenously; hence, TCA cycle activity is very low 
(Strasters and Winkler 1963; Collins, Kristian et al. 2002; Somerville, Cockayne et al. 
2003). These same nutrient rich growth conditions occur during growth in a biofilm flow 
cell. When environmental conditions change and nutrients become growth limiting, 
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staphylococci increase TCA cycle activity and catabolize non-preferred carbon sources 
such as acetate (Somerville, Chaussee et al. 2002). In vitro, the transition from nutrient 
rich conditions to nutrient limited conditions usually occurs concomitant with the 
transition from exponential growth to post-exponential growth. As stated, PIA is 
synthesized when nutrients are abundant (Dobinsky, Kiel et al. 2003); in contrast, TCA 
cycle activity is repressed under these same conditions (Goldschmidt and Powelson 1953; 
Gardner and Lascelles 1962; Somerville, Cockayne et al. 2003). In addition to this 
inverse correlation between PIA synthesis and TCA cycle activity, TCA cycle activity 
actually represses icaADBC transcription and PIA biosynthesis (Vuong, Kidder et al. 
2005; Sadykov, Olson et al. 2008). This causal relationship suggested that de-repressing 
TCA cycle activity would decrease PIA synthesis. Normally, staphylococci de-repress 
TCA cycle activity when nutrients become growth limiting; however, TCA cycle activity 
can be induced by withdrawing a nutrient from the culture medium or hindering the 
transport of that nutrient. Using the latter strategy in the current study, inactivation of the 
glutamine permease resulted in increased TCA cycle activity relative to the parental strain 
UAMS-1 (Fig. 1C and 1D). The increased TCA cycle activity altered the bacterial 
metabolic status (Fig. 1F), the temporal pattern of virulence factor synthesis, and 
transiently decreased PIA synthesis (Fig. 2A-C and 4A-C). These data suggested that 
manipulating the bacterial metabolic status would decrease virulence. To test this 
suggestion, we chose to use a rabbit IE model. This model is thought to be the “gold 
standard” for experimental endovascular infections because it closely mimics its human 
counterpart microbiologically, immunologically, histopathologically, pathogenetically 
and anatomically (in terms of organ involvements) (Bayer and Norman 1990).  
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There are at least 4 important phases in the pathogenesis of endovascular 
infections: i) initial seeding of the bloodstream and survival therein; ii) colonization of 
damaged endothelial surfaces; iii) survival and progression of infection at damaged 
endothelial sites, and subsequent hematogenous dissemination to other target organs; and 
iv) reseeding of damaged endothelial sites. The experimental IE model allows one to 
dissect most of these phases and compare the capacity of parental bacterial strains with 
their relevant isogenic mutants defective in specific phenotypes-of-interest. Thus, we 
were able to compare the abilities of the parental UAMS-1 and its glnP mutant strain to 
execute the above endovascular pathogenetic stages. Since the glnP mutation causes a 
delay in biofilm formation secondary to TCA cycle activation and PIA suppression in 
vitro, and the catheter-induced IE model above is dependent at least in part on biofilm-
related vegetation formation, this provided an ideal experimental milieu. Several 
interesting observations emerged from these in vivo studies. Firstly, the bacteremic 
clearance and initial endothelial site colonization phases were not impacted by the glnP 
mutation. As bloodstream clearance is probably most dependent on susceptibility or 
resistance to innate host defenses such as opsonophagocytosis and antimicrobial peptide-
induced killing (Verdrengh and Tarkowski 1997; Yeaman and Bayer 1999; Ganz 2003; 
Clarke and Foster 2006; Nathan 2006), this outcome is not unexpected. Moreover, since 
the colonization phase is related to expression of a cadre of adhesins (Xiong, Bayer et al. 
2004; Clarke and Foster 2006), the non-effect of glnP inactivation on this pathogenetic 
stage is also not surprising. Of note, in the intrinsic virulence experiments by the parental 
or glnP mutant challenge, a differential fitness advantage of the parental strain vs. the 
glnP mutant within catheter-related cardiac vegetations was observed (Table 3). With a 
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reduction in glutamine uptake and activation of the TCA cycle, the delay in biofilm 
formation within vegetations should enable increased access of both cellular and secreted 
host defenses (e.g., platelet microbicidal proteins (Yeaman and Bayer 1999)) at this site, 
translating into enhanced clearance of the glnP mutant from this location. Finally, in the 
two major hematogenous dissemination target organs in this model (i.e., kidneys and 
spleen), achievable bacterial densities in animals infected with the parental strain 
significantly exceeded those of the glnP mutant. This outcome undoubtedly reflects the 
larger bacterial burden in biofilm-associated vegetations of parental-infected animals 
available for subsequent septic embolization to such target organs.   
 
Conclusion. The close linkage of the TCA cycle and virulence determinant synthesis 
(Somerville, Chaussee et al. 2002; Somerville, Cockayne et al. 2003; Vuong, Kidder et al. 
2005; Zhu, Weiss et al. 2007) can be exploited to modify the temporal pattern of 
virulence factor synthesis (Fig. 2A-C and 4A-C) and attenuate virulence (Table 3). In 
addition, increasing TCA cycle activity could potentially increase the in vivo 
susceptibility of S. aureus to bactericidal antibiotics (Kohanski, Dwyer et al. 2007). 
Taken together, these data suggest that vaccines directed against unique epitopes of 
bacterial amino acid transporters, such as GlnP, could provide therapeutic benefits 
beyond facilitating immune system recognition of the infectious agent. Specifically, 
vaccines directed against amino acid transporters capable of inducing TCA cycle activity 
would theoretically facilitate protection/treatment by three different means: i) 
conventional immune mediated recognition and killing of bacteria; ii) attenuation of 
virulence due to disruption of the temporal pattern of virulence factor synthesis; and iii) 
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enhancement of killing by bactericidal antibiotics (Kohanski, Dwyer et al. 2007).   
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Table 1: Strains and plasmids used in this study 
Bacterial 
strains and 
plasmids 
Relevant properties
a
  
Reference or 
source 
pBluescript II 
KS(+) 
E.coli phagemid cloning vector Stratagene 
pTS1 S. aureus-E. coli temperature-sensitive shuttle vector 
(Greene, 
McDevitt et 
al. 1995) 
pEC4 
pBluescript II KS(+) with ermB inserted into ClaI 
site 
(Bruckner 
1997) 
pYF-4 pBluescript II KS(+) containing a portion of glnP  This study 
pYF-5 
pYF-4 containing the ermB cassette of pEC4 
inserted into the NsiI and BbvCI sites of the glnP  
This study 
pYF-6 
glnP::ermB PCR product of pYF-5 inserted into the 
SmaI site of pTS1 
This study 
pLL38 xylE transcriptional fusion vector 
(Chen, 
Luong et al. 
2007) 
pML3783 
394-bp icaA  promoter fused to the xylE gene of 
pLL38; Spc
R
, Tet
R This study 
pMRS13 
822-bp sspA promoter fused to the xylE gene of 
pLL38; Spc
R
, Tet
R This study 
pCL15 Expression vector; derivative of pSI-1; Cam
R 
(Luong, 
Dunman et 
al. 2006) 
pYM6 
pCL15 with glnP gene under the control of the Pspac 
promoter; Cam
R
   
This study 
RN4220 Restriction-deficient S. aureus cloning strain 
(Novick 
1991) 
UAMS-1 S. aureus osteomyelitis isolate 
(Zhu, Weiss 
et al. 2007) 
UAMS-1-
glnP::ermB 
glnP insertion mutant of UAMS-1 This study 
a 
Amp, ampicillin; Cam, chloramphenicol; Erm, erythromycin; Min, minocycline; Tmp, 
trimethoprim; ts – temperature sensitive origin of replication 
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Table 2: Primers used in this study. 
Primer 
target 
Primer 
designation 
Nucleotide sequence (5′ - 3′) 
PCR product 
use 
 
glnP COL1916-f GTATATCAATCCCACAGCACATG  PCR cloning  
glnP COL1916-r TAATCACTGGCATTCAATCTCC  PCR cloning  
glnP HindIII-SD-glnP-f 
GATAAGCTTAGGGAGGGCTGTATAAATGAAG
TG 
 PCR cloning  
glnP EcoRI-glnP-r 
CTAGAATTCTTAATCACTGGCATTCAATCTCC
CTTC 
 PCR cloning  
ermB ErmBNsiI-f 
CCGATGCATGTGATTACGCAGATAAATAAAT
ACG 
 PCR cloning  
ermB ErmBBbvI-r 
CCGATTGCTGAGGCAAAAGCGACTCATAGA
ATTATTTCC 
 PCR cloning  
RNAIII SARNAIII-f GAAGGAGTGATTTCAATGGCACAAG  Northern blot  
RNAIII SARNAIII-r GGCTCACGACCATACTTATTATTAAGGG  Northern blot  
spa SPA-f ACCTGGTGATACAGTAAATGACATTGC Northern blot 
spa SPA-r GCACCTAAGGCTAATGATAATCCACC Northern blot 
16S 
rRNA 
SA16SrRNA-f GGTCTTGCTGTCACTTATAGATGG Northern blot 
16S 
rRNA 
SA16SrRNA-r GAATTCCACTTTCCTCTTCTGCAC Northern blot 
cna Cna-f AGTGACATGGTCTAATCTTCCGG Northern blot 
cna Cna-r TCCACTTTTGATGGCTTATCTGG Northern blot 
fnbA MW2-fnbAN-f ACTATGAGCGGGCAGTACGATG Northern blot 
fnbA MW2-fnbAN-r GATTGGACCTTGAGCTTGACCATG Northern blot 
sspA sspA(SA)-PstI-f 
CGATCTGCAGGTAAAGGATTTGTAAGGAT
TTCCTATGC 
PCR cloning 
sspA 
sspA(SA)-
BamHI-r 
CTAGGATCCCGTTGTTCTAATGGTTTAAGG
TTACCG 
PCR cloning 
icaA icaA-P1 
CTGCAGCTTATCCTTCAATTTTTATAACCC
CCTAC 
PCR cloning 
icaA icaA-P2 GGATCCGAGTGCAAGAACATTAGACAACG PCR cloning 
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Table 3. S. aureus target tissue densities in rabbit endocarditis model at 48 h post-
infection.  
Bacterial strain 
(no. of animals) 
Challenge dose 
(CFU/ml) 
S. aureus bacterial densities 
(log10 CFU/g of tissue) 
 
Vegetations Kidneys Spleen 
UAMS-1 (n=7) 
10
4 
6.50 ± 1.27 4.50 ± 0.91 5.35 ± 0.90 
UAMS-1-glnP::ermB 
(n=7) 
4.60 ± 1.19* 3.29 ± 0.96* 3.77 ± 1.61* 
UAMS-1 (n=9) 
10
5 
7.29 ± 1.06 4.98 ± 0.88 5.65 ± 0.32 
UAMS-1-glnP::ermB 
(n=9) 
5.74 ± 1.48* 3.53 ± 1.08* 4.29 ± 1.56* 
 
*P < 0.05 versus UAMS-1 parental strain. 
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Fig. 1. Physiological and metabolic characteristics of S. aureus strains UAMS-1 and 
UAMS-1-glnP::ermB. A, Growth curves and pH of culture supernatants for strains 
UAMS-1 and UAMS-1-glnP::ermB grown under aerobic conditions. B, Susceptibility of 
S. aureus strains to the glutamine analog γ-L-glutamyl hydrazide. Data are presented as 
the mean and SEM of 3 independent experiments; P < 0.01 vs. UAMS-1 parental strain 
are indicated by ** and P < 0.05 indicated by *. C, Isocitrate dehydrogenase and 
fumarase activities of strain UAMS-1-glnP::ermB expressed relative to the activities 
present in the parental strain UAMS-1, which was defined as being 100% and is 
represented by the dashed line. Data are presented as the mean and SEM of 2 independent 
experiments each determined in triplicate; for all results the P < 0.01 vs. UAMS-1 
parental strain. D, Isocitrate dehydrogenase and fumarase activities of strain UAMS-1-
glnP::ermB complemented with plasmid pYM6 expressed relative to the activities present 
in the parental strain UAMS-1, which was defined as being 100% and is represented by 
the dashed line. Data are presented as the mean and SEM of 2 independent experiments 
each determined in triplicate. E, Intracellular NADH concentrations during the transition 
from the exponential to post-exponential growth. Data are presented as the mean and 
SEM of three independent experiments each determined in quadruplicate (** P < 0.01 
and * P < 0.05 vs. UAMS-1 parental strain). 
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Fig. 2.  Inactivation of glnP transiently decreases icaADBC transcription and PIA 
biosynthesis. A, icaADBC promoter driven catechol 2,3-dioxygenase activity in strains 
UAMS-1 and UAMS-1-glnP::ermB. Data are expressed relative to the activity present in 
strain UAMS-1 at 2 h post-inoculation and represent the mean and SEM of 3 independent 
experiments. B, Relative PIA accumulation by strains UAMS-1 and UAMS-1-glnP::ermB 
and UAMS-1-arcD::ermB during the transition from the exponential to post-exponential 
growth. The data are presented as the percentage difference in PIA accumulation relative 
to UAMS-1 at 2 h. The results are the mean and SEM of 3 independent cultures. C, 
Representative PIA immunoblot for strains UAMS-1, UAMS-1-glnP::ermB, and UAMS-
1-glnP::ermB complemented with plasmid pYM6. For all results a P < 0.01 vs. UAMS-1 
parental strain is indicated by ** and a P < 0.05 is indicated by *. 
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Fig. 3. Growth of S. aureus strains UAMS-1and UAMS-1-glnP::ermB in a 3-chamber 
flow cell. Bacterial strains were grown at 37° C with a continuous flow (0.5 ml per 
minute per chamber) of TSB containing 0.5% glucose and 3% NaCl. The results are 
representative of three independent experiments.  
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Fig. 4. Inactivation of glnP alters the temporal pattern of virulence factor synthesis. A, 
RNAIII northern blot showing a decreased level of RNAIII in strain UAMS-1-
glnP::ermB relative to strain UAMS-1. The bottom panel is a photograph of an ethidium 
bromide stained agarose gel demonstrating equivalent loading of total RNA. B, Protein A 
western blot. The blots in panels A and B are representative of more than 3 independent 
experiments. C. sspA promoter driven catechol 2,3-dioxygenase activity in strains 
UAMS-1 and UAMS-1-glnP::ermB; for all results the P < 0.01 vs. UAMS-1 parental 
strain. Data are expressed relative to the activity present in strain UAMS-1 at 2 h post-
inoculation and represent the mean and SEM of 3 independent experiments.    
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CHAPTER IV 
 
 
 
RPIR HOMOLOGUES LINK STAPHYLOCOCCUS AUREUS 
VIRULENCE FACTOR SYNTHESIS TO THE HEXOSE 
MONOPHOSPHATE SHUNT  
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Abstract 
 
Staphylococcus aureus is an important human and animal pathogen that can 
synthesize a wide range of virulence factors. These virulence factors are regulated by a 
complex regulatory network that includes the agr quorum sensing system and the SarA 
family of regulators. In addition, the tricarboxylic acid (TCA) cycle has a major function 
in regulating the synthesis of many staphylococcal virulence factors. Some virulence 
factors, such as the capsular polysaccharide, are regulated by TCA cycle activity through 
the supply of biosynthetic intermediates; however, other virulence factors are regulated 
indirectly by TCA cycle activity. Indirect regulation is likely to occur when a metabolite-
responsive regulator (e.g., CcpA) responds to changes in TCA cycle associated 
biosynthetic intermediates, the redox status, and/or ATP. Previously, we observed that 
TCA cycle inactivation leads to an increased intracellular concentration of ribose, leading 
us to hypothesize that a ribose responsive regulator may mediate some of the TCA cycle-
dependent regulatory effects. Using a bioinformatic approach to find putative ribose-
responsive regulators, three RpiR-family regulators were identified in the S. aureus Mu50 
genome. RpiR was first identified in Escherichia coli as a regulator of ribose-5-phosphate 
isomerase, an enzyme in the hexose monophosphate shunt. RpiR family proteins have N-
terminal domains
 
containing a helix-turn-helix DNA binding motif and a C-terminal 
sugar isomerase binding domain. To determine if the S. aureus RpiR regulators create a 
bridge between the hexose monophosphate shunt and virulence factor synthesis, the three 
rpiR homologues (orfs SAV0317, SAV0193 and SAV2315) were inactivated, and the 
effects on the hexose monophosphate shunt activity and virulence factor synthesis were 
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assessed. Deletion of sav0193 or sav2315 decreased transcription of rpiA (ribose-5-
phosphate isomerase) and zwf (glucose-6-phosphate dehydrogenase), indicating the 
proteins encoded by these genes regulate hexose monophosphate shunt transcription. In 
addition, inactivation of sav0193 or sav2315 dramatically increased the transcription or 
stability of RNAIII, the effector molecule of the agr quorum sensing system. Consistent 
with this increase in RNAIII levels, deletion of sav2315 decreased protein A biosynthesis 
and increased the accumulation of capsular polysaccharides. These data confirm a close 
linkage of central metabolism and virulence factor synthesis in S. aureus. 
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Introduction 
 
 Staphylococcus aureus is an important human and animal pathogen that is capable 
of causing a wide variety of diseases (Lowy 1998). The pathogenicity of S. aureus 
depends on its ability to synthesize virulence factors that facilitate colonization, immune 
evasion, and nutrient acquisition. Virulence factor synthesis is controlled by a complex 
network of regulatory proteins including the agr quorum sensing system and the SarA 
family of transcriptional regulators (please see Chapter 1). In addition, the tricarboxylic 
acid (TCA) cycle is important for regulation of staphylococcal virulence factor synthesis 
(Vuong, Kidder et al. 2005; Sadykov, Olson et al. 2008; Somerville and Proctor 2009; 
Zhu, Xiong et al. 2009; Sadykov, Mattes et al. 2010). The two most common types of 
regulation are genetic regulation and metabolic regulation; hence, TCA cycle-dependent 
regulation most likely occurs via one or both of these mechanisms. Genetic regulation 
occurs through the repression or induction of enzyme synthesis, while metabolic 
regulation controls enzyme activity through the availability of substrates and co-factors 
(e.g., feedback inhibition). An example of metabolic regulation is synthesis of capsular 
polysaccharide, which is regulated by TCA cycle activity through the supply of 
oxaloacetate for gluconeogenesis (Sadykov, Mattes et al. 2010). Other virulence factors 
such as polysaccharide intercellular adhesin (PIA) are genetically regulated by TCA cycle 
activity through transcriptional repression of the operon that codes for the enzymes of 
PIA biosynthesis (i.e., icaADBC) (Vuong, Kidder et al. 2005; Sadykov, Olson et al. 2008). 
TCA cycle-dependent genetic regulation likely depends on response regulators that can 
sense metabolic changes associated with TCA cycle activity fluctuations (Somerville and 
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Proctor 2009).  
To identify TCA cycle-responsive regulators, we characterized the metabolomic 
changes associated with TCA cycle stress (Sadykov et al., submitted for publication). By 
comparing the intracellular concentrations of metabolites between S. epidermidis strain 
1457 and its isogenic aconitase mutant, we found that TCA cycle inactivation leads to an 
increased intracellular concentration of ribose. This implies that if there is a regulator that 
can respond to the concentration of ribose, then the activity of that regulator will likely be 
altered. The prototype ribose-responsive regulator, RpiR, was first identified in 
Escherichia coli as a regulator of ribose-5-phosphate isomerase B (rpiB), which catalyzes 
the reversible isomerization of ribulose-5-phosphate and ribose-5-phosphate (Sorensen 
and Hove-Jensen 1996). Members of RpiR family often act as transcriptional regulators 
of sugar catabolism and RpiR homologues have been identified as repressors and 
activators in both Gram-negative and Gram-positive bacteria, including E. coli, 
Pseudomonas putida, and Bacillus subtilis (Sorensen and Hove-Jensen 1996; Yamamoto, 
Serizawa et al. 2001; Daddaoua, Krell et al. 2009). To identify putative ribose response 
regulators, the S. aureus Mu50 genome (Kuroda, Ohta et al. 2001) was searched for RpiR 
family members. Three open reading frames were identified as having significant amino 
acid homology to RpiR (between 21-23% identity and 45-46% positive); namely, 
SAV0317, SAV0193 and SAV2315. Similar to other members of the RpiR family of 
proteins (Bateman 1999), the S. aureus homologues are predicted to have an N-terminal 
helix-turn-helix DNA binding motif and a C-terminal sugar isomerase binding (SIS) 
domain.  
Based on NMR metabolomic data demonstrating that TCA cycle stress alters the 
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intracellular concentration of ribose, we hypothesized that one or more RpiR homologues 
may link the hexose monophosphate shunt to virulence regulation in S. aureus. To test 
this hypothesis, three single mutants, three double mutants, and a triple mutant of the 
RpiR homologues SAV0317, SAV0193 and SAV2315 were made in S. aureus strain 
UAMS-1 and the effects on hexose monophosphate shunt activity, RNAIII transcription, 
capsular polysaccharide biosynthesis, PIA accumulation, and the ability to form a biofilm 
were assessed. 
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Materials and Methods 
 
Bacterial strains and growth conditions. Strains and plasmids used in this study are 
listed in Table 1. E. coli strains were grown in 2x YT broth (Sambrook and Russell 2001) 
or on a 2x YT agar, and S. aureus strains were grown in tryptic soy broth (TSB) (BD 
Biosciences) or on TSB-containing 1.5% agar. Unless otherwise stated, all bacterial 
cultures were inoculated 1:200 from an overnight culture (normalized for growth) into 
TSB, incubated at 37ºC, and aerated at 225 rpm with a flask-to-medium ratio of 10:1. 
Antibiotics were purchased from Fisher Scientific or Sigma Chemical and, when used, 
were used at the following concentration: E. coli ampicillin at 100 µg/ml; S. aureus, 
erythromycin at 8 or 10 µg/ml, chloramphenicol at 10-15 µg/ml, and tetracycline at 10 
µg/ml. 
 
Construction of S. aureus rpiR mutants. To inactivate rpiRA (orf SAV0317), a 2.559 kb 
fragment was PCR amplified using primers SAV0316-BamHI and SAV0318-SacI (Table 
2) and cloned into the SmaI site of pBluescript II K/S(+) (Stratagene) to generate the 
plasmid pYF-7. The ermB cassette of pEC4 was amplified using primers 
pEC4ErmBNdeIF and pEC4ErmBNdeIR (Table 2) and ligated into the NdeI site within 
rpiRA of pYF-7 to yield the plasmid pYF-8. The rpiRA::ermB fragment of pYF-8 was 
cloned into the BamHI and SacI sites of pTS1 to create the plasmid pYF-9. The 
temperature-sensitive plasmid pYF-9 was isolated from S. aureus strain RN4220 and 
introduced into strain UAMS-1 by electroporation. Transformed bacteria were used to 
construct the rpiRA mutant using the temperature shift method of Foster (Foster 1998).  
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 To inactivate rpiRB (orf SAV0193), the gene splicing by overlap extension 
(Horton, Ho et al. 1993) technique was used to replace a 741 bp internal region of rpiRB 
with the cat gene from plasmid pTS-1. For PCR, genomic DNA from S. aureus strain 
UAMS-1 was used as a template for the amplification of regions flanking rpiRB. PCR 
primers BamHI-SAV0192-f and cat-SAV0193-r (Table 2) were used for amplification of 
a 1.5 kb region upstream of rpiRB and a 1.5 kb region of the rpiRB downstream region 
was amplified using cat-SAV0193-f and SacI-SAV0195-r primers (Table 2). The cat gene 
was amplified from pTS-1 using primers SAV0193-cat-f and SAV0193-cat-r (Table 2). 
The resulting 3.9 kb PCR product consisted of an internal 816-bp cat gene with DNA 
flanking the rpiRB gene. The 3.9 kb PCR product contained BamHI and SacI sites that 
were used for ligation into pTS1-d digested with SacI and BamHI to generate pYM-4. 
Plasmid pYM-4 was used to construct an rpiRB mutant (UAMS-1-rpiRB::cat) using the 
referenced temperature shift method (Foster 1998).  
 Gene splicing by overlap extension was used to replace a 614 bp internal region of 
rpiRC (orf SAV2315) with the tetM gene from plasmid pJF-12 (Table 1). A 1.5 kb region 
upstream of rpiRC was amplified using primers BamHI-SAV2312-f and tetM-SAV2315-r 
(Table 2) and primers tetM-SAV2315-f and KpnI-SAV2316-r (Table 2) were used for 
amplification of a 1.6-kb downstream region. tetM was amplified from pJF-12 using 
primers SAV2315-tetM-f and SAV2315-tetM-r (Table 2). A 5.4 kb PCR product 
consisting of the 2.3 kb tetM gene and DNA flanking the rpiRC gene with BamHI and 
KpnI sites was inserted into pTS1-d digested with BamHI and KpnI to generate pYM-5. 
Plasmid pYM-5 was used to construct a strain UAMS-1 rpiRC mutant (UAMS-1-
rpiRC::tetM) using temperature shifts. To minimize the possibility that any phenotype(s) 
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were the result of random mutations occurring during temperature shifts, all resulting 
mutations were back-crossed into wild-type strain UAMS-1 using transducing phage Φ85 
(Foster 1998). All mutants were verified by PCR and Southern blot analysis (Fig. 1). 
Construction of the rpiR double mutants and the triple mutant were made using 
transducing phage Φ85. 
 
Construction of rpiR complementing plasmids. Plasmids pCL15 and pCL15-ermB 
(Table 1), containing a Pspac promoter, were used to construct the rpiRA, rpiRB and rpiRC 
complementation plasmids pYF-10, pYF-11 and pYF-12. The promoterless genes from S. 
aureus strain UAMS-1 were PCR amplified using the primers listed in Table 2 and 
ligated into plasmids pCL15 or pCL15-ermB. Plasmids were isolated from S. aureus 
strain RN4220 and electroporated into S. aureus strain UAMS-1-rpiRA, -rpiRB and -
rpiRC mutants. 
 
Northern blot analysis. To determine if inactivation of rpiR affected transcription of 
hexose monophosphate shunt genes, northern blot analysis was performed on ribose 5-
phosphate isomerase A (rpiA) and glucose-6-dehydrogenase (zwf, orf SAV1505). RNAIII 
transcript levels were also evaluated to determine the effect of rpiR inactivation on the 
agr system. Northern blots were performed as described (Sambrook and Russell 2001), 
except that total RNA was isolated using the FastRNA Pro Blue kit (Qbiogene) and 
purified using an RNeasy kit (Qiagen). Probes for Northern blotting were generated by 
PCR amplification of unique internal regions of RNAIII, rpiA, and zwf (Table 2) and 
labeled using the North2South random prime labeling kit (Pierce). Detection was 
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performed using the chemiluminescent nucleic acid detection module (Pierce).  
 
Glucose-6-dehydrogenase activity assay. To determine if rpiR inactivation affects 
hexose monophosphate shunt activity, glucose-6-dehydrogenase (G6PD) activity was 
measured as described (Bergmeyer, Bergmeyer et al. 1983). Protein concentrations were 
determined using a modified Lowry assay (Pierce Chemical). 
 
Western blot analysis. To determine if inactivation of rpiR affected protein A 
biosynthesis, protein A was collected as described (Vytvytska, Nagy et al. 2002) and 
western blot analysis was performed (Towbin, Staehelin et al. 1979).  
 
Hemolytic assay. The mRNA for δ-toxin is contained within RNAIII (Janzon and 
Arvidson 1990). To determine if inactivation of any rpiR homologue altered -toxin 
accumulation, a semi-quantitative microtiter plate assay was used as described 
(Fitzgerald, Hartigan et al. 2000). Briefly, horse red blood cells (RBCs; Colorado Serum 
Company) were washed three times in phosphate-buffered saline (PBS; pH 7.2) and 
suspended at 2% (v/v) in PBS. Bacteria were grown in TSB for 15 hours, centrifuged at 
for 16100 x g for 5 minutes, supernatants were collected, and 2-fold serial dilutions were 
made in PBS. Hemolytic assays were started by mixing 100 μL of freshly prepared 2% 
horse RBCs with 100 μL serial of the appropriate culture supernatant 2-fold serial 
dilutions. The microtiter plates were incubated at 37°C for 30 min followed by 12 h at 
4°C. After incubation, the supernatant fluids were collected and hemoglobin release was 
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measured at 595 nm. Each experiment was repeated three times and the mean and SEM 
were calculated. 
 
Polystyrene primary attachment assay. The primary attachment assay was performed 
as described by Lim et al. (Lim, Jana et al. 2004). Briefly, bacterial cultures (2 h post-
inoculation) were diluted into TSB to yield approximately 300 CFU. Bacteria were 
poured onto polystyrene Petri dishes (Fisher Scientific) and incubated at 37ºC for 30 min. 
Following incubation, the Petri dishes were rinsed three times with sterile PBS (pH 7.5) 
and covered with 15 ml of TSB containing 0.8% agar maintained at 48ºC. The percentage 
of bacteria attached to the polystyrene was defined as the number of CFU remaining in 
petri dishes after washing compared to the number of CFU in unwashed TSB plates. The 
experiment was repeated three times and the mean and SEM were calculated.  
 
Capsule immunoblot assay. To determine if rpiR inactivation altered capsule 
biosynthesis, capsule accumulation was quantified using immunoblots as described 
(Luong, Newell et al. 2003), except that immunoblots were developed using a 
chemiluminescent horseradish peroxidase (HRP) substrate (Millipore). For the capsule 
blots, bacteria (1.25 OD660 units) were harvested after overnight growth in tryptic soy 
broth at 37°C, with a flask-to-medium ratio of 20:1, and aerated at 225 rpm. 
  
PIA immunoblot assay. PIA accumulation was determined after 2, 4 and 6 h of growth 
as described (Zhu, Weiss et al. 2007). The data are presented as the percent difference in 
PIA accumulation relative that by strain UAMS-1 at 2 h. 
101 
 
 
Flow cell biofilm formation. S. aureus strains were grown in flow cell chambers (Stovall 
Life Science) as described (Zhu, Weiss et al. 2007). To assess bacterial growth, at 12 h 
post-inoculation and every 4 h thereafter, effluent samples were collected, the pH was 
measured, and the chamber was photographed.  
 
Proteomic Analyses. Bacterial cells (2 h and 6 h post-inoculation) were harvested by 
centrifugation and suspended in 1.0 ml of lysis buffer containing 50 mM ammonium 
bicarbonate and 1.5 mM phenylmethylsulfonyl fluoride (PMSF). The samples were 
homogenized for 40 seconds at speed 6.0 m/s in a FastPrep instrument (MP Biomedical). 
The lysate was centrifuged for 5 min at 20,800 x g at 4ºC. The protein extract was 
suspended, denatured, alkylated, and digested by Trypsin (Roche) at 37ºC. The tryptic 
peptides were then desalted using PepClean C-18 spin columns according to 
manufacturer’s instructions (Thermo scientific).  
Fully automated off-line two dimensional chromatographic experiments were 
performed with a ultimate 3000 Dionex MDLC system (Dionex Corporation) integrated 
with a nanospray source and LCQ Fleet Ion Trap mass spectrometer (Thermofinnigan). 
The first dimension LC separation (Strong Cation-exchange (SCX) chromatography) 
with fraction collection was performed followed by the second dimension LC separation 
(reverse phase chromatography) and detection by tandem mass spectrometry was carried 
out. The first dimensional separation was performed on a 15 cm x 300 µm I.D. SCX 
column (Polysulfoethyl, 1mm I.D x 15 cm, 5 µm, 300A Dionex). 50 µl of samples were 
loaded onto first dimension SCX column and eluted using a salt gradient (0-600 mM) of 
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45 minutes. The second dimension separation was included on-line sample pre-
concentration and desalting using a monolithic C 18 trap column (Pep Map, 300 um I.D, 
5 µm, 100A, 1mm monolithic C18 column). The loading of the sample on the monolithic 
trap column was conducted using the micro pump at a flow rate of 300 nl/min. The 
desalted peptides was then eluted and separated on a C 18 Pep Map, 75 um I.D X 15 cm, 
3 µm, 100A column applying an acetonitrile gradient (ACN plus 0.1% formic acid, 90 
minute gradient including 25 minutes reequlibriation at a flow rate of 300 nl/min) and 
introduced into the mass spectrometer using the nano spray source. The LCQ Fleet mass 
spectrometer was operated with the following parameters: nano spray voltage 2.0 kV, 
heated capillary temperature 200°C, full scan m/z range 400-2000. The LCQ was 
operated in data dependent mode with 4 ms/ms spectra for every full scan, 5 micros can 
averaged for full scans and ms/ms scans, 3 m/z isolation width for ms/ms isolations and 
35% collision energy for collision induced dissociation. Dynamic exclusion was enabled 
with exclusion duration of 1 min.  
The MS/MS spectra were searched against S. aureus MRSA252 databases using 
MASCOT (Version 2.2 Matrix Science). Database search criteria were as follows: 
enzyme: Trypsin, Missed Cleavages: 2; mass: monoisotropic; fixed modification: 
carbamidomethyl (C); peptide tolerance: 2Da; MS/MS fragment ion tolerance: 1Da. 
Probability assessment of peptide assignments and protein identifications were 
accomplished by Scaffold (version Scaffold 3.0 Proteome Software Inc.). Only peptides 
with ≥95% probability were considered. Criteria for protein identification included 
detection of at least 2 unique identified peptides and a protein probability score of ≥95%.  
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Hydrogen peroxide susceptibility assay. To determine if the rpiR inactivation affects 
hydrogen peroxide susceptibility, S. aureus strains UAMS-1, UAMS-1-rpiRC and 
UAMS-1-rpiRABC were grown in TSB for 15 h and diluted to an optical density at 
600nm (OD600) of 0.05 into sterile medium containing increasing concentrations of 
hydrogen peroxide (Fisher Scientific). . Cultures were grown at 37°C with shaking (225 
rpm) for 4 h. Bacterial densities were determined by measuring the OD600. 
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Results 
 
Characterization of rpiR mutants. Bioinformatic analysis of the Mu50 genome (Kuroda, 
Ohta et al. 2001) revealed the presence of three RpiR homologues; specifically, SAV0317, 
SAV0193 and SAV2315. For simplicity, these homologues were designated RpiRA 
(SAV0317), RpiRB (SAV0193), and RpiRC (SAV2315). To assess the effects of 
inactivating the rpiR homologue genes on growth, growth studies were performed and the 
optical densities and pH of the culture media were measured (Fig. 2A). Inactivation of 
any single rpiR homologue in UAMS-1 did not alter the growth rate, growth yield, or the 
pH profile of the culture medium (Fig. 2A). Similarly, the double mutants and the triple 
mutant had the growth rates and growth yields equivalent to the wild-type strain UAMS-
1 (Fig.2B). Interestingly, the pH profile of the culture medium for the triple mutant had 
an increased rate of alkalization relative to the wild-type strain, suggesting it had an 
increased rate of acetic acid utilization (Fig.2B). These results demonstrate the growth of 
the rpiR mutants is equivalent to that of the isogenic wild-type strain.  
 
RpiR homologues regulate hexose monophosphate shunt activity. As stated, RpiR was 
first identified in E. coli as a repressor of the hexose monophosphate shunt gene rpiB 
(Sorensen and Hove-Jensen 1996). Similarly, the Pseudomonas putida RpiR homologue, 
HexR, regulates zwf which encodes G6PD, the rate-controlling enzyme of the hexose 
monophosphate shunt (Daddaoua, Krell et al. 2009). These data led us to hypothesize that 
one, or more, of the RpiR homologues in S. aureus would regulate transcription of hexose 
monophosphate shunt genes. To test this hypothesis, transcription of the hexose 
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monophosphate shunt genes rpiA (ribose-5-phosphate isomerase A) and zwf (sav1505; 
codes for G6PD) in the rpiR mutant strains was assessed by northern blot (Fig. 3A and 
3C). In addition, the enzymatic activity of G6PD was measured in the UAMS-1 rpiR 
mutant strains and strain UAMS-1. As expected, inactivation of rpiRB and rpiRC 
decreased transcription of both rpiA and zwf relative to the parental strain UAMS-1; 
however, rpiRA inactivation had only a minor effect on rpiA and zwf mRNA levels (Fig. 
3A). Complementation of the UAMS-1 rpiRB and rpiRC mutants, increased levels of 
rpiA mRNA (Fig. 3C), confirming the transcriptional changes are due to the inactivation 
of the correct rpiR genes. Surprisingly, inactivation of rpiRA in either an rpiRB or rpiRC 
mutant strain increased the transcription or stability of rpiA and zwf mRNA to wild-type 
levels (Fig. 3A), suggesting an antagonistic effect between RpiRA and both RpiRB and 
RpiRC. Because zwf mRNA migrates on an agarose gel near ribosomal RNA and to 
confirm the northern blot data, the activity of G6PD was assessed in the wild-type and 
rpiR mutant strains (Fig. 3B). Consistent with the northern blot data, mutation of rpiRB 
or rpiRC leads to decreased exponential growth phase (2 h) G6PD enzymatic activity 
(Fig. 3B) relative to the wild-type strain UAMS-1. Also consistent with the northern blot 
data is the antagonist effect of RpiRA on G6PD activity in both rpiRB and rpiRC mutant 
backgrounds. In contrast, only rpiRB inactivation significantly decreased G6PD 
enzymatic activity during the post-exponential growth phase (8 h) relative to the wild-
type strain (Fig 3B). Overall, these data demonstrated that S. aureus RpiR homologues 
RpiRB and RpiRC have a positive regulatory function in the hexose monophosphate 
shunt regulation and that RpiRA is antagonistic to this regulatory function. 
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Inactivation of rpiRC delays biofilm development and decreases the synthesis of cell 
wall-associated virulence determinants. NMR metabolomic data indicated the 
intracellular concentration of ribose varied in response to stressors that induce biofilm 
formation and PIA accumulation in S. epidermidis (Sadykov et al., unpublished data). 
Because the RpiR homologues have been reported to respond to hexose monophosphate 
shunt intermediates in other bacteria (Daddaoua, Krell et al. 2009), we wanted assess the 
effects of rpiR inactivation on PIA accumulation and biofilm formation (Fig. 4). 
Inactivation of any rpiR homologue resulted in minimal or no change in the accumulation 
of PIA (Fig. 4A and 4B). In S. aureus, biofilms can form in the absence of PIA 
biosynthesis (Boles, Thoendel et al. 2010); therefore, the lack of any significant effect of 
rpiR inactivation on PIA accumulation did not preclude the possibility that one or more of 
the RpiR homologues would affect biofilm formation. Inactivation of rpiRC delayed 
biofilm maturation; however, the gross morphology of the biofilms formed by the wild-
type and rpiRC mutant strains was similar after 24 h of growth (Fig. 4C). The delay in 
biofilm maturation and the absence of any attenuation of PIA accumulation was 
consistent with a PIA-independent biofilm being formed. PIA-independent biofilms 
frequently involve protein adhesins such as protein A (Merino, Toledo-Arana et al. 2009). 
To determine if inactivation of rpiRC decreased adhesin synthesis, polystyrene 
attachment assays were performed on the wild-type and rpiR mutant strains (Fig. 4D). 
Consistent with delay in biofilm formation, strains containing a mutation in rpiRC had a 
significantly decreased (p < 0.01) ability to attach to polystyrene relative to the parental 
strain (Fig. 4D). Taken together, these data suggest the synthesis of cell wall-associated 
adhesins was decreased by rpiRC inactivation.  
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The association of protein A with PIA-independent biofilm formation and the 
decreased ability of rpiR mutant strains to adhere to polystyrene, suggest that cell-
associated adhesin synthesis is impaired by inactivation of one or more RpiR homologues. 
Protein A is primarily synthesized during the exponential growth phase and it is 
considered representative of cell wall-associated protein synthesis. To determine if rpiR 
inactivation altered the exponential growth phase expression of protein A and potentially 
other cell wall-associated proteins, the exponential growth phase accumulation of protein 
A was assessed by western blotting. Mutations in either rpiRA or rpiRB did not affect the 
accumulation of protein A; however, inactivation of rpiRC completely inhibited the 
exponential growth phase accumulation of protein A (Fig. 4E). Interestingly, rpiRA 
inactivation did not antagonize the expression of protein A in the rpiRC mutant 
background, suggesting the antagonistic effects of RpiRA are confined to regulation of 
the hexose monophosphate shunt. In total, these data suggest that RpiRC acts as a 
regulatory bridge between the hexose monophosphate shunt and virulence factor 
synthesis in S. aureus.  
 
RpiRC represses RNAIII transcription or message stability. RNAIII is the effector 
RNA of the agr quorum sensing system and a negative regulator of protein A (spa) 
(Novick and Geisinger 2008). Mutation of rpiRC eliminated the exponential growth 
phase accumulation of protein A (Fig. 4E); raising the possibility that RNAIII 
transcription or stability was increased. To determine if rpiR inactivation affected RNAIII 
levels, northern blot analysis of RNAIII was performed on all rpiR mutant strains 
throughout a 12 hour growth cycle (Fig. 5A and Fig. 5B). As expected, rpiRC inactivation 
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increased the RNAIII transcript level relative to the parental strain during the exponential 
growth phase (2 hour) (Fig. 5A). Complementation of the rpiRC mutation with pYF12 
decreased the level of RNAIII relative to the rpiRC mutant strain, confirming the 
increased RNAIII level was due to rpiRC inactivation (Fig. 5C). Consistent with the 
protein A western blot and the attachment assays (Fig. 4E and 4D), we did not observe an 
antagonistic effect of rpiRA inactivation on the exponential growth phase (2 h) 
transcription or stability of RNAIII in either an rpiRB or rpiRC mutant background (Fig. 
5A). Although RNAIII levels were largely independent of RpiRA or RpiRB in the 
exponential growth phase, rpiRB inactivation increased the post-exponential growth 
phase RNAIII transcript levels (Fig 5B). RNAIII is both a riboregulator and the coding 
sequence for δ-toxin (Janzon and Arvidson 1990); therefore, if RNAIII levels are 
increased, then it is likely that -toxin synthesis is increased. Using a hemolytic titer 
assay, the increased RNAIII levels correlated with an increase in hemolysis activity due 
to -toxin (Fig. 6A). In total, these data indicate that RpiRC represses RNAIII 
transcription during the exponential growth phase, while RpiRB represses RNAIII 
transcription during the post-exponential growth phase.  
 
Inactivation of rpiRC dramatically increases capsule accumulation. RNAIII is a 
positive regulator of capsule gene (cap) transcription (Dassy, Hogan et al. 1993; 
Pohlmann-Dietze, Ulrich et al. 2000; Luong, Sau et al. 2002); thus, an increase in RNAIII 
levels should correlate with an increase in capsule biosynthesis. To determine if rpiR 
inactivation effects capsule biosynthesis, capsule accumulation was assessed using a 
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capsule immunoblot. Consistent with the increased RNAIII levels, inactivation of all 
three rpiR genes increased capsule accumulation (Fig. 6B); however, it was most 
apparent in strains having a mutation in rpiRC. These data strongly suggest that the 
RpiR-dependent de-repression of RNAIII facilitates virulence determinant expression and 
that the RpiR proteins act as a bridge between the hexose monophosphate shunt and 
virulence factor synthesis.  
 
Inactivation of rpiRC alters the proteome. To identify changes in cytosolic protein 
content in strain UAMS-1 and the rpiRC mutant strains, cell-free lysates were prepared 
from strains UAMS-1, UAMS-1-rpiRC, and UAMS-1-rpiRABC grown to the exponential 
and post-exponential growth phases and analyzed using LC-MS (Appendix A and B). 
Although rpiRC inactivation resulted in numerous proteomic changes, we were 
specifically interested in changes to hexose monophosphate shunt enzymes and proteins 
that might clarify the increased RNAIII transcript levels. Proteomic analysis identified 
the hexose monophosphate shunt enzymes transaldolase and ribose-phosphate 
pyrophosphokinase as being present at lower concentrations in strains UAMS-1-rpiRC 
and UAMS-1-rpiRABC than in strain UAMS-1, consistent with RpiRC regulating the 
hexose monophosphate shunt. In addition, proteomic analysis suggested there was an 
increase in proteins associated with B; specifically, inactivation of rpiRC increased the 
concentrations of the alkaline shock protein A (Asp23) and RsbU (gi|49242422) 
(Appendix A and B). Because transcription of asp23 is exclusively controlled by σB, 
Asp23 is used as an indicator of σB activity (Kullik, Giachino et al. 1998; Miyazaki, Chen 
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et al. 1999). RsbU is a phosphatase that de-phosphorylates (activates) the anti-anti-sigma 
factor RsbV, which then binds the anti-sigma factor RsbW in a competitive manner to 
increase the concentration of free B (Giachino, Engelmann et al. 2001). In addition to 
regulating transcription of asp23, B regulates transcription of sarA from the sar P3 
promoter (Miyazaki, Chen et al. 1999). SarA is an activator of agrACDB and RNAIII 
(Cheung, Bayer et al. 1997) and rpiRC inactivation increased RNAIII mRNA levels 
relative to the wild-type strain (Fig. 5), suggesting that rpiRC inactivation might increase 
the availability of SarA. Consistent with this suggestion, rpiRC inactivation increased the 
cytosolic concentration of SarA during both the exponential and post-exponential growth 
phases (Appendix A and B). Although not conclusive, these data strongly suggest the 
increased RNAIII levels in rpiRC mutants are due to an increased availability of B, 
which increases sarA transcription and translation, increasing agr and RNAIII 
transcription.   
 
Inactivation of rpiRC decreases peroxide susceptibility. In some strains of S. aureus, 
B has been implicated in the susceptibility to peroxide (Kullik, Giachino et al. 1998; 
Giachino, Engelmann et al. 2001). This observation and the fact that strain UAMS-1-
rpirC had increased ferritin and catalase levels relative to strain UAMS-1, led us to assess 
the susceptibility of strains UAMS-1, UAMS-1-rpiRC, and UAMS-1-rpiRABC to 
peroxide stress (Fig. 7).  As expected, inactivation of rpiRC significantly decreased the 
susceptibility of strain UAMS-1-rpiRC and UAMS-1-rpiRABC to hydrogen peroxide 
relative to strain UAMS-1 (Fig. 7).Taken together, these data demonstrate that the S. 
111 
 
aureus RpiR family of proteins creates a bridge between the hexose monophosphate 
shunt and virulence determinant regulation. 
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Discussion 
 
Three central metabolic pathways (i.e., glycolysis, the hexose monophosphate 
shunt, and the TCA cycle) provide the thirteen biosynthetic intermediates needed to 
synthesize all macromolecules produced in bacteria. By default, virulence determinants 
are synthesized from the thirteen biosynthetic intermediates of central metabolism; hence, 
virulence determinant synthesis is dependent on the endogenous or exogenous 
availability of these intermediates or by-products of these intermediates. Because of the 
importance of these intermediates, bacteria have evolved metabolite responsive regulators 
(e.g., CcpA, CodY) that “sense” the availability of these intermediates or compounds 
derived from them (Somerville and Proctor 2009). These metabolite-responsive 
regulators not only function to maintain metabolic homeostasis but many also regulate 
virulence determinant synthesis (Somerville and Proctor 2009). Although metabolite 
responsive regulators have been identified in S. aureus that respond to changes in 
glycolytic and TCA cycle intermediates or derivatives, none have been identified that 
respond to changes in hexose monophosphate shunt intermediates. To that end, three 
RpiR family members, RpiRA, RpiRB and RpiRC were identified and inactivated in S. 
aureus strain UAMS-1 and the phenotypic changes associated with each RpiR 
homologue were characterized. 
 
Hexose monophosphate shunt regulation. RpiRB and RpiRC positively regulate the 
exponential growth phase transcription of the hexose monophosphate shunt genes rpiA 
and zwf (Fig 3A). In addition, RpiRC positively affects expression of transaldolase and 
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ribose-phosphate pyrophosphokinase (Appendix A and B). Although RpiRB and RpiRC 
are paralogs, there appears to be minimal overlap in function of the two regulatory 
proteins as inactivation of either rpiRB or rpiRC decreases transcription of rpiA and zwf 
to the same extent (Fig. 3A). In other words, RpiRB does not compensate for the loss of 
RpiRC and RpiRC does not compensate for the loss of RpiRB. Interestingly, RpiRA has 
only a slight effect on rpiA and zwf transcription; however, it does antagonize the 
regulatory effects of both RpiRB and RpiRC (Fig. 3A). In double mutants, inactivation of 
rpiRA restores transcription of rpiA and to a lesser extent zwf to near wild-type levels. 
Interestingly, this antagonism only involves RpiRB- and RpiRC-dependent regulation of 
rpiA and zwf but not the RpiRC-dependent regulation of RNAIII (Fig. 5A and 5B). Taken 
together, these data confirm the S. aureus RpiR homologues regulate the hexose 
monophosphate shunt.  
 
RNAIII regulation. Synthesis of RNAIII is under the control of the agr cell-density 
sensing system (Novick, Ross et al. 1993); hence, transcription of RNAIII usually begins 
late in the exponential phase of growth (4 h) (Fig. 5A). The growth rates and growth 
yields of the UAMS-1 rpirA, rpiRB, and rpiRC mutant strains are equivalent to the 
parental strain (Fig. 2A); thus, it was surprising to find that transcription of RNAIII was 
de-repressed during the early exponential growth phase (2 h) in strain UAMS-1-rpiRC 
(Fig. 5A) relative to strain UAMS-1. This RpiRC-dependent de-repression persists into 
the post-exponential (4-6 h) but declines thereafter (Fig. 5A). The more likely 
explanations for the RpiRC-dependent de-repression of RNAIII transcription are either an 
increase in expression of the agr cell-density sensing system or an agr-independent 
114 
 
increase in RNAIII transcription. Proteomic analysis of the cytosolic fractions of strains 
UAMS-1, UAMS-1-rpiRC, and UAMS-1-rpiRABC (Appendix A and B) demonstrated 
that inactivation of rpiRC increased the intracellular concentration of SarA during the 
exponential (2 h) and post-exponential (6 h) growth phases relative to the parental strain 
UAMS-1. The increased level of SarA is likely mediated by an increase in free B due to 
over-expression of RsbU phosphatase activity (Appendix A and B). Consistent with an 
increase in free B, proteomic analysis revealed that rpiRC inactivation resulted in an 
increase in the accumulation of the B-regulated alkaline shock protein A.  These data 
suggest the increased level of RNAIII in strains lacking RpiRC is due to an increase in 
SarA-mediated transcription of RNAIII. Further, these data confirm a direct linkage 
between central metabolism (i.e., the hexose monophosphate shunt) and three major 
virulence regulators (SarA, B, and RNAIII) in S. aureus. Finally, these data demonstrate 
that metabolite-responsive regulators can override the normal temporal pattern of 
virulence determinant synthesis by altering the cell-density sensing system.  
  
Conclusions. Dr. Richard Novick postulated in a “black-box” model (Novick 2003) that 
an “energy signal” derived from intermediary metabolism would, in an unknown (i.e., 
“black-box”) fashion, regulate the transcription of the agr cell-density sensing system. 
Since the introduction of the “black-box” model, several regulators (e.g., CcpA and CodY) 
have been identified that link metabolism to the regulation of virulence determinants 
(reviewed in (Somerville and Proctor 2009)). In the present study, it was observed that 
RNAIII synthesis is co-regulated with central metabolism, specifically the hexose 
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monophosphate shunt, through the action of three RpiR family regulators. Although the 
“black-box” model is largely accurate, based on data presented here and from other 
studies (Seidl, Stucki et al. 2006; Majerczyk, Sadykov et al. 2008; Majerczyk, Dunman et 
al. 2010), the “energy signal” responsible for regulating the transcription of agr is more 
than likely a “carbon signal”.  
In Pseudomonas putida, the DNA binding activity of the RpiR homologue, HexR, 
is modulated by the Entner-Doudoroff pathway intermediate 2-keto-3-deoxy-6-
phosphogluconate (Daddaoua, Krell et al. 2009). All three S. aureus RpiR homologues 
have sugar isomerase binding domains, suggesting their regulatory activity may be 
controlled by intermediates of the hexose monophosphate shunt. Collaborative studies are 
underway to identify the metabolites to which the RpiR homologues bind; hopefully, this 
information will fill in one of the “black-boxes” in S. aureus virulence factor regulation.  
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Fig.1. Southern blots demonstrating the inactivation of rpiRA, rpiRB and rpiRC in strain 
UAMS-1 by the insertion of antibiotic cassettes ermB, cat, and tetM respectively.  
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Fig.2. Growth curves (A) and culture medium pH profiles (B) for strains UAMS-1, 
UAMS-1-rpiRA, UAMS-1-rpiRB, UAMS-1-rpiRC mutants under aerobic growth 
conditions.  
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Fig. 3. Inactivation of rpiR homologues alters hexose monophosphate shunt activity. (A) 
Northern blot demonstrating that inactivation of rpiRB or rpiRC decreases transcription 
of ribose phosphate isomerase A (rpiA) and G6PD (zwf). Ethidium bromide staining of 
23S and 16S rRNA is shown to demonstrate equivalent loading of total RNA. (B) 
Glucose-6-phosphate dehydrogenase activity of strain UAMS-1 and rpiR mutants. Data 
are presented as the means and SEM of two independent experiments each determined in 
triplicate. **, P<0.01; *, P<0.05. (C) Northern blot demonstrating that complementation 
of rpiRB and rpiRC increase transcription of rpiA.  
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Fig.4. Inactivation of rpiR homologues alters the expression of virulence factors and 
delays biofilm formation. (A) Representative PIA immunoblot for strains UAMS-1, 
UAMS-1-rpiRA, UAMS-1-rpiRB, UAMS-1-rpiRC mutant. (B) Relative PIA 
accumulation by strains UAMS-1, UAMS-1-rpiRA, UAMS-1-rpiRB, UAMS-1-rpiRC 
mutant during the transition from exponential to post-exponential growth. The data are 
presented as the differences in PIA accumulation relative to PIA accumulation by UAMS-
1 at 2h. The results are the means and SEM of three independent cultures. (C) Growth of 
S. aureus strain UAMS-1, UAMS-1-rpiRA, UAMS-1-rpiRB, UAMS-1-rpiRC and 
UAMS-1-rpiRABC in a three-chamber flow cell. Bacterial strains were grown at 37°C 
with a continuous flow (0.5ml per minute per chamber) of TSB containing 0.5% glucose 
and 3% NaCl. The results are representative of three independent experiments. (D) 
Adhesion of S. aureus cells to polystyrene. **, P<0.01; *, P<0.05. (E) Protein A Western 
blot. The blot is representative of three independent experiments. 
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FIG. 5. RNAIII Northern blots. (A) Inactivation of rpiRC increases transcription or 
stability of RNAIII relative to that in strain UAMS-1 at early exponential phase (2h and 
4h). Double mutant of rpiRB and rpiRC have synergistic effect. (B) Deletion of rpiRB 
increases transcription or stability of RNAIII at post-exponential phase. The bottom panel 
is a photograph of an ethidium bromide-stained agarose gel demonstrating equivalent 
loading of total RNA. (C) Complementation of rpiRC results in decreased transcription of 
RNAIII.  
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FIG.6 Inactivation of rpiR homologues alters hemolytic activity and capsule biosynthesis. 
(A) Hemolytic activity of strain UAMS-1 and rpiR mutants. All above data represent the 
means and standard errors of the means of three independent experiments. (B) Capsule 
polysaccharide Immunoblot. The blot is representative of three independent experiments.  
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FIG.7 Susceptibility of S. aureus strains to hydrogen peroxide. Data are presented as the 
means and standard errors of the means (SEM) of three independent experiments. **, 
P<0.01; *, P<0.05 (versus the UAMS-1 parental strain). 
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Table 1. Strains and plasmids used in this study. 
Plasmid or strain Relevant genotype and/or characteristic(s) 
Source or 
Reference 
pBluescript II 
KS(+) 
E. coli phagemid cloning vector Stratagene 
pTS1 S. aureus - E. coli temperature-sensitive shuttle vector; AmprCamr 
(Greene, 
McDevitt et al. 
1995) 
pTS1-d Derivative of pTS1 with depletion of plasmid-encoded 3’ region of ermC 
(Sadykov, Olson 
et al. 2008) 
pEC4 pBluescript II KS(+) with ermB inserted into ClaI site (Bruckner 1997) 
pJF12 Plasmid pCR2.1 containing tetM; AmprMinr 
J. Finan and G. 
Archer 
pYF-7 pBluescript II KS(+) containing a portion of SAV0317 This study 
pYF-8 
pYF-7 containing the ermB cassette of pEC4 inserted into the NdeI site of 
SAV0317 
This study 
pYF-9 
SAV0317::ermB PCR fragment of pYF-8 inserted into the BamHI and 
SacI sites of pTS-1 
This study 
pYM-4 Derivative of pTS-1 with SAV0193::cat fragment This study  
pYM-5 Derivative of pTS-1 with SAV2315::tetM fragment This study 
pCL15 Expression vector; derivative of pSI-1; Camr Chia Lee 
pCL15-ermB Replacement of cat with ermB in expression plasmid pCL15; Ermr This study 
pYF-10 pCL15 with SAV0317 gene under the control of the Pspac promoter; Cam
r This study 
pYF-11 
pCL15-ermB with SAV0193 gene under the control of the Pspac promoter; 
Ermr 
This study 
pYF-12 pCL15 with SAV2315 gene under the control of the Pspac promoter; Cam
r This study 
RN4220 Restriction-negative S. aureus (Novick 1991) 
DH5α E. coli cloning host Invitrogen 
UAMS-1 S. aureus clinical isolate 
Mark Smeltzer 
strain collection 
UAMS-1-rpiRA SAV0317 insertion mutant of UAMS-1; Ermr This study 
UAMS-1-rpiRB SAV0193 deletion mutant of UAMS-1; Camr This study 
UAMS-1-rpiRC SAV2315 deletion mutant of UAMS-1; Minr This study 
UAMS-1-rpiRAB SAV0317, SAV0193 double mutant of UAMS-1; Ermr Camr This study 
UAMS-1-rpiRAC SAV0317, SAV2315 double mutant of UAMS-1; Ermr Minr This study 
UAMS-1-rpiRBC SAV0193, SAV2315 double mutant of UAMS-1; Camr Minr This study 
UAMS-1-rpiRABC 
SAV0317, SAV0193, SAV2315 triple mutant of UAMS-1; Ermr Camr 
Minr 
This study 
a Ampr, ampicillin resistant; Camr, chloramphenicol resistant; Ermr, erythromycin resistant; Minr, minocycline resistant. 
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Table 2. Primers used in this study. 
 
Primer 
target 
Primer designation Nucleotide sequence (5′ - 3′) PCR product use 
SAV0317 SAV0316-BamHI GCTGGATCCCGACTGAACAATGAACGCCTAAGTC  PCR cloning 
SAV0317 SAV0318-SacI CCTGAGCTCATCAACGCCGGACAACAAAAGTG  PCR cloning 
ermB pEC4ErmBNdeI-f GCGCATATGCGTTAGATTAATTCCTACCAGTGAC  PCR cloning 
ermB pEC4ErmBNdeI-r GCGCATATGCTCATAGAATTATTTCCTCCCG  PCR cloning 
SAV0193 BamHI-SAV0192-f CCAGGATCCAGAACGAATTATTGCTGCAGTAGG  PCR cloning 
SAV0193 cat-SAV0193-r 
CCACTTTATCCAATTTTCGTTTGTTGTTCACCGTCATATCAA
TGATTTTATGTGG 
 PCR cloning 
 cat SAV0193-cat-f 
CCACATAAAATCATTGATATGACGGTGAACAACAAACGAA
AATTGGATAAAGTGGG 
 PCR cloning 
 cat SAV0193-cat-r 
GCAAGATGCTTCCGGTAATTATCAAGCGACTGTAAAAAGTA
CAGTCGGC 
 PCR cloning 
SAV0193 cat-SAV0193-f 
GCCGACTGTACTTTTTACAGTCGCTTGATAATTACCGGAAG 
CATCTTGC 
 PCR cloning 
SAV0193 SacI-SAV0195-r GCAGAGCTCGTTGAATAAGTGCTTCTACCGCATAC  PCR cloning 
SAV2315 BamHI-SAV2312-f CCAGGATCCGATTCCTAAACTATGGAGTCGATGGG  PCR cloning 
SAV2315 tetM-SAV2315-r 
CGTAAGAGCATATTTGTAAAGGAATCTCCGAGACCTCATTT
TAATCACCTTTTGAGG 
 PCR cloning 
 
tetM SAV2315-tetM-f 
CCTCAAAAGGTGATTAAAATGAGGTCTCGGAGATTCCTTTA
CAAATATGCTCTTACG 
 PCR cloning 
tetM SAV2315-tetM-r 
GAAGTTGTTGCTCCCATATGCATCCGATCTCCTCCTTTCCAC
TTTAATTC 
 PCR cloning 
SAV2315 tetM-SAV2315-f 
GAATTAAAGTGGAAAGGAGGAGATCGGATGCATATGGGAGCAACAA
CTTC 
 PCR cloning 
SAV2315 KpnI-SAV2316-r GAAGGTACCAATGGATTGTAGTTGGTATGAGTGAG  PCR cloning 
RNAIII SARNAIII-f GAAGGAGTGATTTCAATGGCACAAG  Northern blot 
RNAIII SARNAIII-r GGCTCACGACCATACTTATTATTAAGGG  Northern blot 
rpiA rpiaf GTGACATGACGCTGGGAATTGG  Northern blot 
rpiA rpiar GTATCCTGTCTCAAACACACCTGTCAG  Northern blot 
SAV1505 SAV1505f GCACCACAATTCTTTGGCGTTATTTC  Northern blot 
SAV1505 SAV1505r AGTACGAATATAGAATGGTACACCAGCC  Northern blot 
SAV0317 BamHI-SD-rpiR-f CAAGGATCCATTAAGATGAAGGGGTGACACAATG Complementation 
SAV0317 SacI-rpiR-r CAAGAGCTCAATCACGATGATTGTCTACAGTTGC Complementation 
SAV0193 BamHI-SAV0193-f 
CTAGGATCCATGACAAATATTTTATATCGCATTGATAAACAG
TTGAG 
Complementation 
SAV0193 SAV0193-r CAAACAACTGAATCACATCAAAAACTTCAATTG Complementation 
SAV2315 BamHI-SAV2315-f 
CTAGGATCCATGTCAAACGTACTAACAGAAATAGATAGTCA
ATATCC 
Complementation 
SAV2315 SAV2315-r GCGTATGTTATACAAGATAAAAGACATGTAAGCTTTG Complementation 
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Appendix A: 2h post-inoculation proteomic analyses 
 Identified Proteins Accession 
Number 
UAMS-1 
(Spectral 
count) 
UAMS-1 
-rpiRC 
(Spectral 
count) 
UAMS-
1 -rpiRC 
(ratio) 
UAMS-1 
-rpiRABC 
(Spectral 
count) 
UAMS-1 
-rpiRABC 
(ratio) 
1 translation elongation factor Tu  gi|49240907 153 502 3.3 581 3.8 
2 dihydrolipoamide succinyltransferase E2 component of 
2-oxoglutarate dehydrogenase complex  
gi|49241731 648 218 0.3 202 0.3 
3 very large surface anchored protein  gi|49241754 37 11 0.3 10 0.3 
4 glyceraldehyde 3-phosphate dehydrogenase 1  gi|49241159 4 126 28.7 130 29.8 
5 putative arginyl-tRNA synthetase  gi|49240966 31 12 0.4 13 0.4 
6 alkaline shock protein 23  gi|49242531 26 55 2.1 108 4.1 
7 50S ribosomal protein L7/L12  gi|49240899 28 84 3.0 77 2.7 
8 chaperone protein  gi|49241957 9 57 6.5 55 6.3 
9 putative bifunctional purine biosynthesis protein  gi|49241366 1 1 1.0 1 1.4 
10 putative membrane protein  gi|49242107 77 19 0.2 17 0.2 
11 putative PTS multidomain regulator  gi|49240693 7 3 0.4 1 0.2 
12 putative lipoprotein  gi|49240817 9 10 1.1 8 0.9 
13 putative surface anchored protein  gi|49242132 4 4 1.0 1 0.2 
14 putative helicase  gi|49242827 1 5 5.2 1 1.0 
15 nitrate reductase alpha chain  gi|49242742 15 4 0.3 4 0.3 
16 putative exodeoxyribonuclease VII large subunit  gi|49241902 1 1 1.0 1 1.4 
17 conserved hypothetical protein  gi|49242216 24 36 1.5 52 2.2 
18 putative enolase  gi|49241163 11 40 3.6 41 3.7 
19 glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing]  
gi|49242505 1 2 1.7 4 3.6 
20 translation elongation factor G  gi|49240906 2 46 21.0 40 18.1 
21 elongation factor Ts  gi|49241549 1 44 44.2 37 36.7 
22 hypothetical phage protein  gi|49241813 7 3 0.4 1 0.2 
23 DNA-directed RNA polymerase beta chain protein  gi|49240901 2 15 6.7 9 4.3 
B 
 
24 putative membrane protein  gi|49241927 2 19 8.7 12 5.6 
25 putative exonuclease  gi|49241667 9 1 0.1 2 0.2 
26 conserved hypothetical protein  gi|49241201 15 41 2.7 32 2.1 
27 30S ribosomal protein S2  gi|49241548 2 32 14.6 38 17.4 
28 putative 3-dehydroquinate synthase  gi|49241783 39 14 0.4 8 0.2 
29 50S ribosomal protein L21  gi|49242020 4 28 6.3 34 7.7 
30 pyruvate kinase  gi|49242068 1 24 24.2 30 29.5 
31 hypothetical phage protein  gi|49242324 1 3 3.5 4 4.3 
32 glutamyl-tRNA amidotransferase subunit B  gi|49242269 1 3 3.5 1 1.4 
33 triosephosphate isomerase  gi|49241161 13 28 2.1 33 2.5 
34 conserved hypothetical protein  gi|49241727 7 2 0.3 1 0.2 
35 DNA-binding protein HU  gi|49241789 7 29 4.3 32 4.8 
36 thioredoxin  gi|49241437 13 23 1.7 36 2.7 
37 putative lipoprotein  gi|49241909 2 2 0.8 2 1.0 
38 glutamate synthase, large subunit  gi|49240825 2 1 0.5 1 0.7 
39 topoisomerase IV subunit A  gi|49241677 1 2 1.7 1 1.4 
40 collagen adhesin precursor  gi|49243016 4 1 0.2 1 0.2 
41 putative stress response-related Clp ATPase  gi|49240883 2 3 1.2 1 0.7 
42 50S ribosomal protein L11  gi|49240896 7 24 3.7 19 2.9 
43 putative peptidase  gi|49242127 4 1 0.2 1 0.3 
44 putative membrane protein  gi|49240437 7 2 0.3 3 0.4 
45 putative glycosyl transferase  gi|49240623 1 1 1.0 1 1.4 
46 putative rod shape-determining protein  gi|49242022 2 3 1.6 5 2.3 
47 putative pyruvate dehydrogenase E1 component, beta 
subunit  
gi|49241386 2 20 9.1 22 9.9 
48 putative membrane protein  gi|49240649 4 2 0.4 1 0.2 
49 putative GMP synthase  gi|49240771 1 2 1.7 3 2.9 
50 preprotein translocase SecA subunit  gi|49241139 1 3 3.5 5 5.0 
51 alkyl hydroperoxide reductase subunit C  gi|49240760 1 16 16.5 23 23.1 
C 
 
52 isoleucyl-tRNA synthetase  gi|49241485 9 4 0.5 5 0.6 
53 dihydrolipoamide dehydrogenase  gi|49241388 1 17 17.3 19 18.7 
54 conserved hypothetical protein  gi|49241469 2 1 0.5 1 0.7 
55 putative membrane protein  gi|49242969 4 4 1.0 3 0.7 
56 trigger factor (prolyl isomerase)  gi|49242047 2 22 9.9 16 7.2 
57 putative UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
gi|49242477 9 3 0.3 4 0.4 
58 putative thiamine biosynthesis protein  gi|49242085 1 2 1.7 1 1.0 
59 DNA-directed RNA polymerase beta' chain protein  gi|49240902 4 3 0.6 2 0.5 
60 maltose operon transcriptional repressor  gi|49241887 1 5 5.2 9 8.6 
61 50S ribosomal protein L29  gi|49242587 1 23 23.4 19 18.7 
62 60 kDa chaperonin  gi|49242384 1 8 7.8 9 9.4 
63 immunodominant antigen A  gi|49242897 1 16 15.6 17 17.3 
64 putative 50S ribosomal protein L25  gi|49240857 1 19 19.1 16 15.8 
65 bifunctional autolysin precursor  gi|49241346 4 4 1.0 5 1.2 
66 acetate kinase  gi|49242081 1 4 4.3 2 2.2 
67 putative ATP-dependent DNA helicase  gi|49241106 2 3 1.2 1 0.7 
68 putative exported protein  gi|49242128 31 12 0.4 6 0.2 
69 30S ribosomal protein S13  gi|49242571 2 9 4.0 9 4.3 
70 cold shock protein  gi|49243029 24 12 0.5 11 0.4 
71 50S ribosomal protein L14  gi|49242585 1 16 15.6 9 9.4 
72 aspartyl-tRNA synthetase  gi|49242004 4 1 0.2 1 0.2 
73 putative aldehyde-alcohol dehydrogenase  gi|49240520 7 1 0.2 1 0.2 
74 50S ribosomal protein L32  gi|49241419 2 21 9.5 16 7.2 
75 putative chromosome partition protein  gi|49241526 4 1 0.2 1 0.3 
76 zinc metalloproteinase aureolysin precursor  gi|49242963 4 1 0.2 4 1.0 
77 putative 2,3-bisphosphoglycerate-independent 
phosphoglycerate mutase  
gi|49241162 1 9 8.7 4 3.6 
78 putative lipoprotein  gi|49240798 4 2 0.4 6 1.5 
D 
 
79 putative cell division protein  gi|49240867 1 1 1.0 1 1.4 
80 ABC transporter ATP-binding protein  gi|49242565 1 1 1.0 3 2.9 
81 putative alanyl-tRNA synthetase  gi|49241992 7 8 1.2 2 0.3 
82 DeoR ramily regulatory protein  gi|49241083 1 1 1.0 5 5.0 
83 putative inosine-5'-monophosphate dehydrogenase  gi|49240770 1 9 8.7 12 12.2 
84 30S ribosomal protein S6  gi|49240724 1 14 13.9 19 18.7 
85 putative ATPase subunit of an ATP-dependent protease  gi|49241265 2 3 1.6 9 3.9 
86 ATP synthase alpha chain  gi|49242458 1 9 8.7 9 9.4 
87 conserved hypothetical protein  gi|49241995 1 2 1.7 1 1.0 
88 50S ribosomal protein L16  gi|49242588 1 10 9.5 10 10.1 
89 putative exported protein  gi|49240647 1 1 1.0 1 1.4 
90 putative pyruvate dehydrogenase E1 component, alpha 
subunit  
gi|49241385 1 11 11.3 17 16.6 
91 sensor kinase protein  gi|49242433 7 3 0.5 1 0.2 
92 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-dia 
minopimelate ligase  
gi|49241311 2 1 0.5 2 1.0 
93 50S ribosomal protein L10  gi|49240898 4 15 3.4 13 3.0 
94 adenylate kinase  gi|49242574 1 14 13.9 7 7.2 
95 fructose-bisphosphate aldolase class I  gi|49242931 1 16 15.6 12 12.2 
96 penicillin-binding protein PBP2B  gi|49241930 1 3 3.5 1 1.0 
97 NAD-dependent malic enzyme  gi|49242072 1 1 1.0 1 1.4 
98 putative transketolase  gi|49241663 1 9 8.7 9 9.4 
99 ATP synthase beta chain  gi|49242456 2 12 5.5 9 4.3 
100 conserved hypothetical protein  gi|49240841 1 2 1.7 3 2.9 
101 6-phosphogluconate dehydrogenase, decarboxylating  gi|49241890 2 3 1.6 3 1.3 
102 hypothetical protein  gi|49242182 1 1 1.0 2 2.2 
103 putative lipoprotein  gi|49240757 1 2 1.7 7 7.2 
104 50S ribosomal protein L1  gi|49240897 1 6 6.1 9 8.6 
105 conserved hypothetical protein  gi|49241296 7 2 0.3 1 0.2 
E 
 
106 putative tagatose-bisphosphate aldolase  gi|49242478 1 14 13.9 14 14.4 
107 30S ribosomal protein S5  gi|49242578 1 8 7.8 4 4.3 
108 hypothetical protein  gi|49240656 1 3 3.5 5 5.0 
109 putative membrane protein  gi|49240652 9 3 0.4 3 0.3 
110 putative cell division protein  gi|49241477 1 7 6.9 4 4.3 
111 putative extracellular sugar-binding lipoprotein  gi|49240576 1 2 1.7 3 2.9 
112 50S ribosomal protein L15  gi|49242576 1 8 7.8 14 13.7 
113 50S ribosomal protein L27  gi|49242018 1 7 6.9 6 6.5 
114 putative glycosyl transferase  gi|49240922 24 3 0.1 1 0.1 
115 dihydrolipoamide acetyltransferase component of 
pyruvate dehydrogenase complex  
gi|49241387 1 12 12.1 12 12.2 
116 30S ribosomal protein S3  gi|49242589 1 10 9.5 6 6.5 
117 penicillin-binding protein 2  gi|49241768 1 2 1.7 1 1.0 
118 aconitate hydratase  gi|49241672 7 2 0.3 4 0.5 
119 ribose-phosphate pyrophosphokinase  gi|49240856 1 2 1.7 1 1.0 
120 putative AMP-binding enzyme  gi|49242934 4 2 0.4 1 0.2 
121 50S ribosomal protein L2  gi|49242592 2 6 2.8 6 3.0 
122 putative type I restriction modification DNA specificity 
protein  
gi|49242185 4 2 0.4 1 0.2 
123 30S ribosomal protein S4  gi|49242089 4 7 1.6 8 1.8 
124 bone sialoprotein-binding protein  gi|49240921 2 1 0.5 1 0.7 
125 factor essential for expression of methicillin resistance  gi|49241696 1 2 1.7 1 1.0 
126 conserved hypothetical protein  gi|49241381 1 3 3.5 3 2.9 
127 MHC class II analog  gi|49242309 2 1 0.5 3 1.3 
128 putative lipoprotein  gi|49241200 4 3 0.6 3 0.7 
129 acyl carrier protein  gi|49241524 9 12 1.4 11 1.2 
130 phosphoenolpyruvate-protein phosphotransferase  gi|49241376 2 10 4.3 6 3.0 
131 putative N utilization substance protein A  gi|49241558 1 3 3.5 4 4.3 
132 50S ribosomal protein L18  gi|49242579 1 7 6.9 10 10.1 
F 
 
133 30S ribosomal protein S9  gi|49242560 1 8 7.8 6 6.5 
134 putative DNA-binding protein  gi|49240765 1 6 6.1 6 6.5 
135 hypothetical phage protein  gi|49241822 18 1 0.1 2 0.1 
136 cell division protein FtsZ  gi|49241478 1 9 8.7 10 10.1 
137 putative phosphofructokinase  gi|49241084 1 2 1.7 1 1.0 
138 glutamine synthetase  gi|49241601 1 10 9.5 7 7.2 
139 GrpE protein (Hsp-70 cofactor)  gi|49241958 9 8 0.9 7 0.8 
140 primosomal protein n'  gi|49241504 1 3 2.6 2 2.2 
141 conserved hypothetical protein  gi|49240924 4 5 1.2 4 0.8 
142 alanine racemase  gi|49242425 4 1 0.2 1 0.2 
143 putative thiol peroxidase  gi|49242083 1 3 2.6 4 4.3 
144 putative regulatory protein  gi|49240484 1 2 1.7 1 1.0 
145 putative exported protein  gi|49242108 1 11 11.3 12 11.5 
146 putative exported protein  gi|49240646 1 3 2.6 2 2.2 
147 Spo0B-associated GTP-binding protein  gi|49242017 1 3 2.6 4 3.6 
148 sodium/hydrogen exchanger family protein  gi|49240986 4 1 0.2 1 0.2 
149 putative lipoprotein  gi|49242273 1 1 1.0 1 1.4 
150 30S ribosomal protein S8  gi|49242581 2 11 5.1 9 3.9 
151 ribosome recycling factor  gi|49241551 4 5 1.2 4 1.0 
152 putative protein-export membrane protein  gi|49242010 1 1 1.0 2 2.2 
153 ATP-dependent Clp protease ATP-binding subunit ClpX  gi|49242046 2 5 2.4 4 2.0 
154 putative 30S ribosomal protein S1  gi|49241792 1 11 11.3 6 5.8 
155 putative lipoprotein  gi|49240750 1 8 7.8 6 6.5 
156 50S ribosomal protein L6  gi|49242580 1 7 6.9 8 7.9 
157 adenine phosphoribosyltransferase  gi|49242008 4 1 0.2 1 0.2 
158 30S ribosomal protein S7  gi|49240905 2 10 4.7 5 2.3 
159 conserved hypothetical protein  gi|49241773 4 1 0.2 1 0.2 
160 putative monooxygenase  gi|49242650 1 3 2.6 1 1.0 
161 conserved hypothetical protein  gi|49241567 4 3 0.6 1 0.2 
G 
 
162 putative riboflavin biosynthesis protein  gi|49241564 7 6 0.9 4 0.7 
163 hypothetical protein  gi|49240472 11 3 0.2 1 0.1 
164 3-oxoacyl-[acyl-carrier-protein] synthase II  gi|49241274 1 2 1.7 4 3.6 
165 50S ribosomal protein L13  gi|49242561 2 5 2.4 6 3.0 
166 putative malate:quinone oxidoreductase 2  gi|49242932 1 5 5.2 7 7.2 
167 DNA-directed RNA polymerase alpha chain  gi|49242569 4 5 1.2 4 1.0 
168 ABC transporter ATP_binding protein  gi|49242710 1 3 2.6 2 2.2 
169 putative phosphoglucosamine mutase  gi|49242512 2 1 0.5 3 1.3 
170 putative membrane protein  gi|49241264 1 3 2.6 1 1.0 
171 MarR family regulatory protein  gi|49241071 1 8 7.8 5 5.0 
172 serine hydroxymethyltransferase  gi|49242466 2 3 1.2 2 1.0 
173 putative fatty oxidation complex protein  gi|49240594 1 1 1.0 1 1.4 
174 putative GMP reductase  gi|49241658 11 1 0.1 1 0.1 
175 glutamyl-tRNA amidotransferase subunit A  gi|49242270 1 3 3.5 5 5.0 
176 putative excinuclease ABC subunit C  gi|49241438 7 1 0.2 1 0.2 
177 fumarate hydratase, class-II  gi|49242222 1 1 1.0 1 1.4 
178 50S ribosomal protein L4  gi|49242594 4 7 1.6 6 1.3 
179 50S ribosomal protein L19  gi|49241533 1 3 2.6 4 3.6 
180 phosphoglycerate kinase  gi|49241160 1 5 5.2 7 7.2 
181 DEAD/DEAH box helicase family protein  gi|49241797 1 2 1.7 1 1.0 
182 putative pyridoxine biosynthesis protein  gi|49240877 1 4 4.3 3 2.9 
183 conserved hypothetical protein  gi|49242516 1 2 1.7 1 1.0 
184 BipA family GTPase  gi|49241401 1 1 1.0 1 1.4 
185 putative thioredoxin  gi|49241192 1 5 5.2 6 5.8 
186 superoxide dismutase  gi|49241931 1 7 6.9 6 5.8 
187 conserved hypothetical protein  gi|49241518 1 2 1.7 2 2.2 
188 deoxyribose-phosphate aldolase  gi|49240510 1 4 4.3 4 3.6 
189 formate acetyltransferase  gi|49240587 1 1 1.0 1 1.4 
190 putative membrane protein  gi|49240396 1 1 1.0 1 1.4 
H 
 
191 putative pyridine nucleotide-disulphide oxidoreductase  gi|49241230 1 3 3.5 3 2.9 
192 conserved hypothetical protein  gi|49241608 1 2 1.7 1 1.0 
193 cold shock protein  gi|49241721 2 12 5.5 4 2.0 
194 putative DNA repair protein  gi|49241898 2 2 0.8 1 0.5 
195 putative oligopeptidase  gi|49241292 2 3 1.2 1 0.7 
196 poly A polymerase family protein  gi|49241775 1 1 1.0 1 1.4 
197 6,7-dimethyl-8-ribityllumazine synthase  gi|49242141 1 3 2.6 2 2.2 
198 sensor kinase protein  gi|49241733 2 1 0.5 1 0.7 
199 50S ribosomal protein L5  gi|49242583 1 4 4.3 5 5.0 
200 putative membrane protein  gi|49242225 1 1 1.0 3 2.9 
201 response regulator protein  gi|49241734 1 1 1.0 1 1.4 
202 hypothetical protein  gi|49242280 1 3 2.6 1 1.0 
203 30S ribosomal protein S21  gi|49241952 1 6 6.1 4 4.3 
204 hypothetical protein  gi|49242953 1 1 1.0 3 2.9 
205 putative glycyl-tRNA synthetase  gi|49241942 1 4 4.3 3 2.9 
206 UDP-GlcNAc 2-epimerase  gi|49242464 2 2 0.8 1 0.5 
207 putative 3-oxoacyl-[acyl-carrier-protein] synthase III  gi|49241273 1 1 1.0 2 2.2 
208 30S ribosomal protein S11  gi|49242570 1 5 5.2 6 5.8 
209 conserved hypothetical protein  gi|49241502 1 3 3.5 5 5.0 
210 50S ribosomal protein L3  gi|49242595 1 1 1.0 3 2.9 
211 putative peptidase  gi|49241689 1 1 1.0 1 1.4 
212 putative phosphate acetyltransferase  gi|49240947 1 1 1.0 2 2.2 
213 putative 50S ribosomal protein L31  gi|49242473 2 4 2.0 4 1.6 
214 putative gluconokinase  gi|49242836 15 1 0.1 1 0.1 
215 conserved hypothetical protein  gi|49242497 1 1 1.0 4 3.6 
216 putative UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
gi|49242453 2 2 0.8 1 0.5 
217 ribonucleoside-diphosphate reductase beta chain  gi|49241118 1 5 5.2 4 3.6 
218 50S ribosomal protein L36  gi|49242572 1 3 3.5 3 2.9 
I 
 
219 staphylococcal accessory regulator A  gi|49240975 1 2 1.7 1 1.4 
220 hypothetical protein  gi|49241371 1 1 1.0 3 2.9 
221 ribonucleoside-diphosphate reductase alpha chain  gi|49241117 1 3 2.6 1 1.0 
222 putative DNA-binding protein  gi|49240719 1 2 1.7 1 1.4 
223 conserved hypothetical protein  gi|49241968 1 3 3.5 4 3.6 
224 coenzyme A disulfide reductase  gi|49241260 4 1 0.2 1 0.2 
225 HPr kinase/phosphatase  gi|49241146 1 2 1.7 1 1.4 
226 plasmid recombination enzyme  gi|49240411 1 1 1.0 1 1.4 
227 putative exported protein  gi|49242825 1 1 1.0 1 1.4 
228 glutamyl-tRNA amidotransferase subunit C  gi|49242271 2 3 1.2 2 1.0 
229 penicillin-binding protein 1  gi|49241473 1 1 1.0 1 1.4 
230 putative mannitol-1-phosphate 5-dehydrogenase  gi|49242510 1 3 2.6 1 1.0 
231 50S ribosomal protein L17  gi|49242568 1 3 2.6 4 3.6 
232 conserved hypothetical protein  gi|49241989 9 3 0.4 2 0.2 
233 putative membrane protein  gi|49242841 2 2 0.8 1 0.5 
234 hypothetical protein  gi|49240758 7 1 0.2 1 0.2 
235 penicillin-binding protein 4  gi|49240999 1 2 1.7 1 1.0 
236 10 kDa chaperonin  gi|49242385 1 3 2.6 3 2.9 
237 fumarylacetoacetate (FAA) hydrolase family protein  gi|49241257 1 2 1.7 3 2.9 
238 conserved hypothetical protein  gi|49241510 1 2 1.7 1 1.0 
239 conserved hypothetical protein  gi|49240648 1 3 3.5 1 1.4 
240 conserved hypothetical protein  gi|49241102 1 2 1.7 1 1.0 
241 putative deoxyadenosine kinase protein  gi|49240916 1 2 1.7 1 1.0 
242 putative glucosyl transferase  gi|49241089 1 2 1.7 1 1.0 
243 glycine cleavage system H protein  gi|49241194 1 5 5.2 1 1.4 
244 putative membrane protein  gi|49240944 1 1 1.0 1 1.4 
245 putative glutamyl-tRNA synthetase  gi|49240886 1 1 1.0 1 1.4 
246 30S ribosomal protein S16  gi|49241530 1 4 4.3 1 1.4 
247 putative universal stress protein  gi|49242080 1 1 1.0 1 1.4 
J 
 
248 putative CTP synthase  gi|49242480 1 1 1.0 2 2.2 
249 conserved hypothetical protein  gi|49242812 1 1 1.0 1 1.4 
250 conserved hypothetical protein  gi|49242817 1 1 1.0 2 2.2 
251 putative membrane protein  gi|49242683 1 1 1.0 2 2.2 
252 putative exodeoxyribonuclease VII small subunit  gi|49241901 1 2 1.7 4 3.6 
253 30S ribosomal protein S10  gi|49242596 1 3 2.6 1 1.0 
254 DNA-directed RNA polymerase delta subunit  gi|49242481 1 3 2.6 3 2.9 
255 putative DNA-binding protein  gi|49242218 1 3 3.5 2 2.2 
256 translation initiation factor IF-1  gi|49242573 1 1 1.0 1 1.4 
257 30S ribosomal protein S19  gi|49242591 1 3 2.6 2 2.2 
258 conserved hypothetical protein  gi|49241484 1 1 1.0 3 2.9 
259 membrane anchored protein  gi|49242387 1 3 2.6 1 1.0 
260 ABC transporter ATP-binding protein  gi|49241000 4 1 0.2 1 0.2 
261 DNA polymerase III, beta chain  gi|49240384 1 2 1.7 1 1.0 
262 conserved hypothetical protein  gi|49241308 1 1 1.0 2 2.2 
263 putative lipoprotein  gi|49241062 7 1 0.2 1 0.2 
264 putative ATP-dependent Clp protease proteolytic subunit  gi|49241154 1 1 1.0 1 1.4 
265 hypothetical phage protein  gi|49242329 1 2 1.7 1 1.0 
266 conserved hypothetical protein  gi|49241999 15 34 2.2 25 1.6 
267 hypothetical protein  gi|49241998 1 1 1.0 1 1.4 
268 adenylosuccinate lyase  gi|49242278 1 1 1.0 1 1.4 
269 putative transcription regulator  gi|49242660 4 1 0.2 1 0.2 
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Appendix B: 6h post-inoculation proteomic analyses 
 
 Identified Proteins Accession 
Number 
UAMS-1 
(Spectral 
count) 
UAMS-1 
-rpiRC 
(Spectral 
count) 
UAMS-
1 -rpiRC 
(ratio) 
UAMS-1 -
rpiRABC 
(Spectral 
count) 
UAMS-1 
-rpiRABC 
(ratio) 
1 dihydrolipoamide succinyltransferase E2 component of 2-
oxoglutarate dehydrogenase complex  
gi|49241731 733 955 1.3 1412 1.9 
2 putative ATP synthase delta chain  gi|49242459 66 121 1.8 175 2.7 
3 translation elongation factor Tu  gi|49240907 877 758 0.9 1003 1.1 
4 DNA-binding protein HU  gi|49241789 665 577 0.9 160 0.2 
5 very large surface anchored protein  gi|49241754 24 28 1.2 38 1.6 
6 putative arginyl-tRNA synthetase  gi|49240966 46 73 1.6 99 2.2 
7 putative membrane protein  gi|49242107 44 114 2.6 134 3.1 
8 alkaline shock protein 23  gi|49242531 184 347 1.9 91 0.5 
9 conserved hypothetical protein  gi|49241727 4 9 2.3 6 1.5 
10 MHC class II analog  gi|49242309 41 18 0.4 16 0.4 
11 putative membrane protein  gi|49240652 31 29 0.9 33 1.1 
12 putative enolase  gi|49241163 133 83 0.6 112 0.8 
13 conserved hypothetical protein  gi|49241995 12 10 0.8 5 0.4 
14 glyceraldehyde 3-phosphate dehydrogenase 1  gi|49241159 133 121 0.9 63 0.5 
15 hypothetical protein  gi|49240742 2 2 1.0 3 1.5 
16 factor essential for expression of methicillin resistance  gi|49241696 9 17 1.9 28 3.1 
17 ferritin  gi|49242263 60 94 1.6 127 2.1 
18 hypothetical phage protein  gi|49241813 21 2 0.1 3 0.1 
19 conserved hypothetical protein  gi|49242216 42 90 2.2 132 3.2 
20 DeoR ramily regulatory protein  gi|49241083 4 9 2.3 8 2.0 
21 putative regulatory protein  gi|49241547 2 2 1.0 8 4.0 
22 putative pyruvate carboxylase  gi|49241406 2 12 6.0 10 5.0 
23 putative lipoprotein  gi|49240757 59 21 0.4 22 0.4 
L 
 
24 conserved hypothetical protein  gi|49241469 11 1 0.1 2 0.2 
25 fibronectin-binding protein precursor  gi|49242833 2 9 4.5 10 5.0 
26 putative pyruvate dehydrogenase E1 component, beta 
subunit  
gi|49241386 123 54 0.4 37 0.3 
27 hypothetical phage protein  gi|49242324 8 23 2.9 10 1.3 
28 dihydrolipoamide dehydrogenase  gi|49241388 93 55 0.6 59 0.6 
29 putative copper importing ATPase A  gi|49242887 1 3 3.0 1 1.0 
30 pyruvate kinase  gi|49242068 99 55 0.6 50 0.5 
31 thioredoxin  gi|49241437 84 48 0.6 89 1.1 
32 putative 30S ribosomal protein S1  gi|49241792 74 50 0.7 39 0.5 
33 conserved hypothetical protein  gi|49240648 69 72 1.0 52 0.8 
34 putative peptidase  gi|49240574 1 3 3.0 1 1.0 
35 DNA polymerase I  gi|49242061 3 5 1.7 5 1.7 
36 DNA-directed RNA polymerase beta' chain protein  gi|49240902 11 14 1.3 11 1.0 
37 translation elongation factor G  gi|49240906 46 42 0.9 37 0.8 
38 putative ATPase subunit of an ATP-dependent protease  gi|49241265 21 6 0.3 9 0.4 
39 putative bifunctional purine biosynthesis protein 
[includes: phosphoribosylaminoimidazolecarboxamide 
formyltransferase and IMP cyclohydrolase]  
gi|49241366 31 19 0.6 29 0.9 
40 putative bifunctional protein  gi|49242654 1 8 8.0 12 12.0 
41 putative surface anchored protein  gi|49242132 1 5 5.0 15 15.1 
42 alkyl hydroperoxide reductase subunit C  gi|49240760 78 48 0.6 29 0.4 
43 hypothetical protein  gi|49240472 1 1 1.0 2 2.0 
44 putative rod shape-determining protein  gi|49242022 1 4 4.0 1 1.0 
45 aconitate hydratase  gi|49241672 31 49 1.6 31 1.0 
46 preprotein translocase SecA subunit-like protein  gi|49242975 1 2 2.0 5 5.0 
47 RpiR family transcriptional regulator  gi|49240564 1 2 2.0 3 3.0 
48 putative deoxyribose-phosphate aldolase  gi|49242490 127 6 0.0 2 0.0 
49 hypothetical protein  gi|49242953 17 4 0.2 1 0.1 
50 putative universal stress protein  gi|49242080 113 22 0.2 4 0.0 
M 
 
51 putative CoA synthetase protein  gi|49241537 27 37 1.4 52 1.9 
52 putative membrane protein  gi|49242326 1 2 2.0 5 5.0 
53 putative inosine-5'-monophosphate dehydrogenase  gi|49240770 41 35 0.9 25 0.6 
54 bifunctional autolysin precursor  gi|49241346 20 15 0.8 17 0.9 
55 fructose-bisphosphate aldolase class I  gi|49242931 62 24 0.4 23 0.4 
56 arsenical pump membrane protein 2  gi|49242147 1 6 6.0 6 6.0 
57 translation initiation factor IF-2  gi|49241561 13 15 1.2 3 0.2 
58 preprotein translocase SecA subunit  gi|49241139 8 7 0.9 14 1.8 
59 putative helicase  gi|49242827 3 2 0.7 2 0.7 
60 putative malate:quinone oxidoreductase 2  gi|49242932 22 39 1.8 25 1.1 
61 aldehyde dehydrogenase family protein  gi|49242475 5 1 0.2 3 0.6 
62 putative exonuclease  gi|49241667 2 2 1.0 3 1.5 
63 phosphoenolpyruvate carboxykinase  gi|49242162 20 20 1.0 27 1.4 
64 ATP synthase beta chain  gi|49242456 33 18 0.5 7 0.2 
65 putative AMP-binding enzyme  gi|49242934 4 9 2.3 10 2.5 
66 formate--tetrahydrofolate ligase  gi|49242101 28 23 0.8 11 0.4 
67 cell division protein FtsZ  gi|49241478 37 32 0.9 26 0.7 
68 putative stress response-related Clp ATPase  gi|49240883 7 4 0.6 1 0.1 
69 glucosamine--fructose-6-phosphate aminotransferase 
[isomerizing]  
gi|49242505 8 1 0.1 3 0.4 
70 chaperone protein  gi|49241957 32 14 0.4 18 0.6 
71 hypothetical protein  gi|49241015 3 3 1.0 3 1.0 
72 glutamate synthase, large subunit  gi|49240825 1 2 2.0 1 1.0 
73 potassium-transporting ATPase B chain  gi|49240444 2 6 3.0 10 5.0 
74 maltose operon transcriptional repressor  gi|49241887 7 26 3.7 5 0.7 
75 DNA-directed RNA polymerase beta chain protein  gi|49240901 11 34 3.1 20 1.8 
76 ABC transporter ATP-binding protein  gi|49243023 1 7 7.0 10 10.0 
77 trigger factor (prolyl isomerase)  gi|49242047 16 30 1.9 19 1.2 
78 putative chromosome partition protein  gi|49241526 2 3 1.5 1 0.5 
N 
 
79 UTP--glucose-1-phosphate uridylyltransferase  gi|49242832 3 3 1.0 1 0.3 
80 dihydrolipoamide acetyltransferase component of 
pyruvate dehydrogenase complex  
gi|49241387 49 15 0.3 12 0.2 
81 conserved hypothetical protein  gi|49241293 18 1 0.1 1 0.1 
82 teicoplanin resistance associated membrane protein  gi|49242700 8 5 0.6 5 0.6 
83 putative amidophosphoribosyltransferase precursor  gi|49241363 6 4 0.7 8 1.3 
84 putative lipoprotein  gi|49240750 25 31 1.2 23 0.9 
85 elongation factor Ts  gi|49241549 28 31 1.1 25 0.9 
86 polyribonucleotide nucleotidyltransferase  gi|49241566 7 5 0.7 5 0.7 
87 putative glycyl-tRNA synthetase  gi|49241942 13 32 2.5 28 2.2 
88 DNA gyrase subunit A  gi|49240388 7 7 1.0 6 0.9 
89 putative type I restriction enzyme  gi|49240566 1 2 2.0 2 2.0 
90 putative restriction and modification system specificity 
protein  
gi|49240790 6 5 0.8 2 0.3 
91 putative transketolase  gi|49241663 29 20 0.7 25 0.9 
92 triosephosphate isomerase  gi|49241161 36 27 0.8 24 0.7 
93 putative pyruvate dehydrogenase E1 component, alpha 
subunit  
gi|49241385 29 20 0.7 17 0.6 
94 catalase  gi|49241655 19 33 1.7 27 1.4 
95 collagen adhesin precursor  gi|49243016 3 1 0.3 2 0.7 
96 putative membrane protein  gi|49242225 6 1 0.2 4 0.7 
97 conserved hypothetical protein  gi|49241256 2 2 1.0 2 1.0 
98 putative GMP reductase  gi|49241658 1 17 17.0 1 1.0 
99 60 kDa chaperonin  gi|49242384 19 15 0.8 16 0.8 
100 penicillin-binding protein 2 prime  gi|49240420 4 1 0.3 1 0.3 
101 putative thiolase  gi|49240593 1 3 3.0 4 4.0 
102 putative RNA binding protein  gi|49242418 2 4 2.0 4 2.0 
103 DNA topoisomerase I  gi|49241542 1 7 7.0 2 2.0 
104 excinuclease ABC subunit A  gi|49241145 1 6 6.0 21 21.1 
105 putative phosphoglycerate mutase  gi|49242761 9 3 0.3 10 1.1 
O 
 
106 30S ribosomal protein S13  gi|49242571 22 17 0.8 14 0.6 
107 putative lipoprotein  gi|49242273 1 5 5.0 2 2.0 
108 acetate kinase  gi|49242081 37 7 0.2 8 0.2 
109 AcrB/AcrD/AcrF family protein  gi|49242605 3 1 0.3 1 0.3 
110 conserved hypothetical protein  gi|49241308 21 24 1.1 25 1.2 
111 preprotein translocase SecY subunit  gi|49242575 1 4 4.0 1 1.0 
112 putative membrane protein  gi|49242969 1 6 6.0 3 3.0 
113 putative septation ring formation regulator  gi|49242087 1 10 10.0 8 8.0 
114 bone sialoprotein-binding protein  gi|49240921 1 3 3.0 4 4.0 
115 phosphoenolpyruvate-protein phosphotransferase  gi|49241376 21 19 0.9 14 0.7 
116 alkaline phosphatase synthesis transcriptional regulatory 
protein  
gi|49242064 2 4 2.0 1 0.5 
117 glutamyl-tRNA amidotransferase subunit A  gi|49242270 9 5 0.6 8 0.9 
118 DNA mismatch repair protein MutL  gi|49241588 1 2 2.0 3 3.0 
119 putative thioredoxin reductase  gi|49241150 30 1 0.0 2 0.1 
120 adenylate kinase  gi|49242574 17 14 0.8 25 1.5 
121 putative succinate dehydrogenase iron-sulfur protein  gi|49241441 6 26 4.3 27 4.5 
122 putative phosphofructokinase  gi|49241084 5 2 0.4 6 1.2 
123 conserved hypothetical protein  gi|49242982 3 1 0.3 1 0.3 
124 cell surface elastin binding protein  gi|49241796 19 4 0.2 7 0.4 
125 50S ribosomal protein L2  gi|49242592 10 10 1.0 14 1.4 
126 ABC transporter ATP-binding protein  gi|49241105 2 2 1.0 1 0.5 
127 threonyl-tRNA synthetase  gi|49242054 3 19 6.4 10 3.4 
128 putative exodeoxyribonuclease VII large subunit  gi|49241902 1 1 1.0 3 3.0 
129 putative exported protein  gi|49242128 5 10 2.0 28 5.6 
130 putative exported protein  gi|49241950 12 10 0.8 13 1.1 
131 glutamyl-tRNA amidotransferase subunit B  gi|49242269 5 7 1.4 5 1.0 
132 putative thiol peroxidase  gi|49242083 12 6 0.5 13 1.1 
133 sensor kinase protein  gi|49242433 1 13 13.0 8 8.0 
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134 ATP-dependent DNA helicase  gi|49242275 5 2 0.4 5 1.0 
135 putative surface anchored protein  gi|49240920 2 2 1.0 3 1.5 
136 conserved hypothetical protein  gi|49241883 1 1 1.0 2 2.0 
137 putative ATP-dependent protease ATP-binding subunit  gi|49241546 5 12 2.4 3 0.6 
138 putative phosphoribosylformylglycinamidine synthase II  gi|49241362 9 15 1.7 7 0.8 
139 topoisomerase IV subunit A  gi|49241677 4 1 0.3 2 0.5 
140 putative 5'-nucleotidase  gi|49240405 2 6 3.0 2 1.0 
141 aerobic glycerol-3-phosphate dehydrogenase  gi|49241593 5 3 0.6 1 0.2 
142 6-phosphogluconate dehydrogenase, decarboxylating  gi|49241890 10 30 3.0 13 1.3 
143 sensor kinase protein  gi|49241733 1 1 1.0 2 2.0 
144 NAD-dependent malic enzyme  gi|49242072 5 3 0.6 7 1.4 
145 conserved hypothetical protein  gi|49241255 1 2 2.0 1 1.0 
146 putative membrane protein  gi|49240649 12 2 0.2 1 0.1 
147 putative exported protein  gi|49242193 2 2 1.0 1 0.5 
148 putative alanyl-tRNA synthetase  gi|49241992 6 6 1.0 3 0.5 
149 putative GMP synthase  gi|49240771 1 17 17.0 21 21.1 
150 putative membrane protein  gi|49240720 2 4 2.0 4 2.0 
151 isoleucyl-tRNA synthetase  gi|49241485 1 5 5.0 26 26.1 
152 putative sodium:dicarboxylate symporter protein  gi|49240762 3 12 4.0 11 3.7 
153 putative gluconate permease  gi|49242835 1 3 3.0 6 6.0 
154 putative regulatory protein  gi|49242954 1 3 3.0 1 1.0 
155 formate acetyltransferase  gi|49240587 17 1 0.1 1 0.1 
156 putative transaldolase  gi|49242155 14 7 0.5 6 0.4 
157 acetyl-coenzyme A synthetase  gi|49242102 8 15 1.9 6 0.8 
158 putative membrane protein  gi|49240653 1 2 2.0 3 3.0 
159 multicopper oxidase protein  gi|49241054 1 2 2.0 1 1.0 
160 putative peptidyl-prolyl cis-isomerase  gi|49242212 2 1 0.5 1 0.5 
161 fumarate hydratase, class-II  gi|49242222 11 7 0.6 9 0.8 
162 ABC transporter ATP-binding protein  gi|49241711 1 7 7.0 1 1.0 
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163 seryl-tRNA synthetase  gi|49240391 10 19 1.9 10 1.0 
164 primosomal protein n'  gi|49241504 9 2 0.2 6 0.7 
165 glutamine synthetase  gi|49241601 9 17 1.9 17 1.9 
166 putative phosphoribosylaminoimidazole carboxylase 
ATPase subunit  
gi|49241358 2 5 2.5 4 2.0 
167 30S ribosomal protein S6  gi|49240724 4 12 3.0 20 5.0 
168 FtsK/SpoIIIE family protein  gi|49242110 5 1 0.2 1 0.2 
169 hypothetical protein  gi|49240656 1 5 5.0 7 7.0 
170 isocitrate dehydrogenase  gi|49242065 11 19 1.7 18 1.6 
171 putative DNA repair protein  gi|49241898 2 1 0.5 1 0.5 
172 putative non-ribosomal peptide synthetase  gi|49240550 1 3 3.0 9 9.0 
173 putative glycosyl transferase  gi|49240623 2 1 0.5 1 0.5 
174 50S ribosomal protein L13  gi|49242561 1 28 28.0 13 13.0 
175 putative hexulose-6-phosphate synthase  gi|49240928 2 2 1.0 5 2.5 
176 lipoprotein  gi|49240487 11 2 0.2 6 0.5 
177 putative tRNA pseudouridine synthase B  gi|49241563 4 2 0.5 5 1.3 
178 conserved hypothetical protein  gi|49240716 2 1 0.5 11 5.5 
179 putative NAD synthetase  gi|49242283 9 8 0.9 5 0.6 
180 resolvase  gi|49242119 4 5 1.3 3 0.8 
181 alkyl hydroperoxide reductase subunit F  gi|49240759 9 5 0.6 2 0.2 
182 2-oxoglutarate dehydrogenase E1 component  gi|49241732 8 3 0.4 1 0.1 
183 putative pyrimidine-nucleoside phosphorylase  gi|49242489 10 4 0.4 3 0.3 
184 putative lipoprotein  gi|49241909 1 3 3.0 5 5.0 
185 phosphoglycerate kinase  gi|49241160 14 4 0.3 6 0.4 
186 putative exported protein  gi|49242970 2 1 0.5 1 0.5 
187 peptide chain release factor 1  gi|49242471 1 3 3.0 1 1.0 
188 putative UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
gi|49242477 4 8 2.0 7 1.8 
189 putative cell division protein  gi|49240867 3 7 2.3 2 0.7 
R 
 
190 putative anti repressor  gi|49242367 1 2 2.0 1 1.0 
191 putative phosphoglucosamine mutase  gi|49242512 14 11 0.8 8 0.6 
192 putative UDP-N-acetylglucosamine pyrophosphorylase  gi|49240855 1 2 2.0 1 1.0 
193 acyl carrier protein  gi|49241524 13 24 1.9 12 0.9 
194 putative exported protein  gi|49242160 7 3 0.4 1 0.1 
195 penicillin-binding protein PBP2B  gi|49241930 4 4 1.0 1 0.3 
196 urocanate hydratase  gi|49242674 12 16 1.3 15 1.3 
197 putative succinate dehydrogenase flavoprotein subunit  gi|49241440 1 13 13.0 12 12.0 
198 putative ketoacyl-CoA thiolase  gi|49240934 2 4 2.0 1 0.5 
199 putative cell division protein  gi|49241477 12 1 0.1 6 0.5 
200 putative glucose-6-phosphate isomerase  gi|49241251 6 8 1.3 1 0.2 
201 putative lipoprotein  gi|49241093 1 8 8.0 14 14.1 
202 serine hydroxymethyltransferase  gi|49242466 9 20 2.2 10 1.1 
203 ornithine aminotransferase  gi|49241246 3 13 4.3 17 5.7 
204 conserved hypothetical protein  gi|49241153 3 3 1.0 1 0.3 
205 putative peptidase  gi|49241986 1 1 1.0 2 2.0 
206 FolD bifunctional protein [includes: 
methylenetetrahydrofolate 
dehydrogenase/methenyltetrahydrofolate cyclohydrolase]  
gi|49241356 10 7 0.7 20 2.0 
207 DNA-directed RNA polymerase alpha chain  gi|49242569 6 21 3.5 15 2.5 
208 nitrate reductase alpha chain  gi|49242742 1 1 1.0 5 5.0 
209 putative glycine cleavage system P-protein  gi|49241914 8 1 0.1 1 0.1 
210 D-3-phosphoglycerate dehydrogenase  gi|49242093 2 2 1.0 1 0.5 
211 adenylosuccinate lyase  gi|49242278 13 11 0.8 9 0.7 
212 30S ribosomal protein S4  gi|49242089 5 13 2.6 19 3.8 
213 putative tagatose-bisphosphate aldolase  gi|49242478 16 19 1.2 13 0.8 
214 putative phosphate acetyltransferase  gi|49240947 6 6 1.0 7 1.2 
215 putative lipoprotein  gi|49240798 1 2 2.0 1 1.0 
216 acetyltransferase (GNAT) family protein  gi|49241468 5 18 3.6 3 0.6 
S 
 
217 50S ribosomal protein L16  gi|49242588 2 18 9.1 21 10.6 
218 putative pyruvate flavodoxin/ferredoxin oxidoreductase  gi|49241581 3 5 1.7 1 0.3 
219 putative CTP synthase  gi|49242480 2 1 0.5 3 1.5 
220 50S ribosomal protein L1  gi|49240897 9 8 0.9 13 1.5 
221 putative membrane protein  gi|49240704 2 15 7.5 14 7.1 
222 putative membrane protein  gi|49240796 6 10 1.7 13 2.2 
223 putative dUTP pyrophosphatase  gi|49242347 2 2 1.0 3 1.5 
224 putative DNA topoisomerase  gi|49242599 2 1 0.5 3 1.5 
225 putative oligopeptidase  gi|49241292 1 8 8.0 5 5.0 
226 putative homoserine dehydrogenase  gi|49241649 1 2 2.0 2 2.0 
227 hypothetical protein  gi|49241267 1 1 1.0 4 4.0 
228 putative lipoic acid synthetase  gi|49241214 12 6 0.5 4 0.3 
229 3-oxoacyl-[acyl-carrier-protein] synthase II  gi|49241274 11 4 0.4 1 0.1 
230 putative succinyl-CoA ligase  gi|49241538 13 20 1.5 12 0.9 
231 putative molybdate-binding lipoprotein precursor  gi|49242623 7 3 0.4 5 0.7 
232 recombinase A  gi|49241577 3 1 0.3 2 0.7 
233 RGD-containing lipoprotein  gi|49240571 1 8 8.0 9 9.0 
234 conserved hypothetical protein  gi|49240841 2 1 0.5 1 0.5 
235 putative ribonuclease R  gi|49241167 1 3 3.0 1 1.0 
236 ABC transporter ATP-binding protein  gi|49241203 1 13 13.0 17 17.1 
237 conserved hypothetical protein  gi|49241567 6 11 1.8 6 1.0 
238 L-lactate dehydrogenase 2  gi|49242927 13 9 0.7 3 0.2 
239 fumarylacetoacetate (FAA) hydrolase family protein  gi|49241257 9 8 0.9 4 0.4 
240 DNA polymerase III PolC-type  gi|49241556 1 2 2.0 1 1.0 
241 putative monooxygenase  gi|49242650 1 1 1.0 2 2.0 
242 arginine deiminase  gi|49242961 13 1 0.1 1 0.1 
243 putative O-acetylserine (thiol)-lyase  gi|49240869 11 9 0.8 6 0.5 
244 putative cell division protein  gi|49241476 2 2 1.0 1 0.5 
245 putative thiamine pyrophosphate enzyme  gi|49240559 1 3 3.0 3 3.0 
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246 aspartyl-tRNA synthetase  gi|49242004 8 3 0.4 3 0.4 
247 conserved hypothetical protein  gi|49241500 1 3 3.0 1 1.0 
248 putative NAD-specific glutamate dehydrogenase  gi|49241247 8 11 1.4 7 0.9 
249 DNA ligase  gi|49242274 2 3 1.5 9 4.5 
250 immunoglobulin G binding protein A precursor  gi|49240483 9 1 0.1 1 0.1 
251 putative exported protein  gi|49240646 3 2 0.7 1 0.3 
252 histidyl-tRNA synthetase  gi|49242005 2 2 1.0 1 0.5 
253 putative peptidase  gi|49242127 8 15 1.9 18 2.3 
254 putative aminotransferase  gi|49240913 3 20 6.7 13 4.4 
255 putative asparaginyl-tRNA synthetase  gi|49241772 1 12 12.0 21 21.1 
256 putative membrane protein  gi|49242896 3 1 0.3 1 0.3 
257 cytosol aminopeptidase family protein  gi|49241231 3 2 0.7 1 0.3 
258 conserved hypothetical protein  gi|49241773 2 1 0.5 3 1.5 
259 manganese-dependent inorganic pyrophosphatase  gi|49242290 3 8 2.7 4 1.3 
260 putative ATP-dependent protease ATP-binding subunit 
ClpL  
gi|49242878 2 3 1.5 1 0.5 
261 conserved hypothetical protein  gi|49241518 4 16 4.0 14 3.5 
262 putative L-serine dehydratase, alpha chain  gi|49242860 5 6 1.2 4 0.8 
263 50S ribosomal protein L5  gi|49242583 1 13 13.0 14 14.1 
264 DNA gyrase subunit B  gi|49240387 1 6 6.0 7 7.0 
265 nucleoside permease  gi|49240879 1 3 3.0 4 4.0 
266 putative imidazolonepropionase  gi|49242673 4 3 0.8 3 0.8 
267 putative extracellular glutamine-binding protein  gi|49242229 3 2 0.7 1 0.3 
268 putative sigma factor sigB regulation protein  gi|49242422 1 9 9.0 5 5.0 
269 dihydropteroate synthase  gi|49240870 1 1 1.0 2 2.0 
270 putative helicase  gi|49242435 2 1 0.5 2 1.0 
271 putative pyridine nucleotide-disulphide oxidoreductase  gi|49241230 10 19 1.9 3 0.3 
272 50S ribosomal protein L6  gi|49242580 7 17 2.4 10 1.4 
273 chromosome replication initiation/membrane attachment gi|49242056 3 1 0.3 2 0.7 
U 
 
protein  
274 S-adenosylmethionine synthetase  gi|49242161 3 2 0.7 3 1.0 
275 putative mannitol-1-phosphate 5-dehydrogenase  gi|49242510 5 1 0.2 1 0.2 
276 peptide chain release factor 2  gi|49241140 2 1 0.5 4 2.0 
277 porphobilinogen deaminase  gi|49242042 3 1 0.3 1 0.3 
278 conserved hypothetical protein  gi|49240912 4 1 0.3 1 0.3 
279 aminotransferase class-V protein  gi|49242086 1 2 2.0 1 1.0 
280 putative purine nucleoside phosphorylase  gi|49242491 3 11 3.7 7 2.3 
281 putative ornithine carbamoyltransferase  gi|49242960 22 1 0.0 1 0.0 
282 conserved hypothetical protein  gi|49241999 32 1 0.0 1 0.0 
283 putative N utilization substance protein A  gi|49241558 3 6 2.0 1 0.3 
284 putative choline dehydrogenase  gi|49242937 1 2 2.0 1 1.0 
285 putative methionyl-tRNA synthetase  gi|49240846 1 4 4.0 6 6.0 
286 ABC transporter ATP_binding protein  gi|49242710 1 2 2.0 10 10.0 
287 putative transcriptional regulator  gi|49242846 5 12 2.4 10 2.0 
288 DNA polymerase III, beta chain  gi|49240384 10 9 0.9 1 0.1 
289 putative exported protein  gi|49241174 2 1 0.5 1 0.5 
290 putative pur operon repressor  gi|49240852 3 1 0.3 1 0.3 
291 putative adenylosuccinate synthetase  gi|49240399 5 19 3.8 1 0.2 
292 50S ribosomal protein L4  gi|49242594 5 18 3.6 12 2.4 
293 putative excinuclease ABC subunit C  gi|49241438 1 1 1.0 2 2.0 
294 30S ribosomal protein S8  gi|49242581 3 7 2.3 11 3.7 
295 putative single-stranded-DNA-specific exonuclease  gi|49242009 2 1 0.5 1 0.5 
296 conserved hypothetical protein  gi|49242516 1 4 4.0 1 1.0 
297 conserved hypothetical protein  gi|49241968 29 7 0.2 1 0.0 
298 putative DNA-binding protein  gi|49240765 5 3 0.6 4 0.8 
299 arginase family protein  gi|49242677 2 2 1.0 1 0.5 
300 conserved hypothetical protein  gi|49242284 2 1 0.5 1 0.5 
301 ABC transporter ATP-binding protein  gi|49242504 3 1 0.3 1 0.3 
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302 putative exported protein  gi|49240668 16 3 0.2 1 0.1 
303 putative lipoprotein  gi|49241200 7 1 0.1 4 0.6 
304 ATP synthase alpha chain  gi|49242458 6 7 1.2 13 2.2 
305 putative phosphoribosylamine--glycine ligase  gi|49241367 5 9 1.8 6 1.2 
306 putative transport protein  gi|49242882 2 4 2.0 1 0.5 
307 putative phosphoribosylaminoimidazole-
succinocarboxamide synthase  
gi|49241359 4 10 2.5 7 1.8 
308 citrate synthase II  gi|49242066 7 10 1.4 5 0.7 
309 30S ribosomal protein S9  gi|49242560 13 13 1.0 9 0.7 
310 putative S30EA family ribosomal protein  gi|49241138 17 8 0.5 6 0.4 
311 lipoprotein  gi|49241122 10 3 0.3 8 0.8 
312 serine protease  gi|49242188 1 3 3.0 1 1.0 
313 aldo/keto reductase family protein  gi|49242159 3 18 6.0 11 3.7 
314 putative selenocysteine lyase  gi|49241205 3 1 0.3 1 0.3 
315 sodium:neurotransmitter symporter family protein  gi|49240812 5 12 2.4 6 1.2 
316 putative exported protein  gi|49241326 2 1 0.5 1 0.5 
317 3-hydroxy-3-methylglutaryl coenzyme A synthase  gi|49242876 3 8 2.7 15 5.0 
318 penicillin-binding protein 2  gi|49241768 2 2 1.0 1 0.5 
319 aldehyde dehydrogenase family protein  gi|49242884 4 1 0.3 1 0.3 
320 ATP-dependent Clp protease ATP-binding subunit ClpX  gi|49242046 5 2 0.4 1 0.2 
321 putative exported protein  gi|49242108 8 13 1.6 12 1.5 
322 50S ribosomal protein L29  gi|49242587 9 8 0.9 9 1.0 
323 putative exported protein  gi|49241180 1 4 4.0 1 1.0 
324 putative protease  gi|49241315 1 4 4.0 1 1.0 
325 putative cardiolipin synthetase  gi|49242441 1 2 2.0 1 1.0 
326 putative DNA polymerase  gi|49241848 1 1 1.0 3 3.0 
327 putative adenosylmethionine-8-amino-7-oxononanoate 
aminotransferase  
gi|49242771 2 1 0.5 1 0.5 
328 hypothetical protein  gi|49241949 5 2 0.4 3 0.6 
W 
 
329 putative 2-amino-3-ketobutyrate coenzyme A ligase  gi|49240909 1 6 6.0 1 1.0 
330 putative fatty acid synthesis protein  gi|49241521 2 1 0.5 1 0.5 
331 glyceraldehyde 3-phosphate dehydrogenase 2  gi|49242058 5 3 0.6 5 1.0 
332 carbamate kinase  gi|49242958 7 2 0.3 1 0.1 
333 fibrinogen and keratin-10 binding surface anchored 
protein  
gi|49242956 2 1 0.5 1 0.5 
334 50S ribosomal protein L32  gi|49241419 4 10 2.5 7 1.8 
335 site-specific recombinase  gi|49240435 1 1 1.0 3 3.0 
336 6-phosphofructokinase  gi|49242069 2 6 3.0 1 0.5 
337 putative GTP-binding protein  gi|49241961 2 1 0.5 4 2.0 
338 Spo0B-associated GTP-binding protein  gi|49242017 2 1 0.5 1 0.5 
339 putative exported protein  gi|49240516 1 1 1.0 3 3.0 
340 putative potassium-transporting ATPase B chain  gi|49242431 1 1 1.0 2 2.0 
341 RNA polymerase sigma factor  gi|49241939 1 2 2.0 2 2.0 
342 ribose-phosphate pyrophosphokinase  gi|49240856 5 2 0.4 3 0.6 
343 acetyl-CoA acetyltransferase  gi|49240713 7 1 0.1 1 0.1 
344 alcohol dehydrogenase  gi|49240964 7 1 0.1 1 0.1 
345 amidase  gi|49241803 1 2 2.0 2 2.0 
346 putative lipoprotein  gi|49241384 1 2 2.0 2 2.0 
347 30S ribosomal protein S3  gi|49242589 4 3 0.8 8 2.0 
348 putative chaperonin  gi|49240868 1 2 2.0 1 1.0 
349 putative type I restriction modification DNA specificity 
protein  
gi|49242185 7 6 0.9 2 0.3 
350 hypothetical protein  gi|49241063 5 5 1.0 1 0.2 
351 immunodominant antigen A  gi|49242897 14 6 0.4 4 0.3 
352 putative membrane protein  gi|49240417 2 7 3.5 4 2.0 
353 lipase precursor  gi|49240681 1 2 2.0 1 1.0 
354 peptide chain release factor 3  gi|49241313 1 1 1.0 2 2.0 
355 alanine racemase  gi|49242425 1 2 2.0 2 2.0 
X 
 
356 putative glucose-6-phosphate 1-dehydrogenase  gi|49241884 1 8 8.0 9 9.0 
357 putative protease  gi|49242097 4 1 0.3 1 0.3 
358 putative lipoprotein  gi|49241802 8 1 0.1 1 0.1 
359 extracellular solute-binding lipoprotein  gi|49242759 1 9 9.0 2 2.0 
360 conserved hypothetical protein  gi|49241381 1 2 2.0 2 2.0 
361 50S ribosomal protein L7/L12  gi|49240899 10 8 0.8 2 0.2 
362 beta-lactamase precursor  gi|49242122 1 4 4.0 1 1.0 
363 putative betaine aldehyde dehydrogenase  gi|49242938 7 2 0.3 4 0.6 
364 sodium/hydrogen exchanger family protein  gi|49240986 2 1 0.5 1 0.5 
365 transcription antitermination protein  gi|49240895 7 5 0.7 1 0.1 
366 putative peptidase  gi|49241689 8 1 0.1 1 0.1 
367 putative sulfatase  gi|49241104 1 1 1.0 3 3.0 
368 putative peptidase  gi|49241908 1 7 7.0 4 4.0 
369 ABC transporter extracellular binding protein  gi|49240988 3 8 2.7 2 0.7 
370 lipoamide acyltransferase component of branched-chain 
alpha-keto acid dehydrogenase complex  
gi|49241894 7 4 0.6 1 0.1 
371 conserved hypothetical protein  gi|49241360 7 8 1.1 10 1.4 
372 putative membrane protein  gi|49241264 1 3 3.0 1 1.0 
373 putative aldolase  gi|49240494 11 4 0.4 3 0.3 
374 putative membrane protein  gi|49241534 1 1 1.0 2 2.0 
375 glycerol kinase  gi|49241592 1 8 8.0 4 4.0 
376 50S ribosomal protein L21  gi|49242020 16 3 0.2 5 0.3 
377 staphylococcal accessory regulator A  gi|49240975 1 3 3.0 5 5.0 
378 putative D-isomer specific 2-hydroxyacid dehydrogenase  gi|49242649 1 4 4.0 1 1.0 
379 putative UTP--glucose-1-phosphate uridylyltransferase  gi|49242520 3 1 0.3 1 0.3 
380 transcription elongation factor  gi|49241984 3 6 2.0 3 1.0 
381 integrase  gi|49242376 1 7 7.0 5 5.0 
382 prephenate dehydrogenase  gi|49241688 1 1 1.0 2 2.0 
383 superoxide dismutase  gi|49241931 12 6 0.5 9 0.8 
Y 
 
384 putative single-strand DNA-binding protein  gi|49240725 1 3 3.0 1 1.0 
385 beta-lactamase regulatory protein  gi|49242121 1 1 1.0 2 2.0 
386 putative thioredoxin  gi|49241192 3 8 2.7 9 3.0 
387 putative dioxygenase  gi|49242852 1 2 2.0 1 1.0 
388 putative UDP-N-acetylglucosamine 1-
carboxyvinyltransferase  
gi|49242453 2 3 1.5 1 0.5 
389 uracil phosphoribosyltransferase  gi|49242465 7 3 0.4 6 0.9 
390 50S ribosomal protein L17  gi|49242568 1 7 7.0 6 6.0 
391 putative carbamoyl-phosphate synthase, pyrimidine-
specific, large chain  
gi|49241495 2 2 1.0 1 0.5 
392 3-oxoacyl-[acyl-carrier protein] reductase  gi|49241523 3 1 0.3 2 0.7 
393 mevalonate kinase  gi|49240949 1 2 2.0 1 1.0 
394 ABC transporter ATP-binding protein  gi|49242773 1 1 1.0 2 2.0 
395 hypothetical protein  gi|49240767 7 7 1.0 3 0.4 
396 putative peptidase  gi|49241891 6 3 0.5 1 0.2 
397 50S ribosomal protein L15  gi|49242576 5 8 1.6 3 0.6 
398 putative extracellular sugar-binding lipoprotein  gi|49240576 4 1 0.3 1 0.3 
399 putative peptidoglycan pentaglycine interpeptide 
biosynthesis protein  
gi|49242606 3 1 0.3 1 0.3 
400 putative lipoprotein  gi|49240795 2 2 1.0 1 0.5 
401 30S ribosomal protein S12  gi|49240904 2 4 2.0 4 2.0 
402 putative glycoprotease  gi|49242404 1 1 1.0 2 2.0 
403 D-alanine--D-alanine ligase  gi|49242437 2 12 6.0 1 0.5 
404 antibacterial protein  gi|49241466 10 1 0.1 14 1.4 
405 putative aldehyde dehydrogenase  gi|49240539 5 3 0.6 4 0.8 
406 putative lipoprotein  gi|49240799 3 8 2.7 6 2.0 
407 L-lactate dehydrogenase 1  gi|49240604 3 1 0.3 1 0.3 
408 conserved hypothetical protein  gi|49242849 2 1 0.5 1 0.5 
409 conserved hypothetical protein  gi|49241484 6 6 1.0 4 0.7 
Z 
 
410 putative membrane protein  gi|49240396 1 1 1.0 2 2.0 
411 6,7-dimethyl-8-ribityllumazine synthase  gi|49242141 3 6 2.0 7 2.3 
412 hypothetical protein  gi|49242788 1 2 2.0 2 2.0 
413 conserved hypothetical protein  gi|49241443 3 5 1.7 1 0.3 
414 conserved hypothetical protein  gi|49241207 1 8 8.0 6 6.0 
415 conserved hypothetical protein  gi|49241875 2 1 0.5 2 1.0 
416 signal recognition particle protein  gi|49241529 1 1 1.0 3 3.0 
417 putative oligopeptide transport ATP-binding protein  gi|49241282 3 1 0.3 1 0.3 
418 probable cadmium-transporting ATPase  gi|49241056 3 1 0.3 1 0.3 
419 putative membrane protein  gi|49242947 1 2 2.0 3 3.0 
420 diaminopimelate decarboxylase  gi|49241719 6 1 0.2 1 0.2 
421 HPr kinase/phosphatase  gi|49241146 1 3 3.0 1 1.0 
422 putative zinc-binding dehydrogenase  gi|49242536 2 2 1.0 1 0.5 
423 putative 6-carboxyhexanoate--CoA ligase  gi|49242768 1 3 3.0 1 1.0 
424 conserved hypothetical protein  gi|49242653 1 2 2.0 2 2.0 
425 membrane anchored protein  gi|49242387 1 5 5.0 8 8.0 
426 putative phosphoribosylformylglycinamidine cyclo-ligase  gi|49241364 7 3 0.4 1 0.1 
427 ABC transporter ATP-binding protein  gi|49242684 4 1 0.3 1 0.3 
428 putative naphthoate synthase  gi|49241340 2 4 2.0 6 3.0 
429 hypothetical phage protein  gi|49242357 1 1 1.0 3 3.0 
430 ribonucleoside-diphosphate reductase beta chain  gi|49241118 3 7 2.3 6 2.0 
431 50S ribosomal protein L10  gi|49240898 6 4 0.7 6 1.0 
432 putative cyclophilin type peptidyl-prolyl cis-trans 
isomerase  
gi|49241243 1 7 7.0 5 5.0 
433 autolysis and methicillin resistant-related protein  gi|49241350 1 3 3.0 2 2.0 
434 putative exodeoxyribonuclease VII small subunit  gi|49241901 16 3 0.2 1 0.1 
435 PTS system, glucose-specific IIA component  gi|49241742 7 3 0.4 2 0.3 
436 putative 3-oxoacyl-[acyl-carrier-protein] synthase III  gi|49241273 1 3 3.0 1 1.0 
437 conserved hypothetical protein  gi|49241517 1 5 5.0 2 2.0 
AA 
 
438 putative 50S ribosomal protein L25  gi|49240857 8 3 0.4 8 1.0 
439 chorismate synthase  gi|49241784 2 1 0.5 1 0.5 
440 transposase A 1  gi|49240431 
(+1) 
1 11 11.0 5 5.0 
441 cation efflux family protein  gi|49242762 1 1 1.0 5 5.0 
442 ribonucleoside-diphosphate reductase alpha chain  gi|49241117 1 1 1.0 2 2.0 
443 putative molybdenum cofactor biosynthesis protein  gi|49242617 2 1 0.5 1 0.5 
444 signal peptidase Ib  gi|49241254 3 1 0.3 1 0.3 
445 hypothetical protein  gi|49240622 1 6 6.0 1 1.0 
446 glycine cleavage system H protein  gi|49241194 17 1 0.1 1 0.1 
447 acetyl-coenzyme A carboxylase carboxyl transferase 
subunit beta  
gi|49242071 2 3 1.5 1 0.5 
448 putative 6-phospho-3-hexuloisomerase  gi|49240929 1 3 3.0 1 1.0 
449 glycolytic operon regulator  gi|49241158 1 2 2.0 1 1.0 
450 arginase  gi|49242515 4 3 0.8 1 0.3 
451 aldo/keto reductase family protein  gi|49241088 1 6 6.0 6 6.0 
452 GrpE protein (Hsp-70 cofactor)  gi|49241958 6 3 0.5 1 0.2 
453 ImpB/MucB/SamB family protein  gi|49241687 1 1 1.0 3 3.0 
454 haloacid dehalogenase-like hydrolase  gi|49241218 3 5 1.7 1 0.3 
455 conserved hypothetical protein  gi|49241102 1 1 1.0 4 4.0 
456 conserved hypothetical protein  gi|49241152 1 2 2.0 2 2.0 
457 putative acyltransferase  gi|49242096 3 1 0.3 1 0.3 
458 capsular polysaccharide synthesis enzyme  gi|49240528 1 2 2.0 2 2.0 
459 hypothetical phage protein  gi|49241851 1 1 1.0 4 4.0 
460 putative quinol oxidase polypeptide II precursor  gi|49241354 5 2 0.4 5 1.0 
461 putative glutamyl-tRNA synthetase  gi|49240886 4 3 0.8 2 0.5 
462 putative ATP-dependent Clp protease proteolytic subunit  gi|49241154 2 4 2.0 4 2.0 
463 putative phosphoribosylformylglycinamidine synthase I  gi|49241361 5 3 0.6 2 0.4 
464 D-specific D-2-hydroxyacid dehydrogenase  gi|49242856 5 1 0.2 1 0.2 
BB 
 
465 putative polypeptide deformylase 2  gi|49241383 2 1 0.5 1 0.5 
466 putative exported protein  gi|49242176 1 1 1.0 3 3.0 
467 putative cobalt transport protein  gi|49242563 2 1 0.5 1 0.5 
468 putative nucleoside diphosphate kinase  gi|49241785 1 3 3.0 1 1.0 
469 hypothetical phage protein  gi|49241861 2 1 0.5 2 1.0 
470 putative membrane protein  gi|49242533 4 7 1.8 8 2.0 
471 urease alpha subunit  gi|49242634 1 1 1.0 2 2.0 
472 30S ribosomal protein S2  gi|49241548 6 1 0.2 4 0.7 
473 hypothetical protein  gi|49242048 1 1 1.0 5 5.0 
474 hypothetical protein  gi|49240758 1 4 4.0 4 4.0 
475 putative peptidase  gi|49241704 3 3 1.0 8 2.7 
476 putative 50S ribosomal protein L31  gi|49242473 4 3 0.8 5 1.3 
477 translation initiation factor IF-3  gi|49242052 1 3 3.0 1 1.0 
478 DNA-directed RNA polymerase delta subunit  gi|49242481 4 3 0.8 3 0.8 
479 putative phosphoribosylaminoimidazole carboxylase 
catalytic subunit  
gi|49241357 4 5 1.3 1 0.3 
480 putative membrane protein  gi|49242500 1 7 7.0 4 4.0 
481 sucrose-specific PTS tranporter protein  gi|49240563 1 4 4.0 1 1.0 
482 conserved hypothetical protein  gi|49241025 1 2 2.0 1 1.0 
483 hypothetical protein  gi|49242527 2 1 0.5 1 0.5 
484 conserved hypothetical protein  gi|49240865 1 1 1.0 2 2.0 
485 catabolite control protein A  gi|49242105 2 1 0.5 1 0.5 
486 hypothetical protein  gi|49240748 2 1 0.5 1 0.5 
487 prolyl-tRNA synthetase  gi|49241555 2 1 0.5 1 0.5 
488 alanine dehydrogenase 1  gi|49242079 4 1 0.3 2 0.5 
489 30S ribosomal protein S10  gi|49242596 1 4 4.0 1 1.0 
490 response regulator protein  gi|49241734 2 3 1.5 1 0.5 
491 ABC transporter ATP-binding protein  gi|49241000 1 2 2.0 1 1.0 
492 conserved hypothetical protein  gi|49242074 1 2 2.0 3 3.0 
CC 
 
493 putative membrane protein  gi|49241171 1 3 3.0 2 2.0 
494 hypothetical protein  gi|49242299 1 9 9.0 3 3.0 
495 conserved hypothetical protein  gi|49242388 3 6 2.0 1 0.3 
496 conserved hypothetical protein  gi|49241151 2 1 0.5 1 0.5 
497 putative dihydroorotate dehydrogenase  gi|49242916 2 1 0.5 1 0.5 
498 putative pyridoxine biosynthesis protein  gi|49240877 2 1 0.5 1 0.5 
499 putative hydrolase  gi|49242908 3 2 0.7 1 0.3 
500 putative thioredoxin  gi|49242113 4 1 0.3 1 0.3 
501 undecaprenyl pyrophosphate synthetase  gi|49241552 1 4 4.0 1 1.0 
502 AhpC/TSA family protein  gi|49242233 3 6 2.0 1 0.3 
503 conserved hypothetical protein  gi|49242981 11 1 0.1 1 0.1 
504 putative peptidase  gi|49242379 1 2 2.0 1 1.0 
505 hypothetical phage protein  gi|49241867 2 3 1.5 1 0.5 
506 signal transduction protein  gi|49242205 1 1 1.0 5 5.0 
507 glycerophosphoryl diester phosphodiesterase  gi|49240418 1 1 1.0 6 6.0 
508 putative acyl-CoA dehydrogenase  gi|49240595 2 2 1.0 1 0.5 
509 30S ribosomal protein S7  gi|49240905 1 3 3.0 1 1.0 
510 putative non-heme iron-containing ferritin  gi|49242492 1 7 7.0 1 1.0 
511 conserved hypothetical protein  gi|49242133 5 1 0.2 1 0.2 
512 conserved hypothetical protein  gi|49242497 4 3 0.8 1 0.3 
513 hypothetical protein  gi|49241579 1 1 1.0 8 8.0 
514 30S ribosomal protein S16  gi|49241530 2 4 2.0 1 0.5 
515 FdhD/NarQ family protein  gi|49242624 2 1 0.5 1 0.5 
516 glutamine transport ATP-binding protein  gi|49242228 1 2 2.0 1 1.0 
517 putative membrane protein  gi|49242523 2 1 0.5 1 0.5 
518 D-alanyl carrier protein  gi|49241223 1 1 1.0 9 9.0 
519 30S ribosomal protein S11  gi|49242570 3 2 0.7 1 0.3 
520 30S ribosomal protein S19  gi|49242591 1 1 1.0 3 3.0 
521 response regulator protein  gi|49241871 2 1 0.5 1 0.5 
DD 
 
522 hypothetical protein  gi|49241998 1 1 1.0 3 3.0 
523 50S ribosomal protein L23  gi|49242593 1 2 2.0 1 1.0 
524 conserved hypothetical protein  gi|49242813 2 1 0.5 1 0.5 
525 putative cytochrome ubiquinol oxidase  gi|49241378 2 1 0.5 1 0.5 
526 putative membrane protein  gi|49242779 2 1 0.5 1 0.5 
527 putative 4-oxalocrotonate tautomerase  gi|49241686 4 2 0.5 1 0.3 
528 stage V sporulation protein G  gi|49240854 3 1 0.3 1 0.3 
529 flavohemoprotein  gi|49240603 2 1 0.5 1 0.5 
530 hypothetical phage protein  gi|49241810 1 2 2.0 1 1.0 
531 putative methyltransferase  gi|49241955 1 1 1.0 3 3.0 
532 hypothetical protein  gi|49242669 1 2 2.0 1 1.0 
533 conserved hypothetical protein  gi|49241583 2 1 0.5 1 0.5 
534 conserved hypothetical protein  gi|49241297 1 1 1.0 2 2.0 
535 putative small heat shock protein  gi|49242733 1 3 3.0 1 1.0 
536 putative methyltransferase  gi|49242124 2 1 0.5 1 0.5 
 
